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Abstract 
Introduction 
Malignant brain tumours constitute a small proportion of annual cancer incidence; 
however, the death rate is almost double the rate of incidence of all cases of cancer. This is 
not helped by the difficulties associated with the delivery of drugs to the brain. Steering 
magnetic nanoparticles (MNPs) i.e. superparamagnetic iron oxide nanoparticles (SPIONs) 
in an area of interest has been proposed for directing magnetically labelled drugs to 
clinical targets. A powerful magnetic and field gradient is required to ensure that the drugs 
are directed to the target area. In this case, the deeper the location, the stronger the 
magnetic force required. External permanent magnets can provide a strong magnetic field 
and gradient. We hypothesise that an inexpensive, portable, powerful and external 
Halbach array of 1.1T can be designed to steer SPIONs into brain tumours for drug 
delivery.  
Methodology  
Computational model: A 2-D simulation model of a Neodymium-iron-boron 
(FeNdB-52) magnet was run using Finite Element Method Magnetics (FEMM) software.  
In vitro model: The FEMM model was assembled and produced a Halbach array 
with a magnetic strength of 1.1T. The Halbach array was placed on the top of a 3D printed 
head in order to trap SPIONs (Fe3O4) in a 3D tumour, in contact with the surface of the 
head model. SPIONs were run through a fluid flow system using a syringe pump at 10 
ml/min. The experiment was performed in two parts; the first part was to flow SPIONs 
with different concentrations ranging from 0.1mg/ml to 20mg/ml. The second part was to 
flow SPIONs, with the same concentrations, but loaded with 50 million white blood cells 
(WBCs) to mimic circulation. The concentration of SPIONs was quantified by inductively 
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coupled plasma spectrometry (ICP). Images of the tumours with trapped MNPs were also 
obtained by MRI (3T) using a dual gradient echo sequence (TE= 4.60ms, 20ms). The 
uptake of SPIONs and viability of brain cells as well as brain tumour cells was evaluated 
using TEM and flow cytometry. 
Findings 
The strength of the modelled magnetic arrays was 1.6T whereas the actual 
assembled one was 1.1T assessed using Gaussmeter. The concentration of trapped SPIONs 
in the phantom flow model was different depending on the initial concentration of SPIONs 
and the location of the tumours within the head phantom. As expected, the further away 
the tumour was from the magnet, the less SPIONs were trapped.  Trapping was confirmed 
by both ICP and MRI. The SPIONs uptake was observed in the cytoplasm of the cells and 
it was also noted that increasing the concentration of MNPs resulted in increased toxicity 
of the brain cells and brain tumour cells. This suggests that the concentration of iron 
needed to guide drugs with minimal toxicity should be considered.  
Conclusions  
Various Halbach array designs were modelled and an optimised design assembled. 
The in vitro experiments showed that the Halbach arrays could trap SPIONs with or 
without WBCs inside the tumour at different distances- up to 10 cm. This suggests that 
Halbach arrays have the potential to trap therapeutic drugs labelled with iron particles and 
we believe this would be useful for targeting of anti-cancer therapies to brain tumours. 
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1.1 Brain structure overview 
The central nervous system consists of the brain and the spinal cord. These two 
components are responsible for the regulation of different body functions. The brain is 
made up of three different parts namely the forebrain, midbrain and the hindbrain. It also 
consists of several lobes of the cerebral cortex which are responsible for different high 
order functions in an organism. The main lobes include the frontal lobe, the parietal lobe, 
the occipital lobe, the cerebellum lobe, the temporal lobe and the brain stem. Inside the 
lobes, there are different parts which perform different regulatory functions either as part 
of the central nervous system or the endocrine system. Figure 1.1 shows some of the main 
functional regions located in the lobes. 
 
Figure 1.1: Brain structure. Sagittal view of the of the cerebral cortex showing the main brain lobes and 
different regions of the brain located within the main brain lobes. 
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The brain parenchyma consists of different cell types including the nerve cells or 
neurons and the glial cells. The glial cells provide support and they are located around the 
neurons, and they are of different types including: astrocytes, oligodendrocytes and 
microglia [1]. Furthermore, there are several layers that protect the brain parenchyma and 
these include: the skull, the dura mater, arachnoid mater and pia mater. The dura mater is 
the outer layer that is connected to the skull and where lymphatic vessels are located. In 
the subarachnoid layer located immediately before the pia mater, there is a fluid called the 
cerebrospinalfluid (CSF), which bathes the brain parenchyma. In addition, in the pia mater, 
there are the blood vessels which supply nutrients and oxygen to the parenchyma [2]. The 
blood brain barrier (BBB) inside the blood vessels  is responsible for preventing foreign 
particles (which may damage the brain) from entering into the brain parenchyma. When 
tumours develop in the brain parenchyma region they disturb the BBB to access nutrients 
and oxygen from the blood vessels (Figure 1.2). It has also been shown that the 
functioning and organisation of the BBB can be affected by some pathological conditions 
including multiple sclerosis, epilepsy, auto-immune deficiency syndrome (AIDS), 
dementia and stroke [3]. 
 
Figure 1.2: The brain parenchyma and protective layers. The brain parenchyma covered with three main 
layers including blood vessels, and the development of a tumour within the brain parenchyma and how it 
affects the BBB. 
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1.2 The brain and blood vessels 
The central nervous system does not operate in isolation; instead, it is closely 
linked to other systems in the body. For instance, the brain cells are surrounded by a dense 
network of blood vessels whose function is two-fold. The blood vessels are useful for the 
transportation of nutrients and oxygen to the brain cells and they also protect the brain 
cells from any toxic substances that may affect their neuronal function [4]. There are three 
different types of blood cells: red blood cells, responsible for the transport of oxygen; 
white blood cells (WBCs), which are vital for the defence mechanisms; and platelets, 
which play a key role in blood clotting. These cells originate from the blood stem cells as 
illustrated in Figure 1.3 below. 
 
Figure 1.3: The cellular precursors of the components of blood leading to red blood cells, white blood 
cells and platelets. 
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As indicated above, it is important for the brain cells to be protected from any toxic 
neuronal substances that might be in the blood. The BBB has an endothelial cell layer that 
is tightly connected creating tight junctions which prevents easy entry of substances into 
the brain parenchyma [4]. In addition, there are some supporting cells including astrocytes, 
pericytes and microglia. Each cell plays an important role in the BBB. Astrocyte cells 
surround the basal lamina of the brain capillaries and provide the cellular connection to 
neurons and they play a key role in the maintenance of the barrier properties of the 
endothelium [5] [6]. On the other hand, pericytes cover the endothelium and contribute to 
the structural integrity of the BBB and the induction of barrier properties during 
development [7]. The following Figure 1.4 illustrates the structure of the BBB. Despite 
this level of protection, the brain is not immune to cancers with tumours arising within the 
brain and some that metastasis from other organs to the brain.  
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Figure 1.4: Structure of the BBB showing the endothelial cells and the supporting cells and neurones. The 
endothelial cells are connected tightly and supported by other cells such as the pericytes and astrocytes to 
protect the brain. 
 
1.3 Brain tumours 
Brain tumours are a result of uncontrolled growth of cells. They can be classified 
into two main categories namely: benign and malignant tumours. Benign tumours do not 
have any cancerous cells and can be easily treated. In contrast, malignant tumours have 
cancerous cells and they can spread quickly making it difficult for them to be treated. 
Lumen of blood vessel 
Blood 
Astrocyte 
Basement membrane Neuron 
Endothelial cells 
Pericyte 
Neuron 
Endothelial cells 
Basement membrane 
Pericyte 
Astrocyte 
Brain Microglia 
Tight junction 
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Although these tumours occur rarely, they account for approximately 2% of all cases of 
cancer in adults [8]. Around 4400 people in the UK are diagnosed with a brain tumour 
every year and this is equivalent to a rate of 7 per every 100 000 in the total population 
annually (Cancer Research UK, 2019). Although malignant brain tumours constitute a 
small proportion of annual cancer incidence, the death rate of brain tumour patients is 
almost double the rate of incidence of all cases of cancer as these are extremely difficult to 
treat [9].  
Brain tumours can occur in any region within the brain, however, 26% of brain 
tumours occur in the frontal lobe, as it is the largest area in the brain and covers almost 
two-fifths of the human brain. Tumours in the temporal lobe are considered to be 19% and 
12% in the parietal lobe. Less occur in the rest of the lobes i.e. 5% cerebellum, 4% brain 
stem, 3% occipital lobe and 2% ventricle [10]. As can be seen from Figure 1.5 below, 
brain tumours occur in different places within the brain, and therefore result in different 
distances from the surface of the head. 
 
Figure 1.5: Brain tumours and the different location/distance within the brain. 
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As mentioned earlier, brain tumours can originate from either brain cells or are 
derived from metastases from other body parts. The tumours that arise from brain cells are 
referred to as primary tumours and in the US, for example, between 2010 and 2014, these 
accounted for approximately 2% of  all  cancers,  with  an  overall  annual  incidence   of   
22   per   100000   population [11]. It is worth bearing in mind that these rates are age-
adjusted. Crude incidence rates are calculated by dividing the total number of cases by the 
total population; hence, the statistics cannot be compared to crude rates from other 
populations (for example, UK) where the age distribution is different. 
Brain metastases start from tumours located in different parts of the body such as 
the lungs and the breasts. These two types of cancer are among the most common brain 
metastases where 50% of the patients with lung tumours and 20% of patients with breast 
tumours develop metastatic brain tumours [12][13][14]. Brain metastases arise from the 
intravasation of cancer cells into the main circulation system, either directly or through the 
lymphatic system [15].  
There are several types of primary brain tumours which can occur in both adults 
and children. For example, gliomas and astrocytomas are among the most common. 
Figure 1.6 illustrates the most common tumours in adults and in children [16] [11]. 
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Figure 1.6: Common types of brain tumours. (a) Adults and (b) Children. 
 
(a) 
(b) 
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Each type of brain tumour is named according to the main type of cells present 
where the cancer is located. For instance, gliomas are tumours that originate from the glial 
cells and examples of these tumours include astrocytomas, oligodendrogliomas and 
ependymomas [11]. According to the World Health Organisation (WHO), gliomas 
constitute the most common type of brain tumours representing 80% of all malignant 
primary brain tumours in adults [17]. Gliomas are also classified according to their 
malignancy grade ranging from grade 1 to 4, where grade 4 represents the most aggressive 
form of brain tumour. For example, when astrocytomas reach grade 4 level, they are called 
glioblastomas [18]. These brain tumours are found in both adults and children [19]. 
However, primary glioblastomas are more prevalent in adults, where they represent more 
than 90% of cases in patients who are above 50 years [20]. 
Brain tumours can occur at any age in both genders, however, it has been found that in 
general brain tumour cases increase from age 30 up to 75. It appears there is a drop in the 
number of cases of brain tumour after the age of 75 and the reasons for this are not clear. It 
is argued that this might be a result of tumours of the brain being less likely to be 
investigated and detected among the elderly [8]. On the other hand, an increase in the 
incidence of other conditions such as strokes among the elderly might be an indicator of 
the presence of brain tumours. This is because one of the symptoms of brain tumours is 
stroke. It is possible that physicians may fail to detect brain tumours and just focus on the 
strokes. However, it has been suggested that physicians may not have the appetite to 
conduct thorough investigations [8]. Brain tumours are more likely to appear in males than 
in females with a male: female ratio of 1.5:1. Despite this general incidence ratio, in some 
types of cancer such as meningioma’s, women are actually more likely to develop the 
cancer than men [8]. 
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Recent studies indicate that brain tumours arise from genetic mutations which 
disrupt the existing regulatory mechanisms, making it possible for the cancerous cells to 
continue to multiply and spread [8]. Alterations of the genetic material can be caused by 
different neurocarcinogens that can be chemical, physical and/ or biological. The 
development of brain tumours can therefore be attributed to both genetic and 
environmental factors. It is possible that genetic alterations can be inherited from one 
generation to another, hence it becomes important to trace family histories when 
investigating brain tumours. An example of this phenomenon can be the predisposition to 
brain tumours, in particular, with genetic changes in the TP53 gene which has been found 
in patients with gliomas [8]. On the other hand, individuals may develop brain tumours 
that are a result of changes in their own internal environment. For example, changes in the 
cell environment may affect metabolic processes including oxidation, detoxification, DNA 
stability and repair and immune functioning. These changes can lead to the alteration of 
the structure of specific genes [8].  
Apart from the main factors such as the genetic alterations and changes in the 
environment, there are also a number of risk factors that can contribute to the development 
of brain tumours. Patients exposed to ionising radiation are likely to develop brain 
tumours. For instance, it was observed that the use of low dose radiation as treatment for 
tinea capitis and skin disorders in children resulted in the development of brain tumours in 
adulthood [13].  
1.4 Current therapeutic methods for brain tumour 
Various therapeutic systems can be employed to treat brain tumour patients. These 
include surgery, chemotherapy, radiotherapy and more recently, immunotherapy and 
targeted therapy [21]. The treatment choice is decided by the physicians depending on 
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several factors which include the condition of the patient such as age as well as the 
condition of the tumour, for instance, the tumour grade, size, location and whether the 
tumour is in a single or multiple locations in the brain.  The currently available treatment 
options for brain tumours are discussed in the following section. 
1.4.1 Surgery 
Surgical resection is one of the first options for the treatment of brain tumour 
patients. It involves the removal of the tumour mass from the affected part of the brain. 
However, as due to the type as well as the location of some brain tumours, surgical 
resection is not always effective [16]. This is because the malignant tumour can be located 
in a sensitive region of the brain where it cannot be removed completely [16]. In addition, 
the malignant brain tumour may not be well defined, making it difficult for the surgeon to 
remove the tumour without damaging some of the other brain tissue. The malignant cells 
can penetrate into healthy tissues surrounding the tumour, hence, it is possible for the 
malignant tumour to recur after the initial surgery [22]. Therefore, surgery is often 
followed by radiotherapy [23] and/ or chemotherapy which can be either oral 
Temozolomide or an implanted Carmustine wafer [24]. 
1.4.2 Chemotherapy 
One of the primary treatments for brain tumour is Chemotherapy and it involves 
the use of anticancer (cytotoxic) drugs. It can be administered during the surgery to 
remove the tumour and this is called a Gliadel implant. Alternatively, it can be given after 
surgery and together with or after any other brain tumour treatment such as radiotherapy. 
There are different ways of administering chemotherapy into the brain including, for 
example, oral Temozolomide and intravenous Carmustine [24]. Although chemotherapy is 
designed to destroy cancer cells, it can also affect healthy cells leading to the weakening of 
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the body’s immune system and causing some side effects, for example, increased chance 
of infection, easy bruising or bleeding, hair loss and fatigue among others. 
1.4.3 Radiotherapy 
This is also referred to as radiation therapy and is a common treatment for brain 
tumours which uses high energy beams, i.e. X-ray and/ or proton beam therapy (PBT), of 
external radiation to destroy cancer cells [25]. It can be used when the surgeon cannot 
remove the tumour or can be used after surgery. Similarly to chemotherapy, radiotherapy 
also produces side effects and this has been an area of interest to researchers in an effort to 
find ways of reducing the side effects and improve the quality of patient’s lives [26].  In 
addition, radiotherapy can be combined with chemotherapy to produce significant 
improvements in the treatment of many tumours. A study by Komatar et al. revealed that 
the combination of radiotherapy and chemotherapy such as Temozolomide helps to 
improve the survival of brain tumour patients [27]. The study established that after 28 
months of treatment, the average survival for patients who were treated with radiotherapy 
and Temozolomide was 14.6 months while the average was 12.1 months for those treated 
with radiotherapy alone. On the other hand, it is argued that the combined use of 
radiotherapy and chemotherapy increases the  drug side effects [28], thus creating a 
difficult choice for patients and physicians between remaining duration and quality of life. 
1.4.4 Immunotherapy 
This is another form of cancer treatment where a patient’s immune system is 
stimulated in order to fight cancerous cells. The human immune system consists of the 
lymph glands, spleen and white blood cells. Some cells of the immune system are able to 
identify cancer cells as abnormal and destroy them. However, this is not a reliable way to 
eliminate or kill all the cancer cells for various reasons including: 1). The immune system 
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cannot destroy all the cancer cells; 2). Cancer cells produce signals to protect themselves 
from being attacked by the immune system, 3). The cancer cells hide or escape from the 
immune system (Cancer Research UK, 2019). 
There are several types of immunotherapy and these include: vaccines, monoclonal 
antibodies, adoptive cell therapy, checkpoint inhibition and virotherapy. 
 Vaccines 
These work in the same way that vaccine’s for other diseases work, where a 
weakened version of the pathogen is introduced into the body to stimulate the immune 
system. The vaccine activates the dendritic cells (DCs) to produce antigens that are 
transported through the lymphatic vessels to lymph nodes in order to activate T-cells. The 
activated T-cells help to develop immunity against cancer cells [29]. Some studies 
involving the use of cancer vaccines to treat brain tumours have been conducted and have 
shown promising results [30]–[32]. For example, the first case of brain tumour patient who 
had primary intracranial tumour, that was treated with DC-based immunotherapy was 
reported in 2000 by Lia et al. [33]. The patient underwent surgical resection first, and then 
injected with three immunisations of autologous DCs. The results showed that the patient 
responded positively to the vaccine, that is, the patient developed measurable cellular 
immune responses against vaccine antigens. 
 Adaptive Cell Therapy 
This method is aimed at directly activating the T-cells to enhance immunity [34]. It 
involves isolation and ex-vivo expansion of a sample of tumour specific T-cells from the 
patient’s blood and then transferring T-cells into the patient to develop immunity. This 
technique has been investigated in several in vitro studies and showed positive results [32], 
[35], [36]. Brown et al., developed a chimeric antigen receptor (CAR) T cell 
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immunotherapy to treat glioblastoma (GBM). GBM was derived from a patient and 
injected into mice. The result showed  improving in anti-tumour activity which providing 
vital insights of translation of CAR T cells for GBM [37]. 
 Checkpoint inhibition 
Immune checkpoint therapy has recently exploded into the cancer treatment scene 
and involves the enhancement of T-cells by blocking certain proteins (immune 
checkpoints) that weaken the normal activity of cytotoxic T-cells. In this case, the T-cells 
are boosted to destroy the cancer cells more effectively [38]. These inhibitors have shown 
efficacy in certain tumours like melanoma and are currently administered to patients with 
this cancer [39] [40]. Currently, a number of clinical trials of checkpoint inhibitors in 
glioblastoma (i.e. programmed death ligand1-PDL1) are ongoing, i.e. phase III trial was 
established in 2014 as well as phase I and II in 2016 , hence, the outcomes of the studies 
are yet to be reported [41].  
 Virotherapy 
This is one of the immunotherapy methods used to treat brain tumours by 
programming viruses to attack cancerous cells whilst avoiding damage to healthy tissues 
using the common types of oncolytic viruses [42]. Clinical trials carried out in the recent 
past have demonstrated that oncolytic viruses are effective in treating human tumours. 
Cockle et al. indicate that most clinical studies have focused on intratumoural delivery in 
the treatment of tumours [43]. For example, an oncolytic herpes simplex virus-1 
(HSV1716), has been used in adults by injection into the brain and superficial tumours. 
The aim was to determine if it was safe to use HSV1716 with young cancer patients with 
relapsed or refractory extracranial cancers. A single dose of HSV1716 was administered to 
8 patients and two doses to one patient. No dose limiting toxicities were observed. Overall, 
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HSV1716 was shown to be safe and effective for use in children and young adults with 
late stage aggressive cancer [44].  
Of note, some of these therapies are still in clinical trials for brain cancer and in the 
next few years, it will become apparent if these are suitable for this disease type and will 
progress to be an approved therapy for brain cancer. 
1.5 Challenges of treating brain tumours  
Despite the improvements made in diagnostic imaging of brain tumours using approaches 
such as radio-isotope imaging, computed tomography (CT) and magnetic resonance 
imaging (MRI), the treatment of brain tumours remains a big challenge. This is mainly due 
to the difficulties associated with the delivery of drugs to the brain. Basically, 100% of 
large-molecule pharmaceutics including peptides, recombinant proteins, monoclonal 
antibodies, Ribonucleic acid interference (RNAi) based drugs and gene therapies do not 
cross the BBB [45] [46] [47]. This is due to the structure of the BBB, the series of closely 
packed endothelial cells with tight junctions in between them and supporting protective 
cells (Figure 1.4) makes it difficult to deliver drugs across the BBB into the brain tumours. 
The BBB functions as a barrier preventing all neurotoxins as well as drugs from invading 
the brain cells. The development of a brain tumour can disrupt the BBB (as shown in 
Figure 1.2) resulting in the leaking of some foreign substances into the brain cells. 
However, in most cases large parts of the BBB remain intact, thereby preventing drug 
delivery. This constitutes a big challenge in the treatment of brain tumours using 
traditional methods, such as intravenous injection of anti-cancer drugs, given that the drugs 
cannot penetrate the BBB [48]. It is also known that despite disruption of the BBB it is still 
difficult for anti-cancer drugs to treat brain tumours. This is due to the differences between 
the size of the anti-cancer drugs and the endothelial pore size in malignant tumours. In a 
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study by Watkins et al. (2014) it was revealed that displacement of the astrocytic end feet 
from an endothelial cell by a single invading tumour cell would be enough to cause local 
breaching of the BBB [49]. However, it is unlikely that the size of this local disruption is 
sufficient to allow drug penetration in meaningful quantities to reach the tumour site 
without direct navigation of the drug. Bearing in mind that areas with invasion do not get 
enhanced during contrast-enhanced MRI. In addition, it has been shown that the high 
metabolic demands of high-grade glioma creates hypoxic areas that trigger increased 
expression of Vascular Endothelial Growth Factor (VEGF) and angiogenesis which leads 
to the formation of abnormal vessels and a dysfunctional BBTB [50]. The invasive 
potential of glioma causes widespread proliferation of high-grade glioma cells outside 
regions of the disrupted BBTB and inside areas of otherwise normal brain, where the 
function of the barrier is still much more intact. In most cases, this includes the areas that 
do not show gadolinium enhancement on T1 weighted MRI [51]. As a result, both in low-
grade and high-grade glioma, the BBB and the BBTB barrier form a major obstacle in 
brain tumour therapy by preventing the delivery of sufficient quantities of potentially 
effective therapeutic agents [50]. 
 In addition, traditional cancer treatment methods such as radiotherapy and 
chemotherapy have the disadvantage of affecting other healthy cells or tissues as they are 
distributed throughout the body. This results in some side effects that include loss of 
immunity, dizziness and fatigue. Some of the techniques to improve drug delivery across 
the BBB and to spare the healthy cells by concentrating the anti-cancer drugs to the area of 
interest (tumour) are discussed in the following section. 
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1.6 Drug Delivery techniques for brain tumours 
Drug targeting therapy is a cancer treatment that involves the delivery of drugs to 
specific location or area of interest in the body [52]. This technique can improve the 
outcome of brain tumour treatment by allowing preferential delivery of drugs to the cells 
of interest and ensuring that the drug molecules react exclusively with the cancer cells 
without affecting the other healthy cells. One of the drug targeting techniques which has 
already been used clinically for the treatment of brain tumours is focused ultrasound 
therapy [53]. 
1.6.1 Focused Ultrasound therapy 
Focused ultrasound therapy is a non-invasive therapeutic technique, which involves 
focusing beams of ultrasound energy to target areas deep in the brain without affecting the 
surrounding tissues. It works in two different ways in the treatment of cancer including: 1) 
High intensity focused ultrasound (HIFU) to thermally destroy the cancer and 2) 
Disrupting the BBB temporarily to allow anticancer drug delivery. By temporarily 
disrupting the BBB using pulsed ultrasound combined with injected microbubbles it is 
possible to enhance the delivery of anticancer drugs to the brain in patients with recurrent 
brain tumours [53]. 
A recent in vivo study explored the potential of a new strategy to deliver anticancer 
drugs to brain tumours using this ultrasound technique [54]. This strategy involved 
administering radioisotopes (64Cu-AuNCs) to the brain through the nose using focused 
ultrasound intranasal (FUSIN). It uses focused ultrasound (FUS) to induce microbubble 
cavitation to enhance drug delivery to the brain tumour via the intranasal (IN) route. The 
aim of this study was to evaluate the effectiveness of this technique compared with the 
traditional treatment method which involves administering the drug intravenously (IV). In 
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the first group of mice, a total of 8 drops (24μL) were administered to each mouse IN and 
then this was followed by FUS. In the second group, 3.7 MBq/mouse were administered 
IV through the tail vein. The histological analysis showed that FUSIN resulted in the 
accumulation of most of the radioisotope in the brain with low concentrations in other 
organs such as lungs, spleen, kidneys and heart compared to the IV route. The histological 
analysis also indicated that no damage was caused to the tissues in the nose, trigeminal 
nerve and the brain. Therefore, it was concluded that FUSIN is a safe and promising 
technique to target brain tumour. 
Another study confirmed the effectiveness of using FUS in combination with 
microbubbles under MRI guidance in the treatment of Gliomas in a rat model. This 
technique is called Magnetic Resonance Image-guided Focused Ultrasound (MRI-FUS).  
The aim of the study was to evaluate the effectiveness of MRI-FUS in the treatment of 
brain tumours such as Diffuse Intrinsic Pontine Glioma (DIPG). The results confirmed that 
MRI-FUS could open the BBB and facilitate the penetration of the chemotherapeutic agent 
(Doxorubicin) [55]. 
1.6.2 Photodynamic therapy 
The interest in photodynamic therapy (PDT) came up as a result of the 
ineffectiveness of the other standard therapies for malignant tumours. This technique 
makes use of the toxicity of singlet state oxygen which is generated by irradiating a laser 
of 664 nm wavelength on the photosensitiser [56] [57]. Research revealed that the singlet 
oxygen state generated from photochemical reactions is toxic and leads to direct damage to 
the tumour cells (necrosis and apoptosis), the shutdown of brain tumour vascular tissues 
and enhancement of the body’s immune system [58] [59]. This technique was used in a 
number of in vitro and in vivo studies and showed promising results, which could be 
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verified, in clinical studies [53] [54] [55] [56].  Although PDT proved to be an effective 
treatment method for malignant brain tumours, its downside is that it involves an operation 
to remove the tumour and to expose the location of the tumour to the laser.  
1.6.3 Magnetic Field Technique 
One of the approaches used to deliver anticancer drugs is the use of magnetic 
fields. This involves generating a static magnetic field and field gradient from either a 
permanent, resistive or superconducting magnet. The force on a magnetic particle is 
proportional to the product of the local field and field gradient. The magnetic field can be 
positioned internally using an implanted magnet [60], or externally on the surface of the 
patient or even completely surrounding the patient using the large volume fields found in 
whole body magnetic resonance imaging (MRI) systems [61] [62]. Implanted magnets 
involve inserting small pieces of magnetic material close to the target location in the 
patient’s body. This approach helps to generate powerful magnetic field strength and field 
gradient for the attraction and concentration of drugs into the target area. A number of 
studies have shown the effectiveness of this technique in targeting drug delivery to the 
spinal cord [63], heart [64], and brain [60]. This method is not commonly used because of 
the need to carry out surgery to implant the magnetic material which might be a risky 
procedure for the patients [65].  
Using an external magnetic field technique in cancer treatment is referred to as 
magnetic drug targeting. This approach constitutes the main focus of this study as will be 
discussed in the following section. 
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1.7 Magnetic Drug Targeting for cancer therapy 
 Overview 
Efforts to find efficient ways to deliver drugs to tumour locations have continued 
and recent research has seen the development of another promising technique called 
magnetic drug targeting (MDT). This technique can be applied in the delivery of drugs for 
the treatment of many different types of tumours [66]. MDT involves the delivery of 
anticancer drugs loaded with MNPs to the targeted area, i.e. tumours. These MNPs are 
controlled using external magnetic fields focused on the tumour [67]. This type of target 
directed drug injection attempts to concentrate the anticancer drug at the tumour site by 
enhancing its effectiveness and at the same time reducing unwanted side effects by 
preventing the targeting of healthy tissues and organs [68] [52] [69].  Unlike traditional 
methods such as chemotherapy, in this case, the anticancer drug is concentrated at the 
target cells away from the reticular endothelial system (RES) (Figure 1.7). The RES is 
known to sequester drugs from circulation preventing them from reaching their target 
location.  
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Figure 1.7: Comparison of traditional and MDT in the treatment of cancer 
(a) Traditional approach: anticancer drugs are injected into the bloodstream and most go to the RES organs, 
(b) MDT approach: most of the injected anticancer drugs reach the tumour. 
 
In MDT, an anticancer drug is attached to MNPs and injected intravenously into 
the patient, i.e. through the artery or vein [70]–[72]. These MNPs will circulate in the 
bloodstream, and once the external magnet is placed on the target area the MNPs will be 
directed towards the tumour. MDT can take place either before the MNPs pass through the 
liver (this is referred to as the first pass method) [67] [68] or after the MNPs have passed 
through the liver (commonly used approach) [63] [69] [70] depending on whether the 
MNPs have been injected through the vein or artery.  The MNPs will accumulate in the 
tumour and then release the anticancer drugs to destroy the tumour cells. In some cases the 
MNPs can be administered outside the blood flow; for example, in the treatment of inner 
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ear tumours, a small amount of gel containing MNPs loaded with anticancer drugs is 
placed either on the round window membrane [77] or intranasally [78].  
Research interest in the area of MDT started in the middle of the 20th Century. In 
1956 Gilchrist and others published a seminal paper focusing on the study of selective 
radiofrequency inductive heating of the lymph nodes after 20.100 nm sized MNPs were 
injected into the lymph nodes close to the location of the tumour, following surgical 
removal [79]. After that, Turner et al., combined this radiofrequency heating method with 
embolization therapy [80]. In 1965, Meyers found that these MNPs could be driven to the 
desired location by using an external magnetic device. From this, he came up with the idea 
of using this approach to target lymph nodes as well as using these small particles as a 
contrast agent. Therefore, MDT was first explored in 1965 when Meyers showed that 
small iron particles accumulated in the veins in the legs of a dog following intravenous 
injection, via application of an external magnet (horse shoe-shape) [81]. After that Hilal 
and others described how magnetic catheters could be used to deposit and selectively 
embolise arterio-venous malformations with small magnets [82]. In the 1970s and for the 
first time, spherical magnetic microspheres were made and worked well in an in vivo study 
using an animal model for tumour treatment as well as for magnetic resonance contrast 
agents [83][84]. They developed a technique of targeted hyperthermia to target rabbit 
kidneys. The heat was produced by magnetic hysteresis produced in small ferromagnetic 
microspheres subjected to a time-varying magnetic field. The results showed that by using 
such a technique, the 42 ⁰C therapeutic temperature threshold and above, could be reached 
in the target tissue [84].  Further research has continued to demonstrate that MDT is an 
efficient approach in the delivery of anticancer drugs to the target area. For instance, in a 
recent study by Price et al.,  it was demonstrated that MDT successfully delivered a 
chemotherapeutic drug loaded with iron oxide nanoparticles into the lungs in a mouse 
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model [85]. Of note, this was carried out in a healthy mouse model and the authors did not 
demonstrate any therapeutic effect of the chemotherapy in a tumour model.  
 The application of MDT in cancer treatment 
A number of research studies conducted to date have revealed that MDT has 
several applications in the treatment of cancer. Several anticancer drugs have been 
delivered using MDT as shown in Table 1.1. 
Drug Application Reference 
Mitomycin C (trimethylene carbonate (TMC) 
and 5,5-dimethyl trimethylene carbonate 
(DTC) ) 
Potential hepatic carcinoma 
therapeutics 
[86] 
Yttrium-90 (Human serum albumin) Bimodal radionuclide-
hyperthermia cancer therapy 
[87] 
Doxorubicin (albumin) Cancer therapy [88] 
Oxantrazole (chitosan) Cancer therapy (i.e. mouse 
hepatoma) 
[89] 
5-FLUOROURACIL (bovine serum albumin 
(BSA)) 
Tumour of hepatoma [90] 
Adriamycin (albumin) Cytotoxic effect on tumour 
cells (i.e. melanoma cells) 
[90] 
Vancomycin (starch) cytotoxic effect on tumour 
cells  
[91] 
Table 1.1: Examples of some drugs and their applications in MDT 
 
White blood cells (WBC) called ‘monocytes’ have also been used to magnetically 
target gene therapies and viruses to tissues including tumours [92] [93] [94]. In 2008, 
Muthana et al. showed that monocytes transfected with green fluorescent protein (GFP) 
successfully take up superparamagnetic iron oxide (SPIO) [92] and can be guided from 
circulation to superficial prostate tumours grown in the flanks of mice using an external 
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magnet placed above the tumour. They demonstrated a 3-fold increase in the number of 
tumour-infiltrating monocytes compared to in the absence of a magnetic field [93]. 
A further study by Muthana et al., reported that monocytes differentiated into 
macrophages and loaded with super paramagnetic iron oxide nanoparticles (SPIONs) were 
able to carry a cancer killing oncolytic virus (OV) to tumours located in the prostate of 
mice using pulsed magnetic field gradients in the direction of the tumour using a 
preclinical 7T MRI scanner [93]. The study reported that, by using such an approach, the 
number of OV-loaded macrophages increased in the target i.e. in primary and metastatic 
tumours in mice and tumour growth significantly decreased.  
MRI is used in clinics for diagnostic purposes, and recent in vitro studies show the 
success of MRI in targeting, this is known as Magnetic Resonance Targeting (MRT) 
[93][65]. This technique is used to magnetically steer the magnetised drug to the area of 
interest. In in silico models, researchers called this technique magnetic resonance 
navigation (MRN) where this is based on variation of a field gradient to steer/navigate 
MNPs in real-time to a target [95]. 
In an in vitro study, it was shown that MRI which produced a magnetic field 
gradient (12 T/m), was used successfully to manipulate and track agglomerates of 
superparamagnetic nanoparticles (micron sized) in real time. In this study 132 μl samples 
having 48 mg/ml MNPs in MilliQ H2O were used in a glass tube of 4.1 mm (ID) located at 
the iso-centre of the MRI magnet [96]. 
In an in vivo study aimed at targeting a tumour (Leukemia cells) using MDT, 0.2 
mL of Gemcitabine loaded with Fe3O4 /Chitosan was injected intravenously into each 
mouse [97]. An external magnet with magnetic strength of 1.1 T was used to direct the 
MNPs to the tumour site. The tumour (leukaemia cells) was first introduced into the mice 
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and left to grow in the upper part of right flank of the mice for six days after which the 
drug loaded with MNPs was injected into the mice. After 2 hours, an external magnet was 
placed on the tumour site and it showed that in treated mice the MNPs accumulated on the 
periphery of the tumour while no significant accumulation of MNPs was observed in the 
control mice. It was interesting to observe that when the magnet was placed on the tumour, 
the MNPs were trapped on the periphery of the tumour and when the magnet was 
removed, the MNPs diffused into the tumour. It could have been interesting if more details 
were provided about the magnetic device, i.e. the structure and the size as well as the time 
that the magnet was placed on the tumour site. However, the results from this study helped 
to confirm the efficiency of using a magnetic gradient to direct the MNPs into the target 
area, hence, the potential for using MDT in cancer treatment [94]. 
The first clinical trials in patients involving MDT were conducted by Lübbe et. al. using 
MNPs attached to epirubicin with patients who had facial tumours that could not be 
surgically removed [98]. They conducted a Phase I clinical trial using MDT in patients 
with advanced and unsuccessfully pre-treated cancers or sarcomas. It was concluded that 
the MNPs were successfully directed to the tumours in about one-half of the patients. In 
addition, no toxicity was reported to the organ tissues which means MDT is a safe 
technique to be used for cancer treatment. Although the reason why treatment did not work 
in the other half of the patients was not provided, the study made important conclusions 
that it appears that the effectiveness of the MDT treatment is still dependent on individual 
patients’ conditions and disease-related problems. The need to conduct a further study 
design aimed at comparing conventional treatments with the new treatment within one 
patient was cited as of crucial importance in order to get rid of the interindividual 
differences observed in the study. 
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Following the success of the Lübbe trials, more researchers have been motivated to 
explore further applications of MDT. For example, Pankhurst et al. has been investigating 
the use of MDT to deliver mesenchymal stem cells to sites of vascular injury in mouse 
models [99]. In the same vein, Häfeli et al. made use of implanted magnets located behind 
the cornea to collect stem cells for retinal regeneration [100]. Using MNPs combined with 
ultrasound, it has been possible to deliver therapeutics across the BBB [101]. Similarly, 
there has been a growing interest in the application of SPIONs in the delivery of thermal 
energy to tissues [99] [100]. This same technique has been used to generate targeted 
hyperthermia in prostate cancers [102]. In this thesis, focus will be placed on exploring the 
use of MDT in cancer treatment.  
1.8 Magnetic Nanoparticles for Drug Delivery   
MNPs have been utilised in different ways in the medical field. They are used for 
diagnostic purposes, i.e. as a contrast agent for MRI [104]. In addition, MNPs are used for 
therapeutic purposes, for example, drug delivery. The use of MNPs in drug delivery started 
in the late 1970s [105]. The structure and properties of the MNPs make them useful in 
biomedical applications and their use in drug targeting has been made possible by their 
magnetic properties which enable them to be directed to target areas using an external 
magnetic field. The materials that are commonly used for drug delivery contain metal or 
metal oxide nanoparticles (NPs) such as SPIONs. The SPIONs used for MDT should be 
coated with organic materials such as fatty acids, polymers or polysaccharides and this 
helps the attachment of the therapeutic agent or anticancer drugs [106]. 
There are many different magnetic materials that are commercially available, 
however, not all of them can be used for drug delivery in vivo because some of them are 
highly toxic, for example, cobalt and chromium. Iron oxides are relatively safe and are 
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currently being used as MRI contrast agents in the clinic [107]. The common iron-oxides 
include hematite (α-Fe2O3), magnetite (Fe3O4) and maghemite (γ-Fe2O3). They are 
different in their structure and this confers them different chemical and physical properties. 
Magnetite and maghemite are the commonly used magnetic materials in MDT because of 
their chemical and physical properties which include their high permeability and high 
resistance to corrosion as well as their stability under ambient conditions [108]. 
MNPs are materials of micron size [109] and many are available commercially 
including ferromagnetic (super-paramagnetic) nanoparticles (NPs), paramagnetic NPs and 
diamagnetic NPs. Ferromagnetic NPs are more preferable in biomedical applications 
because of their biocompatibility, low toxicity, affordability, high magnetic moment, 
availability and tunable cellular uptake [110] [65]. Unlike paramagnetic and diamagnetic 
NPs, ferromagnetic NPs show response to a magnetic force even after immediately 
removing the applied magnetic field [111] [112]. Ferromagnetic (super-paramagnetic) NPs 
can be classified into two types; Superparamagnetic Iron Oxide (SPIOs) or (Fe3O4) which 
are greater than 50nm in diameter and Ultra-small Superparamagnetic Iron Oxide 
(USPIOs) which are smaller than 50nm [113]. The most popular MNPs used in biomedical 
application are Fe3O4 SPIOs [112]. 
Different sized MNPs have been documented for both in vitro and in vivo studies; 
100 nm MNPs are typically used in human studies, including drug & gene delivery, and 
hyperthermia [112] and MNPs from 500 nm – 5 µm in size have been documented in 
animal studies [61]. The size of MNPs is a crucial parameter for reaching the target 
location without causing occlusion of blood vessels [114]. Large MNPs are useful as they 
resist the velocity of the bloodstream and hydrodynamic force that can be controlled by an 
external magnetic field. However, large MNPs can lead to aggregates forming in 
capillaries and other blood vessels, which can result in obstruction of the vessel and 
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occlusion of blood to tissues [114]. In contrast, it is difficult for MNPs in the micron size 
range to be controlled by a high magnetic field, as the velocity of the bloodstream is very 
high, enough to release the particle from the magnetic force and push them away [115]. In 
turn, a low gradient field can contribute to MNP aggregation even in case of small MNPs, 
due to the attractive forces between them. MNP aggregation can result in blood clot 
formation. Thus the size of MNPs is a crucial parameter that should be considered in MDT 
applications [116]. 
Coating of the MNPs is important for addressing the aggregation challenge, 
protection against corrosion and reduction of toxicity. MNPs are generally known to be 
highly reactive due to their high surface to volume ratio, hence the need to apply a coating 
to prevent corrosion. MNP materials should be coated to avoid the leaching of substances 
that can be potentially harmful to cells in vivo applications. In addition, coating is essential 
for the conjugation of the therapeutic agent to the MNPs. Different biocompatible 
materials are used to coat MNPs. These include polymers, activated carbon, silica or gold 
in order to prevent toxicity as well as reduce particle aggregation [112]. Apart from gold, 
because of its high cost [117], [118], different materials can be used for coating depending 
on the purpose or application. For example, for drug delivery: some polymers can be used 
for coating such as carbohydrates (dextran) [118], polyvinyl alcohol [119], for tumour 
targeting and MR imaging, starch [69] and proteins (e.g. albumin) [120] can be used and 
for immunoassay, lipids can be used [121]. It is important to take into account the 
application and the hydrophobic properties of the polymers, i.e. solubility in water and 
mechanical strength when selecting a suitable coating for the MNPs  [107] [119] [122].  
In order to enhance the attachment of the therapeutic agents to MNPs, organic 
linkers can be used. They also play an important role in controlling the release of the 
therapeutic agents. Examples of organic linkers include amine (-NH2), carboxylic acid (-
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COOH), aldehyde (-CHO) and thiol (-SH) [107]. The typical structure of a MNP is shown 
in Figure 1.8 below. 
 
 
Figure 1.8: The general structure of a MNP consisting of magnetic core, protective coating and the 
organic linkers which are attached to the therapeutic agent.  
 
Research into drug delivery has also revealed the potential of using other carriers 
such as naturally existing blood platelets and other biomolecules such as liposomes in 
delivering drugs in cancer treatment. For example, the body’s natural platelets have been 
shown to be carriers in the delivery of drugs to the targeted tumour due to their size and 
ability to penetrate the BBB [123]. For instance, studies revealed that a chemotherapeutic 
drug called doxorubicin was successfully attached to the natural platelets without 
disrupting the structure of the platelets, hence, the potential to deliver drugs without being 
destroyed by the body’s defence system [124] [125]. In addition, biomolecules called 
liposomes have been shown to have an ability to combine with several compounds 
including MNPs and therapeutic agents. As a result, liposomes can also be used as 
effective carriers in drug delivery for cancer treatment [126]. There are various studies 
focusing on the effectiveness of liposomes in drug delivery and the use of platelets, 
however, this is beyond the scope of the current study.  
Magnetic core 
Protective coating 
Organic linker 
Therapeutic agent 
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1.8.1 Application of MNPs 
MNPs have several biomedical applications and their use depends on 
biocompatibility and their level of toxicity. In turn, these features are determined by the 
nature of the magnetic materials used, the size of the composite nanoparticles including the 
core and the coating component. It is evident from the literature that MNPs’ application 
can be divided into two broad areas which include diagnosis and therapy. For example, it 
is well known that in diagnostic procedures, MNPs are used as contrast agents to enhance 
the quality of MRI images [127]. Apart from their role in the imaging of tissues and cells, 
the MNPs are also used for labelling and tracking individual cells [128]. In addition, 
MNPs play an important role in the delivery of therapeutic agents including drugs, genes, 
viruses and radionuclides, among others. The MNPs are able to combine and form 
complexes with the different therapeutic agents thereby facilitating their delivery into 
different sites. On the other hand, the delivery of the MNPs loaded with therapeutic agents 
can be driven by the use of an external magnetic field, i.e. MDT. Several examples of 
using MNPs in MDT applications have been widely discussed in literature. For example, 
MNPs can be conjugated with therapeutic viruses for gene delivery systems in cancer 
treatment [129]. In this case, the attachment of adenoviral particles to MNPs using an 
external magnetic field facilitates the protection of the virus from inactivation by the 
body’s immune system and delivery to the target area [130]. MNPs attached with 
therapeutic viruses have a transfection rate in vivo (of NIG-3T3 cells) that is 3-4 times 
higher than therapeutic viruses lacking MNP functionalisation [131]. This result, therefore 
provides the basis for the potential use of therapeutic viruses in clinical treatments [132]. 
Another example for the application of MNPs in drug delivery for cancer therapy was 
demonstrated in vivo by using iron oxide NPs loaded with a chemotherapeutic agent 
(DOX) which was delivered into the lungs using an external magnetic field. The results 
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indicated that the MNPs were effective carriers for the delivery of chemotherapeutic 
agents in cancer treatment [85]. 
Magnetic hyperthermia is one of the applications of MNPs in cancer treatment. 
This involves the generation of heat by exposing the MNPs to an external alternating 
magnetic field [133]. This technique has been used since 1957 by [79] who was able to 
heat several tissues using γ -Fe2O3 ranging between 20-100nm exposed to a 1.2 MHz 
magnetic field. The positive outcome of this study led to the development of other models 
by other researchers which are being used up to the present day [134]–[136]. In general, 
this technique involves introducing the MNPs in the target area followed by the heating of 
these particles by applying an alternating current magnetic field. Heat is generated at a 
temperature of 42˚C (above the therapeutic threshold) and should be kept in place for at 
least 30 minutes to ensure the destruction of cancerous cells. Magnetic hyperthermia has 
the advantage of ensuring that the generated heat is focused on the targeted cells, hence, 
does not cause the damage of healthy cells. Figure 1.9 below provides a summary of the 
biomedical applications of the MNPs.  
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Figure 1.9: The main applications of MNPs 
 
1.9 General Physics principles of applying external magnetic 
field on MNPs. 
An applied external magnetic force on MNPs with a hydrodynamic fluid flow is 
considered in this scenario. 
Three main forces are considered when a magnetic force is applied, these include; 
blood advection forces induced by blood plasma convection, magnetic drift induced by the 
applied magnetic field and diffusion forces induced both by Brownian diffusion [137] and 
the scattering effect that colliding and shearing red blood cells have on MNPs. 
Before describing the three main forces, it is worth mentioning the magnetic field 
first. 
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1.9.1 Magnetic field 
A magnetostatic field is described best by Maxwell’s equations as follows [137];  
(Bold letters indicate vector quantities). 
𝛻 × 𝑯 = 𝑱     Equation 1.1 
𝛻.𝑩 = 0     Equation 1.2 
𝑩 =  𝜇°(𝑯 + 𝑴) = 𝜇°(𝑯 + 𝑥𝑯)  Equation 1.3 
Where,: 
 ∇ : gradient operator [units/m] 
 ?⃑?  : magnetic field [T] 
 ?⃑?  : magnetic intensity [A/m] 
  𝑗  : current density [A/m2 ] 
 ?⃑⃑?  : material magnetization [A/m]  
𝑥: magnetic susceptibility 
 𝜇° : permeability of a vacuum 4𝜋 × 10
−7 N/A2.  
However, in this thesis only the magnetostatic field was considered as a permanent 
magnet was used. Hence, the magnetic field was calculated and plotted using FEMM 
software which is useful for magnetostatic problems.  
1.9.2 Magnetic forces on MNPs 
A ferrofluid consists of many magnetisable MNPs, which are mainly 
superparamagnetic. This means that MNPs are strongly magnetised in the presence of an 
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external magnetic field and then lose their magnetisation once the magnet is removed. 
Neglecting particle-to-particle interactions, which are small due to particle reorientations 
and anti-aggregation coatings, the magnetic force acting on each MNP under the effect of 
external magnet is given by 
𝑭𝒎 = (𝒎 ∙ ∇) 𝑩                               Equation 1.4 
Where (m) is the magnetic dipole moment of a MNP. 
By assuming that the applied magnetic field is only acting in the y-axis, Eq 1.4 can be 
written as; 
 𝑭𝒎,𝒚 = 𝒎 
𝑑𝐵
𝑑𝑦
= 𝑉𝑚 𝛥𝑥 𝑩 
𝑑𝐵
𝑑𝑦
 
                                                𝑭𝒎,𝒚 =
𝑉𝑚 𝛥𝜒
𝜇°
 (𝑩. 𝛻) 𝑩                     Equation 1.5 
 𝑉𝑚 is the volume of the magnetic particle. In cases where a cell or anticancer drug 
is loaded with multiple MNPs and an aggregation of MNPs exists, the particles will 
generally behave as a single MNP.  
Δχ is the relative magnetic susceptibility of the particle. This can be interpreted as a 
relationship between the induced magnetisation and the strength of the inducing field and 
this unique characteristic can be calculated for each type of MNPs in a given 
configuration. In MDT procedures, the amount of force that can be applied on the MNP is 
directly proportional to Δχ, and this is the difference between the magnetic susceptibility 
of the particle and that of the external medium. Given that the normal biological tissue and 
fluids such as the blood have magnetic susceptibility that is usually negligible in 
comparison to the MNP, Δχ is equivalent to the magnetic susceptibility χ of the particle. 
The external magnetic field and its spatial variation (magnetic field gradient) is 
expressed by the vector product with the gradient operator, (B∙∇) B. The amount of force 
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that can be applied to a magnetic particle is proportional to the field strength, and this is 
true up to field strengths that approach the saturation magnetisation for a given particle 
(typically 0.5 <B< 1.0 T). The field strength depends on the strength of the magnetic 
device as well as the distance between the magnetic device and the MNPs.  
It is worth mentioning that the magnetic force unit that was used in this study is 
T2/m. This is for two main reason; 1) magnetic field strength was measured in Tesla, 
hence, field gradient was measured in T/m. Therefore, it was more convenient to measure 
magnetic force in T2/m. 2) to convert from T2/m to Newton it is required to know the 
actual volume of MNPs where this was not the main interest of this study. In the simulated 
Halbach models (using FEMM) the main interest was to measure the strength of the 
magnet at different distances where no MNPs was included, so the unit of the magnetic 
force that was used is T2/m. For the rest of the experiments, the major interest for this 
study was to see trapping of MNPs at different distances, thus, the volume of MNPs was 
not calculated and is difficult to predict. Thus, using T2/m as a unit of magnetic force was 
more convenient for this study and used for consistency throughout the thesis. However, 
we showed the relationship between MNPs size and magnetic force in Figures 1.9 and 3.3.  
In the case of applying an external magnet to the MNPs flowing inside a single 
vessel, the following forces were considered; 
1.9.3 Magnetic drift velocity (Stokes drag force) 
When MNPs flow in the blood stream, the magnetic force described in Eq 1.5 is 
applied. MNPs will accelerate in the direction of this force until an equilibrium velocity 
(VR) is reached. The opposing force on a spherical MNP, which is called the Stokes drag 
force [138], is given by 
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𝑭𝑫 = 6𝜋𝑎𝜇𝜂𝑽𝑹    Equation 1.6 
Where  
       α: radius of the particle [nm] 
𝜂 : the dynamic fluid viscosity [kg m/s].  
      𝑽𝑹: equilibrium velocities [m/s] 
When both forces, 𝑭𝒎 and 𝑭𝑫  are equal, then the MNP has reached its equilibrium 
relative velocity; 
 𝑭𝒎 + 𝑭𝑫 = 0                                  Equation 1.7 
 
MNP size plays a major role in MDT, Figure 1.10 the relationship between 𝑭𝒎 , 𝑭𝑫   and 
MNPs size under the effect on magnet. 
 
 
Figure 1.10: The behaviour of MNP; no magnet –left, side and under magnetic force (Fm) and drag force 
(FD)- right side.  
 
 
Chapter One 
- 38 - 
 
1.9.4 Advection force 
In any fluid flow, the fluid velocity profile in a tube or channel is curved. The 
highest value of the fluid velocity is at the centreline while zero value is found at the walls. 
This is because of a no-slip boundary condition. An example of this is water, where the 
curved shape is parabolic (Newtonian fluids). On the other hand, blood is a non-Newtonian 
fluid which is described as having plug flow. This is due to the clotting protein fibrinogen 
[137]. The fluid velocity of such flow can be expressed as; 
𝑣𝐵⃑⃑ ⃑⃑ =  𝑣𝐵𝑚𝑎𝑥  (1 −
𝑟
𝑅
)    Equation 1.8 
Where 
 𝑣𝐵⃑⃑ ⃑⃑ : the blood velocity in [m/s] 
 𝑣𝐵𝑚𝑎𝑥 : the maximum centerline velocity [m/s] 
 r: the radial location [m] 
 R: the radius of the vessel [m] 
 
1.9.5 Diffusion forces 
There are two main types of diffusion that occur for MNPs within a blood vessel, 
including Brownian thermal motion and particle scattering due to collisions with blood 
cells. 
Brownian thermal motion refers to the random motion of MNPs under the action of 
thermal fluctuations and is calculated by a diffusion coefficient 
𝐷𝐵 = 
𝐾𝐵𝑇
6𝜋𝜇𝑎
                          Equation 1.9  
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Here, 𝐾𝐵 is the Boltzmann constant and T is the absolute temperature.  
When blood cells collide with MNPs this causes particles to scatter, which can be 
considered as further diffusion. The coefficient of scattering for diffusion (𝐷𝑆) is in the 
range 10−11 − 10−10m2/s [137]. 
The overall MNP diffusion is thus described as the sum of Brownian and scattering 
diffusion; 
𝐷𝑇𝑜𝑡𝑎𝑙 = 𝐷𝐵 + 𝐷𝑆                Equation 1.10 
Particle size and vessel radii affect the diffusion of nanoparticles. The largest 
diffusion coefficients occur in large vessels (arterioles and arteries) whereas cell scattering 
effects are high for small particles where Brownian diffusion is large. The smallest 
diffusion coefficients occur in small vessels (capillaries) where scattering effects are 
negligible and with large particles where Brownian diffusion is low. The typical range of 
total particle diffusion coefficients in humans is between  1 × 10−14 and 6 × 10−10m2 /s 
[137]. 
1.10 Challenge of using MDT in brain tumour treatment 
There are several advantages associated with the use of MDT in biomedical 
applications. This includes the high level of precision in terms of delivering drugs to the 
target region resulting in the destruction of cancerous cells only without affecting the 
surrounding healthy cells [139]. However, the use of MDT is limited by a number of 
factors including lack of thorough understanding of how the MNPs interact with cells as 
well as their overall transportation in the human body [140] and the fact that the MNPs 
will be left permanently in the target tissues constituting the threat of causing long term 
side effects [141]. Although MRI is a powerful tool that can be used in MDT, its downside 
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is that it is large in size, meaning that there can be problems surrounding its portability and 
cost feasibility/effectiveness of the device is a major concern. In an effort to address the 
challenges associated with the use of MRI, the use of single permanent external magnet 
has been considered as an alternative. However, their weak magnetic field (range between 
0.1-0.5T) makes it difficult to target deep tumours, i.e. brain tumours.  
To address the cited limitations of single permanent external magnets, developing 
such magnets using the Halbach array technique has become an interesting area for many 
researchers. The following section discusses the development of Halbach array techniques 
for MDT and this is the focus of this thesis. 
1.11 Halbach 
As mentioned earlier, permanent magnets have been used in the design of MDT 
devices, however, they are limited in terms of treating deep tumours due to their weak 
magnetic strength. As a result, researchers have been exploring how the permanent 
magnets can be developed to produce stronger magnetic field to enable the treatment of 
deep cancers. Klaus Halbach discovered a way of arranging the permanent magnets to 
produce a strong magnetic field and his design became known as the Halbach array [142]. 
A Halbach array refers to a specific arrangement of permanent magnets which are 
equal in size, shape and magnetic flux property [143]. The array has a spatially rotating 
magnetisation pattern, which results in weakening the magnetic field on one side of the 
array, while boosting it on the other side, by at least a factor of 1.2 compared to other 
conventional permanent magnet arrays. The strong magnetic field is due to the 
superposition of field lines generated by the individual magnets. Figure 1.11 illustrates an 
example of a Halbach array model that shows the magnetisation orientation pattern which 
induces a strong magnetic field on one side. Due to the Halbach array properties, that is a 
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magnetic field on one side, lightweight, portable and inexpensive, makes Halbach arrays 
the best choice for this project (MDT).  
 
 
Figure 1.11: Halbach array pattern-left side and generated magnetic field-right side. 
 
 Halbach array design has been used extensively in industrial applications and 
researchers have also explored its use in biomedical applications. This thesis focuses on 
the development of Halbach arrays for cancer treatment. In this section, reference will be 
made to the historical development of Halbach array models and designs and specific 
studies involving the application of Halbach arrays in MDT. 
The development of Halbach array magnetic devices has led to various studies 
including in silico, in vivo and in vitro. In general, most of the studies have been conducted 
in silico as a basic step towards the development of Halbach arrays to be used in MDT 
[144] [145] [146] [116]. 
In silico 
A study conducted by Baun and Blumler aimed at the development of a Halbach 
array design to be used for guiding SPIONs [147]. They modelled Halbach arrays in 
Strong 
Weak 
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FEMM to generate a magnetic field of 0.5T. Their model consists of two layers of magnets 
in a Halbach cylinder shape (Nd2Fe14B), the inner layer had 16 magnets, in a dipole 
configuration and these were surrounded by 8 magnets in a quadrupole configuration. The 
whole model with an overall mass of 9kg was assembled and tested in the lab to steer 
SPIONs by mechanical rotation. It was considered that the model developed in this 
particular study was unsuitable for the present study because of the large size and low 
magnetic field which cannot adequately steer MNPs to deep target areas. 
 Barnsley et al. compared the effectiveness of Halbach arrays and other permanent 
magnet designs in steering SPIONs to target areas. This was achieved by developing a 
mathematical model in order to simulate the trajectory of the SPIONs as well as the effect 
of Halbach arrays and other permanent magnets on the trajectory of the particles. The 
study results indicated that Halbach arrays were more effective in directing SPIONs to the 
target areas compared to other permanent magnet designs [148]. 
The Halbach array design should produce a strong magnetic field and field gradient 
in order to trap MNPs in MDT. In a study conducted by Odenbach, this was demonstrated 
using a flow phantom with a half-Y branched tube design. The main tube represented the 
artery from which a tumour supplying artery was simulated by side branches[149]. The 
behaviour of the MNPs was affected by the viscosity of the magnetic suspension, and on 
the other hand, the viscosity was affected by the magnetic field strength. When the 
magnetic field was stronger, more MNPs were trapped by the magnet in the side branch 
closer to the magnet. 
In vitro 
Researchers have been exploiting Halbach array designs to develop portable 
magnets that can be used in MDT at relatively deep positions in the body. In a study by 
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Kopcansky et al., a Halbach array magnet consisting of 36 pyramidal shaped magnets was 
constructed with a magnetic field strength of 0.38T which reached between 1.5 to 2cm 
deeper than the simple classical prism permanent magnet (where no different magnetic 
orientations are set) [150].  
In another study by He et al. a portable Halbach array magnet was developed using 
three permanent blocks, each measuring 5cm × 4cm × 4cm [151]. The orientation of the 
magnets was as follows, the magnetisation of the middle magnet was directed at 900 while 
the magnetisation of the two magnets on the sides was directed at 00 and 1800 respectively. 
As a result, the magnetic strength generated in the middle of the magnet was 1.26T at 0 cm 
and 0.28T at 3cm away from the magnet. Although the design generated a relatively good 
magnetic field strength, its downside was the overall large volume making it difficult to be 
applied to patients for MDT. Also, its configuration requires use of other materials, for 
example, the use of screws to keep the magnets in place which can be a challenge when 
assembling the device. 
In vivo 
A few studies have been conducted in vivo to evaluate the effectiveness of Halbach 
arrays in MDT. One of the studies demonstrated the use of an external Halbach array 
magnet helps to facilitate the movement of MNPs to the target site [152]. In their study, 
magnetoliposomes were administered intravenously into a rat-tail and an external magnet 
with magnetic field strength of 0.35T was placed on the right kidney of the rat. For 
comparison purposes, no magnet was placed on the left kidney. The results showed that 
magnetoliposomes were retained in the right kidney and this provided evidence that use of 
a Halbach array external magnetic field was effective in terms of guiding the MNPs to the 
target site. 
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1.12 Project Hypotheses 
Brain tumours constitute one of the major medical challenges in today’s world. 
They can affect people of any age including children; however, they are more common in 
older adults.  
Survival rates are higher in young people compared to old adults. Different 
treatment methods including chemotherapy and radiotherapy have been explored, 
however, it has been shown that brain tumour treatment using these traditional methods is 
not always effective. The use of external magnets to guide the MNPs loaded with drugs is 
a promising alternative treatment method, however, studies have shown that it is difficult 
to target brain tumours at a further depth. There is, therefore, a need to explore alternative 
ways of increasing the magnetic field strength to ensure that magnetised chemotherapeutic 
agents can be directed to deeper brain tumours.  
In this thesis, we hypothesise that an inexpensive, portable, powerful and external 
Halbach array could be designed, modelled and simulated to be used for MDT with the 
purpose of targeting tumours, such as brain tumours at depths of between 5cm or greater. 
1.13 Research aims and objectives  
We used in silico and in vitro modelling to design, build and evaluate Halbach 
arrays for generating magnetic field gradients and forces to target brain tumours. The 
ultimate goal is to generate a personalised magnetic treatment plan based on MRI scans for 
patients with deep tumours.  Figure 1.12 below illustrates the general goal of using a HA 
in MDT. 
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Figure 1.12: Sketch of general aim of Halbach array. 
 
This project is pre-clinical, so in line with the stated goal, a number of steps and 
procedures were followed as highlighted in the four experimental chapters indicated 
below:  
Chapter 3 
The aim was to develop Halbach arrays models using FEMM software with a view 
to identifying the most effective model for brain tumour treatment. The following 
objectives were formulated: 
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 To calculate the magnetic force required to trap MNPs with different sizes 
using Lua scripting. 
 To develop and optimise Halbach array models in order to obtain the highest 
magnetic field/field gradients to reach a maximum target depth. 
 
Chapter 4 
The aim was to assemble Halbach array models which were simulated in FEMM in 
chapter 3 and to evaluate their potential effectiveness for MDT in brain tumours treatment 
by measuring their magnetic field strength, field gradient and magnetic force at different 
distances. The following objectives were formulated:   
 To assemble Halbach array magnets based on the FEMM models. 
 To measure the strength of magnetic field using a Gaussmeter (GM 08, HIRST, 
Magnetic instruments Ltd), as well as to calculate the field gradient and 
magnetic force for each layer of each model at different distances. 
 To optimise the selected Halbach array magnet for the MNP trapping 
experiment with a 3D tumour/head phantom model. 
 To determine the maximum depth where the tumour could be located within the 
brain using the 3D head/tumour phantom model.  
 
Chapter 5 
The aim of this chapter was to demonstrate the ability of the Halbach array of 
model 2 to trap different concentrations of SPIONs (Fe3O4) at different distances.  The 
following objectives were formulated: 
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 To use a 3D printed phantom flow model with plastic and bio-phantom tumours 
to assess the trapping ability of SPIONs at different distances 
 To use a custom-made vasculature model to investigate the amount of time 
required for the SPIONs to be trapped within the vasculature tubing and how 
long the SPIONs remain trapped in the target area after removing the Halbach 
array magnet. 
 To apply different techniques including magnetic resonance image (MRI), 
inductively coupled plasma microscopy (ICP) and nuclear magnetic resonance 
(NMR) to assess iron trapping within the models.  
Chapter 6 
The aim of this chapter was to evaluate the uptake of SPIONs and the viability of 
the brain cells and brain tumour cells following uptake. In line with this, the formulated 
objectives were: 
 To use transmission electron microscopy (TEM) to assess the SPION size and 
evaluate the intracellular uptake of SPIONs in the cells.  
 To assess cell viability following incubation of the different cell types with 
SPIONs for 24h. Flow cytometry was used to measure cell death using 
Propidium iodide (PI). 
The above section summarises the aims and objectives of all the experimental 
chapters. The other chapters, for example, chapter 2 focuses on the discussion of the 
materials and methods employed in the study, and chapter 7 presents the summary of the 
key findings and highlights the potential areas for further studies. 
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2.1 Materials  
List of reagents 
Reagent Company 
Absolute Ethanol  Thermo Fisher Scientific 
Acetone Thermo Fisher Scientific 
Astrocyte Growth Supplement ScienCell 
Basal medium ScienCell 
Collagen IV Thermo Fisher Scientific 
DAPI staining solution Lonza BioWhittaker Ltd 
Dimethyl Sulfoxide (DMSO)  Sigma Aldrich 
DPX Mounting medium  Sigma Aldrich 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
Ultraglutamine, 4.5g/L glucose Lonza DMEM 
medium 
Lonzo BioWhittaker Ltd 
Eosin  Sigma-Aldrich 
Eosin Y  Thermo Fisher Scientific 
FACS buffer Lonza BioWhittaker Ltd 
Ficoll-Paque   Sigma-Aldrich 
Human AB serum Lonza BioWhittaker Ltd., 
Wokingham, UK 
Hydrochloric acid Sigma Aldrich 
Immune-mount Sigma-Aldrich 
Iscove’s Modified Dulbecco’s Medium (IMDM)  Lonza BioWhittaker Ltd 
L-Glutamine (4mM) Lonzo BioWhittaker Ltd 
Nitric acid Sigma Aldrich 
Nuclease free water  Qiagen 
Paraformaldehyde  Sigma Aldrich 
phosphate buffered saline (PBS)  Thermo Fisher Scientific 
Phosphate Buffered Saline (PBs) Lonzo BioWhittaker Ltd 
Propidium iodide (PI) Thermo Fisher 
ProLong Gold Antifade mountant  Invitrogen 
Potassium Ferranocyanide  Sigma Aldrich 
Super PAP pen  Thermo Fisher Scientific 
Trypan blue  Sigma-Aldrich 
Trypsin/EDTA Lonzo BioWhittaker Ltd 
TO-PRO-3 Thermo Fisher 
 
List of materials 
Material Supplier 
Bio tumour phantom PureImagingPhantom 
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Block of steel Magnet Expert Company, UK 
Coverslips Scientific Laboratory Supplie 
Cytospin slide champers Thermo Fisher Scientific 
Falcon tube Thermo Fisher Scientific 
IRON (III) OXIDE Sigma-Aldrich 
Loctite Control Super Glue Adhesive First4Magnets 
Masterflex® L/S® Series Peristaltic Pumps Cole-Parmer 
Neodymium Iron Boron (NdFeB)-grade N52 Magnet Expert Company, UK 
Silicon tubing Fisher Scientific UK Ltd 
Superflex clear sealant Fisher Scientific UK Ltd 
Superfrost Plus Microscope Slides Thermo Fisher Scientifi 
Steel sheet of 30 Magnet Expert Company, UK 
Syringe pump Master Dual Pump,WPI 
Tissue culture flasks (Nunc EasYFlask) 25cm2; 75cm2; 
125cm2 
Thermo Fisher Scientific 
Vials, Bijou; Polypropylene Fisher Scientific UK Ltd 
3D tumour/head phantom Advanced Manufacturing 
Research Centre (AMRC), 
Sheffield, UK 
 
List of equipment and Apparatus 
Equipment and apparatus Company 
Automated Cell Counter BIO-RAD 
Bench centrifuge SANYO 
Compound light microscope Olympus 
Cytocentrifuge Thermo Fisher Scientific 
FACSCalibur Becton Dickinson 
Gaussmeter (GM 08) HIRST Magnetic instruments Ltd 
Inductively coupled plasma atomic emission 
spectroscopy (ICP-AES) 
SPECTRO 
Incubator SANYO 
Laminar airflow hood Heraeus 
Light microscopy  Leica DM1000 
Micropipette Eppendorf 
Nikon A1 Confocal  Nikon 
Pipetboy Integra 
Refrigerator BioCold 
Sensitive balance Sartorius 
Transmission Electron Microscopy (TEM)  FEI Tecnai Biotwin 
Water bath Grant 
3T MRI GE Healthcare, Milwaukee, USA 
9.4T NMR Bruker BioSpin, Coventry, UK 
 
Chapter Two 
- 51 - 
 
List of cell lines 
Name Provided by Original resource 
Human astrocyte cells (HA) Dr.Claire Garwood, SITraN, The 
University of Sheffield 
ScienCll 
Human Brain Microvascular 
Endothelial (hBMVEC/D3) 
Dr. Julie Simpson, SITraN, The 
University of Sheffield 
 
Cedarlane, Canada 
Human brain tumour cells 
(U138MG) 
Dr.Spencer Collis, 
Oncology and 
 Metabolism, The 
University of Sheffield. 
 
ATCC 
 
List of commercial kits 
Kit Company 
AM kit ScienCll 
EGM-2 MV bulletkit  Lonzo BioWhittaker Ltd 
 
List of software 
 
2.2 Methods 
2.2.1 FEMM modelling 
Finite Element Method Magnetics (FEMM) is a finite element software bundle 
used for solving 2D planar in low frequency magnetics and electrostatics problems 
(http://www.femm.info/wiki/HomePage). The bundle consists of an interactive shell 
encompassing graphical pre- and post-processing and includes a mesh generator and 
various solvers. In addition, a scripting language, Lua 4.0, is integrated with the 
Software Supplier 
Excel  Microsoft office 2018 
Fiji https://imagej.net/Fiji [184] 
Finite Element Method Magnetics (FEMM) http://www.femm.info/wiki/HomePage 
GraphPad Prism 7 Graph Pad Inc. 
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programme. Lua was used to create batch runs of SPIONs. In this project, FEMM was 
used to model Halbach array magnets of 1 cm3 with different magnetisation orientations 
and Lua scripting was used to run the simulation of SPIONs movement under the effect of 
magnetic force.    
To create a FEMM model; firstly, the magnetic problem option was selected. Then, 
the type of problem was selected as axisymmetric. In order to draw the model graphically, 
the nodes mode was also selected to start drawing the model at a desired size, e.g. 1 × 1cm. 
Then each node was connected using segment lines. After that, the material type of the 
magnet was defined, for this study - a Neodymium-Iron-Boron-N50 magnet. It was 
important to draw the model within a defined boundary to create magnet flux density plots. 
In this model, “air” was selected as the material type of the boundary. Once the model was 
completed “mesh” was run to ensure that each magnet in the model was included in the 
simulation. Finally, the simulation of the model was run and the model was then ready for 
analysis by plotting the flux density. The details of each model are discussed in chapter 3.    
2.2.2 Halbach array assembly 
Next the Halbach array was assembled based on the FEMM models. Each magnet 
was placed on a steel sheet of 30 × 30 cm, which was used to hold and keep the magnets in 
place. An adhesive super glue (Loctite Control Super Glue Adhesive), was used to stick 
the magnets together. After gluing two magnets, a block of steel was placed on top of the 
glued magnet faces to hold them together for several hours (between 7 and 24h). After 
that, the steel block was removed and the next magnet placed in position. This process was 
repeated until the assembly was complete. The strength of the magnetic field was 
measured using a Gaussmeter (GM 08). The Halbach arrays were then used to assess their 
ability to trap SPIONs at different distances.  
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2.2.3 Trapping SPIONs in a flow fluid system using Halbach 
arrays  
2.2.3.1 Flow model of 3D tumour/head phantom 
To test the ability of the Halbach arrays to trap SPIONs, a 3D phantom flow model 
was made by Advanced Manufacturing Research Centre (AMRC), University of Sheffield, 
UK. A 3D head was printed based on optical and MR scan data, which geometrically 
mimics the surface of the head of a patient. Tumours were also printed, these were made of 
a plastic synthetic polymer and were approximately 3 cm in diameter (typical of a human 
brain tumour) [153]. The tumours had a complex network on the inside and had an inlet 
and outlet for connecting to a flow system using plastic tubing of 1 mm diameter. A 
peristaltic pump, infusion rate of 10ml/min (Master Dual Pump, WPI) was used to pump 
SPIONs (Fe3O4) through the tumour. The SPIONs were pumped through silicon tubing of 
1mm internal diameter, which was connected to the tumour using a Superflex clear sealant. 
The tumour was designed so that it could be placed at different distances underneath the 
3D printed head i.e. 0, 5 and 10cm away from the head to mimic the potential locations of 
the tumour within the brain. A Halbach array was then placed on top of the 3D printed 
head in order to trap SPIONs in the tumour. A range of SPION concentrations was used 
including 0.1, 1, 5, 10, 20 mg/ml. The experiments were performed in two parts; the first 
part was to flow SPIONs with different concentrations. Additional techniques were used to 
validate the trapping of SPIONs such as 3T MRI, T2* and ICP. See Figure 2.1 for a 
schematic. 
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2.2.3.2 Flow model 3D Bio-phantom tumour  
A Bio-phantom model was used to mimic a brain tumour where the tumour tissue 
was made from a unique composition of an ultra-soft urethane based rubber developed by 
Pure Imaging Phantoms (UK). The material is realistic in terms of ultrasound and 
mechanical properties and suitable for medical imaging such as ultrasound, MRI and CT. 
The components of the tumour phantom were designed using a computer-aided 
design software (CAD) based on real anatomical models extracted from MRI scans of 
actual patients. The models were then used to 3D print moulds which were later used to 
cast the tumour and the entire phantom. The advantage of this model is that it is suitable 
for MRI scans where the T1 and T2 values were mimicked. This was achieved by applying 
a solid homogeneous piece of material that had MR properties close to the average 
properties of human brain tissue. The tumour used also had a complex network from inside 
and had two inlets to be connected to the flow tubes. 
SPIONs in a tube 
Pump 
Flow direction      
Tube 
Magnet 
3D printed head 
3D printed tumour 
with holder 
Matrix grid 
Collected SPIONs  
Figure 2. 1: 3D phantom flow model- Plastic tumour model 
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To create a flow model, the tumour was connected to plastic tubing of 1 mm 
diameter which was the size of the tumour inlets, and then it was attached to the main 
tubing model - U shaped plastic tubing of 3 mm diameter creating a complex vasculature 
model using a Superflex clear sealant (Figure 2.2). This model was connected to an 
advanced peristaltic pump from Cole-Parmer (Masterflex® L/S® Series Peristaltic Pumps, 
model # 77200-62). This pump was able to infuse the flow at 150 ml/min to mimic the 
blood flow rate in human vessels. A Halbach array was placed on top centre of the 
complex tubing model, which had 3mm internal diameter. The tumour was located 5 cm 
away from the magnet. SPIONs of 5mg/ml were pumped through the model using a pump 
at 150 ml/min speed of rate. The aim of this experiment was to assess the MNP trapping 
ability of our Halbach array and to image the trapped SPIONs using a 9.4T MRI. 
 
 
Pump 
3D bio-phantom tumour 
Magnet 
SPIONs in a tube 
Figure 2. 2: 3D phantom flow model- Bio-phantom tumour model 
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2.2.3.3 3T MRI 
The trapped SPIONs in the 3D printed plastic tumour phantom was visualized 
using a dedicated 3T neonatal MRI, located in the Neonatal Intensive Care Unit, Jessop 
Wing, Sheffield. The images were scanned using a dual gradient echo sequence (TE= 
4.60ms, 20ms) to measure T2* as described below.   
2.2.4 MNP quantification 
2.2.4.1  MRI 
The trapped SPIONs in the bio-phantom tumours were visualized using a 9.4T 
(400MHz) NMR, which was operated by a Research Fellow Dr. Steven Reynolds.  
2.2.4.2 T2* 
In MR images, T2* relaxation time refers to the decay of transverse magnetisation caused 
by spin-spin relaxation due to magnetic field inhomogeneity. Accurate measurements of 
T2* in the presence of macroscopic magnetic field inhomogeneity is problematic due to 
signal decay resulting from through-slice dephasing. The two-point method used here, that 
is, the in-phase and opposed-phase MR imaging allows reliable measurements of T2*. This 
approach allows the signal decay due to through-slice dephasing to be characterised and 
removed from the data thereby facilitating an accurate measurement of T2* even at very 
high magnetic field. However, it is worth bearing in mind that the method has got its 
limitations. For instance, other factors such as large voxel size and increased field 
strengths can increase the T2* sensitivity of the sequence. Both of these factors cause more 
dephasing that is due to susceptibility effects. When compared to the three-dimensional 
GRE sequences, two-dimensional GRE sequences are more sensitive to the deleterious T2* 
effects from air-tissue interfaces or implants because of the thicker sections (and generally 
larger voxel sizes) used in two-dimensional imaging. In addition, change in oxygen 
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saturation during specific tasks changes the local T2* which leads to the blood oxygen 
level-dependent effect seen at functional MR imaging [154]. 
 Iron (SPIONs) in tumours were quantified by measuring the ratio of the signal 
intensity (SI) in images acquired with different echo times. In order to calculate T2* of 
SPIONs in the 3D plastic tumour model, a contour was drawn over the tumour on one 
image and copied to the other echo. The mean value of both region of interests (ROIs) 
were taken to do the calculation  [155]. The signal intensity ratios (SIRs)-pixel values were 
extracted from the same region of interest from each tumour for scans with two different 
echo times i.e. TE 4.60 ms and TE 20 ms. This was applied for each tumour with the 
different SPIONs concentration. The following equation was applied to calculate T2*; 
𝑇2∗ =
−∆𝑇𝐸
ln (
𝐼𝑇𝐸2
𝐼𝑇𝐸1
⁄ )
 
Where  
𝐼𝑇𝐸2
𝐼𝑇𝐸1
⁄  is SIRs of TE2 20 ms and TE1 4.60 ms respectively. 
2.2.4.3 Inductively coupled plasma Atomic Emission Spectrometer (ICP-
AES)  
Inductively coupled plasma atomic emission spectroscopy (ICP-AES) was used to 
measure the concentration of trapped SPIONs. The technique was carried out by Mr Neil 
Bramall in the Faculty of Science Mass Spectrometry Centre in the Department of 
Chemistry. In general, ICP is an analytical method for chemical analysis of elements. 
When the element is ionised in the ICP process, electromagnetic radiation is created at 
specific wavelengths. Therefore, the concentration of each element can be measured by 
measuring the strength of the emission. A Spectro-Ciros-Vision Inductively Coupled 
Plasma Atomic Emission Spectrometer ICP-AES was utilized to calculate the quantity of 
Fe as a ratio of metal ions for the SPIONs used in this project. Different MNP 
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concentrations were dissolved in Aqua Regia (King's water a mixture of concentrated 
nitric and hydrochloric acids (HCL) at a molar ratio of 1:1 of nitric acid and HCL. 1ml of 
the SPION sample was added to 1ml of Aqua Regia solution and diluted in 8 ml of dH2O. 
The samples were kept for 24 hours before ICP. Fe content (mg/l) was determined from 
atomic absorption [156].  
2.2.5 White blood cell isolation 
The Sheffield Blood Transfusion Service supplied human platelet-depleted waste 
buffy coats, this was under the ethics of Dr Munitta Muthana (SMBRER 139). In these 
experiments we wanted to mimic SPIONs as though they were in circulation. Red blood 
cells were not used as these coagulate, however white blood cells (WBCs) survive better in 
culture [157].  
In order to isolate WBC, Ficoll density gradient centrifugation was carried out. To 
do this, 20ml of blood was diluted with 30ml of PBS in a 50 ml falcon tube. Then, 30 ml 
of diluted blood was carefully pipetted onto 20 ml of Ficoll-Paque. The mixture was 
centrifuged at 1400 rpm with the brake off for 40 minutes. As a result, 4 layers were 
formed including Plasma, WBCs “creamy layer”, Ficoll and red blood cells. After that, 
WBCs that were isolated by pipette and washed twice in PBS. After the centrifugation, 
complete medium consisting of IMDM medium supplemented with 2% human AB serum 
and 4mM L-Glutamine was used to re-suspend the cell pellet. To count the cells, a 
haemocytometer cell count machine (Bio-Rad) was used. This eliminates any 
contaminated red blood cells from the cell count. Finally, 300,000 cells were seeded with 
2ml of complete medium into a 6 well-plate and incubated for 24 hours at 37⸰C, 5% CO2 
[157]. After 24 hour incubation time, SPIONs of required concentrations i.e. 0.1, 1, 5, 10, 
20 mg/ml were added to WBCs in each well and kept in the incubator for 24 hour prior 
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use. WBC-loaded SPIONs were used in trapping experiment in the presence of the 
Halbach array in the 3D head and tumour model. They also were used to evaluate SPION 
uptake, distribution and cell viability.  
2.2.6 Cell culture 
2.2.6.1 Human astrocyte cells-HA 
Astrocyte cells were originally isolated from human brain (cerebral cortex). They 
were provided by Dr.Claire Garwood, SITraN. The University of Sheffield. They were 
received in a 6 well-plate at passage one and cultured in astrocyte medium (AM) that 
consisted of 500 ml of basal medium, 10 ml of fetal bovine serum (FBS), 5 ml of 
Astrocyte Growth Supplement (AGS) and 5 ml of penicillin/streptomycin solution [158]. 
The cultured cells together with the medium of 9 ml were kept in a T75 flask and 
incubated at 37°C with 5% CO2 in an incubator. Because the components of AM are light-
labile, the medium was kept in dark bottles and not exposed to light for extended periods. 
After using, the medium was stored at 4°C for no longer than a month. 
2.2.6.2 Human brain tumour cells -U138MG 
Human brain tumour cells (U138MG) were received in a frozen vial at passage 
number (3), provided by Dr. Spencer Collis, Oncology and Metabolism, The University of 
Sheffield. The cells were thawed and cultured in Dulbecco’s Modified Eagles Medium 
(DMEM) with 10% FBS and 5% Non-essential Amino Acids (NEAA).  The cultured cells 
with 9 ml medium of were kept in T75 flask and incubated at 37°C with 5% CO2 in an 
incubator [159]. It is recommended that the medium should be stored at 4°C for no longer 
than a month. The tumour cells stored as for the astrocyte cells. 
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2.2.6.3 Human Brain Microvascular Endothelial Cells 
(Hbmvec/D3)  
The Human Brain Microvascular Endothelial (Hbmvec/D3) are adult human brain 
microvascular endothelial cells. They were provided by Dr Julie Simpson, SITraN, The 
University of Sheffield. The cells were cultured in complete EBM-2 medium that consisted 
of 500 ml EBM-2 media, 200 µl of Hydrocortisone, 500 µl Ascorbic Acid, 12.5 ml FBS, 5 
ml Penicillin Streptomycin (Pen/Strep). All the growth factors including 125 µl human 
epidermal growth factor (hEGF), 125 µl Insulin-like growth factor (IGF), 125 µl Vascular 
endothelial growth factor (VEGF) and 500 µl human Fibroblastic Growth Factor (hFGF) 
were pooled together and divided into 10 aliquots of 87 µl each. Each aliquot was then 
added to 50 ml of EBM-2 medium (endothelial basal medium) each time before use, as 
GFs have a short life span [158]. The cultured cells together with the medium were kept in 
a coated T75 flask and incubated at 37°C with 5% CO2 in an incubator.  
To make the collagen coat; the collagen was diluted with distilled water to make a 
final concentration of 150 µg/ml. Before transferring the cultured cells to the flask, the 
flask was coated with 5 ml collagen IV and left in the incubator for at least an hour. After 
one hour, the collagen was removed and the flask was washed with 4 ml PBS once and 
then left in the hood to dry [158]. The collagen was stored at 4°C, should not be kept for 
more than a month. 
2.2.7 Cell harvesting  
This procedure was applied to all types of cells. When the cells were confluent at 
70-80%, the medium was carefully removed and the flask was washed with 4 ml PBS once 
and the PBS was then removed. In order to detach the cells from the flask, 3ml of trypsin- 
Ethylenediaminetetraacetic acid (EDTA) (170,000 U Trypsin/L and 200 mg/L EDTA) was 
added to the cultured cells, and then the flask was kept in the incubator for 5 min. After 
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that, the flask was removed from the incubator and to ensure complete detachment, a 
gentle tapping on the side of the flask with the palm of the hand was applied. The cells 
were then observed under the microscope. The contents of the flask were then transferred 
into a falcon tube. Trypsin/EDTA was neutralised in an equal volume of culture medium in 
preparation for centrifugation (Sanyo® Harrier 18/80). The speed of the centrifuge varied 
depending on cell type and their sensitivity, for example;  
o 650 g for 6 minutes for endothelial cells. 
o 600 g for 5 minutes for astrocyte and brain tumour cells. 
The supernatant was discarded and the cells were resuspended in culture medium 
and counted in trypan blue (Sigma-Aldrich®) to determine cell viability using a TC20 
Automated Cell Counter (Bio-Rad®). Live cells were trypan blue negative.  
2.2.7.1 Seeding densities  
The cells were seeded as described below:   
1. For flow cytometry experiments, cells were seeded onto 6 well plates at 300,000 
cells/well in 2ml of culture medium. 
2. For Prussian blue assays, cells were seeded on to 6 well plates with 13mm 
coverslips (BDH Cover glass), using a seeding density of 500,000 cells/well in a 
final volume of 1ml of culture medium.  
For the TEM assays, cells were plated at a seeding density of 1000 cells/well in a final 
volume of 200 μl of culture medium in 6 well plates. 
2.2.7.2 Incubation of SPIONs with the cultured cells   
When the cells were 60%-70% confluent, the culture medium was removed from 
the 6 well plates and then washed with 2mL PBS then 2mL of fresh pre-warmed medium 
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was added to each well. After that, SPIONs of different concentrations i.e. 0.1, 1 and 5 
mg/ml were added to the cells and kept in an incubator for 24 hours. Endothelial cells, 
astrocyte cells and brain tumour cells were seeded at a density of 300,000 cells/well in 2ml 
of medium.  
2.2.8 Flow cytometry to assess cell viability  
Flow cytometry was used to assess cell viability after adding SPIONs to the cells 
and incubating them for 24 hours. After that, cells were harvested as described above. 
400μl of the cells were transferred from the falcon tube into and 2μl of Propidium Iodide 
(PI) was added to each tube to assess cell death. Propidium iodide is a membrane 
impermeant dye that is generally excluded from viable cells. It binds to double stranded 
DNA by intercalating between base pairs of dead cells [160]. Cell death was measured on 
a FACS Calibur system where 10,000 events were measured from each sample (equivalent 
to 10,000 cells). FlowJo® software was used to analyse cell death by generating a 
fluorescent dot plot based on changes in forward scatter (FSC-H) and side scatter (SSC-H). 
2.2.9 Prussian blue staining to visualise MNP uptake  
Prussian blue staining was used to visualise SPION uptake by cells. After 
incubation with SPIONs cells were harvested and 5 X 105 cells/ resuspended in 1 ml of 
PBS in preparation for a cytospin on glass slides [161]. 1 ml of each this cell suspension 
was added to a slide chamber and centrifuged at 800 rpm for 5 min. The slides were 
carefully removed from cytocentrifuge and left to dry prior to staining.   
To fix the cells on the slide, each slide was dipped into; 
o 95% of ethanol for 5 min, then; 
o 70% of ethanol for 5 min then placed under running water for 5 min. 
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2% of a 1:1 dilution of 1M Hydrochloric acid (1 M HCL) and 2% Potassium 
Ferranocyanide was mixed in a glass bottle inside the fume hood and then the mixture was 
added to the slides and left for 30 min. The slides were washed again by immersing them 
in PBS three times for few seconds and then the slides into 1% eosin for 5 min, then 70% 
ethanol followed by 95% of ethanol. This was followed with acrylonitrile butadiene 
styrene (ABS2) for a few seconds and then left in ABS1 prior to mounting. The slides 
were transferred to the fume hood to mount them by attaching them to coverslips using 
immune-mount. Light microscopy (Leica DM1000) was used to assess MNP uptake by 
viewing the slides at 40x magnification. Mitotic Images plus 2.0 Software was used to take 
the images.   
2.2.10    Transmission Electron Microscopy (TEM)  
TEM was used in the Department of Biomedical Sciences (FEI Tecnai Biotwin) 
operated at 120kV with an Orius 1000 camera. TEM studies were carried out with the 
support of Mr Chris Hill in the Department of Biomedical Science at The University of 
Sheffield. 
2.2.10.1 TEM sample preparation 
After cell harvesting, cells were transferred into 1ml Eppendorf tubes and 
resuspended in PBS. A droplet of this buffer was added onto a carbon-coated copper grid 
for one minute and excess fluid was removed using tissues to leave a thin layer of sample 
over the TEM grid. This was also applied to the samples containing SPIONs only. 
2.2.10.2 Preparation of cells for TEM 
The cells were fixed in fresh 2.5%-3% GlutaradehydeNB in 0.1M Phosphate buffer 
overnight at 40C.  0.1M phosphate buffer was used to wash the specimens two times with 
30 min intervals at 40C. Post fixation; 2% aqueous osmium tetroxide was added for 1 hour 
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at room temperature and washed in the buffer as above. The following procedure was then 
applied at room temperature; 
o Dehydration was performed through a graded series of ethanol concentrations: 
o 75% ethanol for 15 min.  
o 95% ethanol for 15 min.  
o 100% ethanol for 15 min.  
o 100% ethanol for 15 min.  
o 100% x2 ethanol dried over anhydrous Copper sulphate for 15 min. 
The specimens were deposited in propylene oxide, which is an intermediate solvent, for 
two changes of 15 min duration. For infiltration, the specimens were placed in a 50/50 
mixture of Propylene oxide/Araldite resin at room temperature overnight. After this, the 
specimens were placed in full strength Araldite resin at room temperature for 6-8 hours. 
Then they were placed in fresh Araldite resin for 48-72 hours at 60oC. Semi thin sections 
about 0.5um thick were cut on a Reichert Ultracut E ultramicrotome and stained with 1% 
Toluidine blue in 1% Borax. Ultrathin sections, about 70-90 nm thick, were cut on a 
Reichert Ultracut E ultramicrotome and stained for 25 min with 3% of Uranyl Acetate 
followed by staining with Reynold’s Lead Citrate for 5 min. The sections were observed 
using a FEI Tecnai TEM at an accelerating voltage of 80Kv. A Gatan digital camera was 
used to take electron micrograph images. 
2.2.10.3 SPION size determination by TEM 
TEM was carried out to measure the size of SPIONs; this was taken arbitrarily 
from prepared samples. SPIONs were measured by analysing TEM-SPIONs randomly at 
100 and 200 nm magnification scales. ImageJ was used to measure the length of selected 
particles manually.  
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2.3 Statistical analysis 
All statistical analysis was achieved utilising GraphPad Prism (GraphPad Inc, San 
Diego, CA, USA). Statistics were analysed utilising suitable statistical tests and post tests 
as described in the figure legends. Microsoft Excel was also used to prepare data. 
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Developing Halbach arrays for Magnetic Drug Targeting (MDT): 
Modelling Halbach Magnet Arrays. 
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3.1 Introduction  
The current challenge when using external magnets in MDT is the distance 
between the magnet and the target organ [61]. The magnetic field/field gradient, and hence 
the magnetic force, is inversely proportional to the distance, meaning that increasing the 
distance between the magnet and the target leads to a decrease in the strength of the 
magnetic field. Several studies have proposed various Halbach array models in order to 
maximize the magnetic field strength and thus enable it to reach increased depths [116] 
[162] [61]. 
A successful therapeutic depth of 5 cm has already been achieved in human clinical 
trials with a magnetic strength of between 0.2 T and 0.8 T (3 T/m and 100 T/m) [98] and a 
depth of 12 cm and 0.5 T magnetic strength in animal models (i.e. a swine model) [163]. 
MDT was first applied in human clinical trials to treat shallow tumours which were 
inoperable [98]. In this treatment, the chemotherapy drug, in this case epidoxorubicin, was 
magnetised using 100nm coated SPIONs and then administered systemically to 14 patients 
with advanced and unsuccessfully pre-treated malignant tumours or sarcomas. An external 
magnet of 0.8 T was placed for between one to two hours on the target in order to 
concentrate the chemotherapy to the target. The results revealed that the drug was directed 
successfully to the tumours in about 50% of the patients. As explained previously, the 
difference observed in the way patients responded to the treatment was attributed to 
individual differences of the patients’ condition. The study concluded that the treatment 
was still dependent on patients’ conditions and/ or disease related problems in each patient. 
In addition, the results showed that MDT is safe, that is, no organ toxicity was 
observed.  
MDT was also applied in an animal study to target regions of interest (liver and 
lung) in a swine model where iron oxides (Fe2O3) were used at a concentration of 20 
Chapter Three 
- 68 - 
 
mg/ml and a range of sizes (between 0.5 µm and 5 µm). In order to monitor MNP 
retention, iron oxides were labelled with 1 mg/ml of the gamma-emitting isotope 
Technetium 99 (99mTc) [164]. The external magnetic field was generated by a permanent 
neodymium magnet of 250 to 1000 G, which was placed on the target site for about 15—
30 min in order to concentrate the drug (doxorubicin), which was infused at 2 ml/min 
concentration intra-arterially. It was found that the magnet helped to concentrate the drug 
by 40% to 43% compared to the controls. 
There are many studies that have performed in silico modelling of their magnets 
with a potential for MDT. For example, in a study by Kang et al., a 30 mm depth was 
reached when a Halbach array (NdFeB) was simulated using FEMM to produce a 
magnetic field strength of 1.5 T. This study used a rectangular bar magnet consisting of 
five-magnet elements with dimensions of 6.35 mm width x 6.35 mm height x 50.8 mm 
length, and polarisation angles varying clockwise by 90° between successive magnets 
[165].  A Halbach array was also simulated by Barnsley et al., to reach a 5 mm depth. This 
model was further optimised to reach 20 mm and then post optimised to reach 50 mm with 
magnetic field strengths of 0.85T, 0.81T and 0.78T, respectively [166].  
In 2007 a computational study was conducted to simulate a flat magnetic bandage 
using Finite Element Method Magnetics (FEMM) software with the intention to use this to 
target a superficial area including diseased tissues such as non-healing wounds and skin 
tumours [167]. The study compared different models including a single square magnet 
(3.75 cm2 and 0.2 cm thickness) and four button magnets (1.5 cm diameter and 0.4 cm 
thickness). The single magnet had a normal magnet polarisation with the N (north-pole) 
pointed up and S (south-pole) pointed down. The four-magnet model was simulated with 
different arrangements of dipoles (NNNN, NNSS, NSNS). These models were compared 
with a flat magnet Halbach array, which consisted of eight elements with different 
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magnetisation orientations, to see which had the highest magnetic force. It was found that 
the magnet, with a single N, four NNNN, NNSS and NSNS models generated magnetic 
forces of 32, 51, 76 and 90 N, respectively, at 1 cm away from the centre of the magnet, 
while the Halbach array model generated a magnetic force of 100 N at the same distance; 
these figures were calculated numerically using the equation ?⃗? = 𝑚∇|?⃑⃗?|. This result 
confirmed that Halbach array magnets represent a promising technique for MDT.  
The size/volume of Halbach arrays is a crucial parameter that should be considered 
when using Halbach arrays in medicine. In order to achieve a higher magnetic gradient, 
and hence force, a Halbach array with a large volume is required. Exploring this, Sarwar et 
al. reached a depth of 10 cm by using semi-definite quadratic programming to simulate a 
Halbach array model consisting of 36 magnet elements, 2000 cm3 in six layers. This model 
generated a magnetic force nine times greater than one with the same magnetic orientation 
but with only two elements, i.e. a smaller size [61].  
An interesting study investigated the relationship between the magnetic field/force, 
the size of the magnet, as well as the magnetisation orientation, and the ability to capture 
ferromagnetic beads in a microchannel (100 µm high and 1 mm long). The simulation 
procedure was performed using FEMM. A 2D Cartesian static case with no flow was 
considered. Two permanent magnets set up as a uniform field created a zero force zone in 
the middle of the microchannel gap and MNPs were instead trapped at the edges of the 
magnet [168]. It was found that a square bar magnet (200 µm) trapped more MNPs. This 
study showed that it is possible to use FEMM software to predict the force zone and thus 
to indicate where MNPs will be trapped. 
Building on the above work, in this PhD study, FEMM software was employed to 
model Halbach arrays. This software is open source, freeware which is simple to use and 
popular in science and engineering. It is used mainly to solve and analyse electromagnetic 
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problems, including 2D planar, magnetostatic and linear electrostatic problems [169]. This 
software has been used in several areas of science including medicine [170], robotics 
[171], materials science [172], and experimental and particle physics [173].  
FEMM is a group of programmes geared to solve low frequency electromagnetic 
problems on 2D planar axisymmetric domains. FEMM is divided into three parts, 
including the interactive shell, a pre-processor and a post-processor to solve several types 
of problems including magnetics, electromagnetics, heat flow and current flow [174]. 
FEMM also includes the Lua scripting language, which is integrated in the interactive 
shell. The purpose of the Lua scripting language is to run “batch” dynamic simulations and 
it is activated by adding code through the Open Lua Script icon on the File menu [175]. 
Overall, FEMM is useful for modelling both Halbach arrays and the movement of MNPs 
under the effect of a magnetic field and it will therefore be utilised for this study.  
This study was conducted with the primary aim of designing appropriate Halbach 
arrays for the delivery of drugs loaded with MNPs to tumours in the brain. This chapter 
focuses on discussing the computer-based simulations that were conducted to design 
appropriate Halbach arrays.  
3.2 Aims and objectives  
Hypothesis 
We hypothesise that an inexpensive, portable, powerful and external Halbach array 
magnet can be designed, modelled and simulated to be used for MDT with the purpose of 
targeting brain tumours, at depths between 5 and greater, i.e. 10 cm. 
Aims 
To achieve this, two different Halbach array magnets were designed and simulated 
using FEMM software (v4.2). 
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Specific objectives 
 To calculate the magnetic force required to trap SPIONs with different sizes 
using Lua scripting. 
 To develop Halbach array models in order to obtain the highest magnetic 
field/field gradients to reach a maximum target depth. 
 To optimize the Halbach arrays model in order to generate higher magnetic 
field strength at further depths. We will assume that the Maximum Penetration 
Depth (MPD) of the magnetic field is 1% of its original magnetic field strength 
value (close to zero), and will use MPD throughout the thesis. 
3.3 Movement of SPIONs under the influence of a magnetic 
field 
From the Equation 1.2 mentioned earlier, it was found that large volumes of 
SPIONs require large values of magnetic force. This equation was used in FEMM-Lua 
scripting in order to calculate the magnetic forces that effect the movement of SPION. 
In order to model and simulate the movement of SPIONs under the effect of a 
magnetic field, a specific magnet design and SPIONs with diameters of 24 nm, 50 nm and 
70 nm were modelled using FEMM v 4.2. Then, to simulate movement of SPIONs, Lua 
scripting was applied.  
For simplicity, a simple magnet array of two opposed blocks of NdFeB-52 that had 
dimensions of 5.5 cm width, 10.8 cm length, 5.5 cm height, was modelled. The magnets 
were separated by 2.5 cm gap and an attractive force was created in the gap. This simple 
model generated a magnetic field strength of 0.6 T, Figure 3.1. The blue arrows in the 
graphs (in this chapter) indicate the locations where the magnetic field strength was 
measured (perpendicular to the simulated model). 
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After modelling the magnet and SPIONs , the simulation of SPION movement was 
run (Figure 3.2). To simulate the movement of SPIONs under the effect of the magnetic 
field, the code was set up to include the distance to be travelled and whether single or 
groups of particles were moved. The magnetic force on single and multiple SPIONs of 
different volume was then calculated as a function of position. The calculations were saved 
and then exported to Excel to plot the relationship between magnetic force and distance, 
based on the size of SPION, as shown in Figure 3.3. 
Figure 3.1: FEMM simulation of a two-block magnet. This model created a magnetic field of 0.6T, 
which was measured as the blue arrow indicates from the surface up to 4 cm away from the magnet. 
The maximum magnetic field that was created in the model was 1.1 T in the middle of the magnet in 
between the blocks. 
Distance (cm) 
B (T) 
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It was found that the large SPIONs of 70 nm (brown line) required more magnetic 
force, 2 × 10−9 𝑁, than smaller i.e. 24 nm particles (light blue line) that required less than 
1 × 10−9 𝑁 to transport them. When all the different sized SPIONs were grouped to be 
moved at the same time (dark blue line) more magnetic force was required to transport 
them i.e.  3 × 10−9 𝑁. The magnetic force that is required to move or transport the 
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Figure 3.2: FEMM simulation and movement of the magnet and SPIONs of different 
sizes. Blue arrow indicates the direction of MNP movement where magnetic forces were 
calculated. 
  
Figure 3.3: Calculated magnetic force for MNPs vs. distance. Green line represents the movement of 1 nm 
SPION, light blue line represents the movement of 24 nm SPION, grey line represents the movement of 50 
SPION s brown line represents the movement of 70 SPION s, and dark blue line represents group simulation. 
This graph shows the increased magnetic force required with increasing size of SPIONs. 
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SPIONs is therefore strongly dependent on the volume of the SPIONs. These observations 
helped to guide the development of the Halbach arrays models. 
3.4 Development of Halbach array models 
This section presents a discussion of how 2-D simulation models were run using 
FEMM software for different designs of Halbach arrays.   
The magnetic material and the magnetisation direction were defined for each 
magnet element. The magnetisation direction was set up to create either an attractive or a 
repulsive force to create the highest magnetic field and field gradient at a point of interest 
(POI). A finite element mesh was then created for the geometrical model and the magnetic 
problem solved using FEMM. The calculated flux density of the magnet was then 
displayed. To measure the magnetic field at a POI in the model, two points were selected 
and connected to plot a profile and to measure the local magnetic field. Figure 3.4 shows 
the modelling and optimisation procedure used in these studies. 
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In this modelling, Neodymium-Iron-Boron (FeNdB-52) magnetic material was 
used, since this material is the strongest permanent magnetic material available to date.  
The two different designs both had the same magnetic orientations but with 
different polarisation configurations. Model 1 consisted of one layer of three cubic 
magnets, in which the magnetisation of the two magnets at the edges pointed to the one in 
the middle, while the magnetisation orientation of the middle one pointed down, as 
illustrated in Figure 3.5. In the same Figure, Model 2 is also shown which consisted of 
one layer of four cubic magnets that had the same magnetisation orientation as Model 1 
but with a doubling of the middle magnet; i.e. there were two magnets in the middle and 
two at the edges. For optimisation purposes, both models were simulated in multiple 
layers. 
Increase the 
layers of the 
magnet 
Run the 
simulation 
Draw the 
model of the 
magnet 
Select the 
material 
type 
Select the 
orientation 
of each 
magnet 
Draw the 
boundary 
of the 
model 
Measure the 
magnetic 
field/field 
gradient 
Does it reach the 
highest magnetic 
field? 
Does it reach the 
maximum depth? 
Array modelled & 
optimised! 
Change the 
magnetisation 
of the magnet 
Yes Yes 
No No 
Figure 3.4: Schematic diagram of modelling and optimisation routine. The 2-D simulation and 
development process was conducted using FEMM software. 
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Figure 3.5: 2D distribution of magnetic field strength of Halbach array Model 1 and 2. a, b, and c 
represent Model 1 with one two and three layers respectively. d, e, and f represent one, two and three 
layers respectively of Model 2. The pink and turquoise blue colours represent the maximum and minimum 
magnetic field strength respectively. Blue arrows refer to position where magnetic field strength was 
plotted. These models were produced using the FEMM software. 
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3.4.1 Magnetic field strength based on Halbach array models 
The marked difference between the models introduced in the previous subsection is 
the distribution as well as the strength of magnetic field that were obtained. The “pink” 
regions in Figure 3.5 indicate the maximum magnetic field strength, which gradually 
decreases with distance from the magnet, reaching the lowest magnetic field strength 
shown in “turquoise”. The magnetic field strength in Model 1 is very focused in the middle 
of the magnet and starts to emerge from the surface of the magnet and enlarge when the 
number of layers is increased (Figure 3.5 b & c). This model therefore created a strong 
magnetic field on the surface of the magnet but was more focused in the middle of the 
Halbach array. Unlike Model 1, Model 2 generated less magnetic field strength “pink” in 
the middle of the magnet but was stronger at the edge of the magnet with increasing 
number of layers, see Figure 3.5, d & e. Setting up the magnetisation orientations — green 
arrows in the models — resulted in different magnetic field profiles. Figure 3.6 below 
demonstrates how the magnetic field vectors for both models depended on the 
magnetisation orientation. 
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It was observed that increasing the number of layers and hence the volume of the 
magnet resulted in an increase in the strength of magnetic field and hence the field gradient 
and force. Figure 3.7 below demonstrates the differences in magnetic field strength of 
each layer for both models. For example, the first layer of Model 1 (a) generated a 
maximum magnetic field of 1 T with a total of three magnets, whereas b and c, using a 
total of six and nine magnets respectively, generated maximum magnetic fields of 1.1 T 
and 1.2 T, respectively. On the other hand, Model 2 (d) generated a maximum magnetic 
field of 0.95 T using a total of four magnets, whereas (e) and (f), generated maximum 
magnetic fields of 1.2 T and 1.3 T, respectively, using a total of eight and twelve magnets, 
respectively. 
 
 
 
 
Model 1 Model 2 
Figure 3.6: Demonstration of magnetic field vectors for Model 1-LHS and Model 2-RHS. They 
show the focused magnetic field distribution for model 1 and a larger distribution for model 2. 
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It can be seen from Figure 3.7 that adding a third layer to both models generated 
the highest magnetic field. There was a noticeable improvement in the magnetic field 
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strength for Model 2 with a third layer (1.3 T) compared to the first layer of the same 
model (0.95 T).  
To compare both models, it is obvious from Figure 3.7 above that the magnetic 
field strength of the first layer for Model 1 was slightly higher than the magnetic field 
strength of Model 2.  However, at greater distances from the magnet surface, i.e. 2.4 cm, 
Model 2 (0.38T) seems to be more powerful than Model 1(0.28T) of three layers. 
Maximum magnetic field strengths for three layers were 1.3 T and 1.4 T for Models 1 and 
2 respectively. In order to visualise clearly the strength of the magnetic field (shape of the 
curve) of the two models with three layers, 10cm was selected and illustrated in Figure 3.8 
below. 
  
 
It is clear that Model 2 is more powerful in terms of magnetic field strength, hence, 
field gradient and force, than Model 1 at depth, e.g. at 10 cm away from the magnet. 
Model 1 produced 0.01 T, 1 T/m and 2.35 T2/m of magnetic field, field gradient and 
magnetic force respectively. While Model 2 produced 0.08 T, 8 T/m and 18 T2/m magnetic 
field, field gradient and magnetic force at the same distance, respectively. In addition, the 
magnetic force generated from Model 2 is promising in terms of treatment as the focused 
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Figure 3.8: Magnetic field strength and shape of Model 1 and 2 at 10cm away from the magnet. Magnetic field 
of Model 2 was higher than Model 1 and had a curved peak.  
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force at the peak should be able to hold SPIONs loaded with anti-cancer drugs. The Table 
below summarises the main differences in the models. 
 
 
Table 3.1: Magnetic properties of Model 1 and 2 as simulated (a) summarises the magnetic properties of 
Model 1 and Model 2 with (a) first layer and (b) three layers-up to 10 cm. 
 
Since the main aim of this research was to model an external magnet, which has a 
strong magnetic field at depth, Model 2 appears to be the best configuration for the 
application of MDT for brain tumours. Further optimisation was required, however, to 
focus the array on the area of interest and to reach greater depths. Efforts were therefore 
made to improve the basic model design.  
 Model 1 Model 2 
Magnetization orientation 180°, 90°, 0°  180°, 90°, 90°, 0° 
Total number of magnet 
element 
3 elements 4 elements 
Magnetic field strength (B) 1 T 0.95 T 
Magnetic field gradient (G) 10T/m 9.5 T/m 
Magnetic field force (F) 10 T2/m 9 T2/m 
 Model 1 Model 2 
Magnetization orientation 180°, 90°, 0°  180°, 90°, 90°, 0° 
Total number of magnet 
element 
9 elements 12 elements 
Magnetic field strength (B) 1.2 T 1.3 T 
Magnetic field gradient (G) 12 T/m   13 T/m  
Magnetic field force (F) 14.4 T2/m 16.9 T2/m 
(a) 
(b) 
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3.5 Optimisation of the FEMM model 
In order to ensure that the magnetic arrays were focused on the area of interest, the 
effect of iron loaded epoxy resin was modelled. Epoxy resin is commonly used as a strong 
adhesive due to its chemical properties, however, if iron powder is loaded into the epoxy 
resin it can be considered as a magnetically soft material [176] [177]. The reason for using 
iron-loaded epoxy resin is that when a square-shaped magnet array is placed on top of a 
curved head a gap would be created at the edges of the magnet, as shown in Figure 3.9 
below. The iron-loaded epoxy can be used to fill the gap and further steer the magnetic 
field. 
 
In the FEMM model, a triangular shape was modelled to fill the gap with iron-
loaded epoxy resin, as illustrated in Figure 3.10; where the left-hand side picture shows 
Model 2 without optimisation, while the picture on the right-hand side shows the iron-
loaded epoxy resin modelled using pure iron material. It is well known that iron can be 
used to shape magnetic fields [177] [176]. 
 
Iron Loaded 
Epoxy Resin 
Iron Loaded 
Epoxy Resin 
Figure 3.9: Adding iron-loaded epoxy resin to fill the gaps when the magnet is on top of the head. LHS 
shows that when the magnet is attached to the head gaps are created. RHS shows the gaps filled with iron-
loaded epoxy resin. 
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The iron-loaded epoxy resin shown in the Figure 3.10-RHS above helped to shape 
the magnetic field and produced a more focused magnetic field in the middle compared 
with the one without the epoxy resin-LHS, although there was no changes in the strength 
of the magnetic field that was generated with and without the iron-loaded epoxy resin. 
These results can be seen clearly in Figure 3.11 below where both models generated a 
magnetic field strength of approximately 0.8 T.  
 
Iron Loaded Epoxy Resin mode 
Figure 3.10: a 2D distribution of magnetic field using FEEM Software. LHS no iron-loaded epoxy resin, 
RHS with the iron-loaded epoxy resin, showing the creation of a focused magnetic field. Blue arrows 
refer to position where magnetic field strength was measured (perpendicular to the simulated model). 
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3.6 Discussion  
This chapter focused on providing a detailed description of the processes and 
procedures followed in identifying an appropriate Halbach arrays for the therapeutic MDT 
purposes under investigation. Prior to developing the Halbach array models, an 
investigation into the relationship between the volume/size of SPIONs and the magnetic 
force was conducted. It was confirmed through FEMM modelling of SPION movement 
under the effect of magnetic force, that the amount of magnetic force required to move 
SPIONs to the desired site was directly proportional to the volume of the SPIONs, which 
agreed with theoretical predictions [168]. Smaller sized SPIONs require less magnetic 
force while large volumes of SPIONs require higher magnetic force to move the SPIONs 
to the desired depth, Figure 3.3. This implies that the choice of the correct size of SPIONs 
prior to treatment is a vital parameter that should be considered in designing optimal 
Figure 3. 11: The maximum magnetic field of the magnet with and without the epoxy resin produced 
using FEEM Software. Graph on left without the epoxy resin and on the right with the epoxy resin, 
showing no significant difference. 
        Distance (cm)  Distance (cm) 
B (T) B (T) 
Chapter Three 
- 85 - 
 
Halbach magnet arrays to produce the required force to steer/trap SPIONs in a desired 
location.  
Having established the relationship between the size of the MNPs and the magnetic 
force required to move the particles, the next step involved modelling the Halbach arrays. 
This helped to identify a good design for our application by determining the maximum 
magnetic field strength and depth of penetration associated with each model.  
In order to obtain high magnetic force, two crucial parameters should be 
considered; the size of the magnet and the magnetisation orientation of each element [61]. 
It was shown in Figure 3.7 that increasing the number of layers of magnets, that is, having 
a larger volume of magnet, increased the total magnetic field strength, magnetic gradient 
and magnetic force. A Halbach array model that consisted of six layers, including 36 
magnet elements, giving a total magnet size of 2000 cm3 was simulated by Sarwar et al. 
[61]. This Halbach array model reached a high penetration depth of 10 cm away from the 
magnet. Although this penetration depth is quite promising for MDT, the size of the 
magnet is quite massive and heavy and therefore would not be convenient for brain tumour 
patients.   
The configuration of the magnetisation orientations plays a major role in altering 
the magnetic field strength, field gradient and hence magnetic force. Zhu et al., simulated 
two Halbach array models with the same volume and seven magnet elements but different 
magnetisation angles [178]. One model had the following magnetisation angles: 180°, 90°, 
0°, -90°, 180°, 90°, 0° while the second model used -90°, 90°, -90°, 90° and so on. Both 
models generated magnetic flux differently in terms of the strength and the distribution, 
i.e. Model 1 produced a higher magnetic field strength than Model 2 and the magnetic field 
flux was weak on one side and strong on the other side, whereas in Model 2 this was 
distributed equally on both sides [178]. A Halbach array with a high maximum magnetic 
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field strength, however, does not necessarily have high field gradients and hence force. For 
instance, Model 2 in Figure 3.7 showed less magnetic strength than Model 1 but had a 
higher field gradient and hence force, Figure 3.8. 
    Predicting a magnetic force zone is important prior to MDT treatment and this is 
achievable via modelling. Gassner et al., simulated the force distributions that were 
produced by rectangular permanent magnets in a static microchannel using different 
magnetisation orientations. This was to determine where in the channel MNP beads were 
more likely to be trapped. It was found that two permanent magnets set up to create a 
uniform field in attractive mode yielded one force zone in the middle of the magnet gap 
where MNPs were trapped whereas permanent magnets set up in repulsive mode to create 
a field gradient yielded two force zones at the edges of the magnet where the MNPs were 
trapped [168]. 
Soft iron materials have been used in MRI scanners to help increase and focus 
magnetic field flux, known as shimming [179]. In this study, iron-loaded epoxy resin was 
included in the FEMM model- Figure 3.10, aiming to produce more homogenous and 
focused magnetic field flux. The data did not show significant results in terms of 
increasing magnetic field strength, but it did show that the magnetic field flux became 
more focused, with increased trapping force at the POI. This is worth considering when 
applying magnet arrays to patients for the MDT therapeutic process. Although using iron-
loaded epoxy resin has several applications, this has not been performed for MDT 
purposes yet. A device was patented that demonstrated the effect of iron powered on the 
utilization of permanent magnet materials in advanced motors [180]. It was used in an 
electrical motor to eliminate the unwanted thrust force by fitting the iron powder wedges 
between adjacent coil sides in the armature.   
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   In order to validate the Halbach array models that were simulated, physical 
assembly of the magnet arrays was required. The following chapter thus describes how 
these Halbach arrays were assembled and how measurements of field, gradient and force 
performed. These measurements were then compared with the simulations from the 
FEMM models presented in this chapter. 
Limitations: 
In this study, Halbach arrays models were simulated using 2D software, which thus 
precluded forming the 3D shape that we were ultimately aiming to model. With 2D 
modelling it is only possible to model the cross section of the 3D shape and then simulate 
the magnetic field strength. This may produce a result that is not very precise due to the 
difference between the simulated magnet shape and the actual 3D magnet. This software 
was easy to use and free of charge, however. The alternative 3D software that could be 
used to model the Halbach array magnets is COMSOL [181]. This is more precise, 
however, it difficult to use and very costly. 
The other limitation that exists in any magnetostatic computer model is the 
boundary conditions of the model. The function of the boundary is to shield the intensity 
flux and keep it surrounded with magnet. The value of the intensity flux will vary as the 
position of the magnet varies, however, for example, if the boundary was drawn close to 
the magnet, the magnetic field will be higher than if the boundary was drawn a bit further 
than the magnet. This is an important issue that should be considered in future work.
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4.1 Introduction 
A key challenge in the assembly of Halbach arrays is the presence of the forces that 
are generated from the different polarisation angles between each magnet. These forces, 
mainly repulsive forces, should be overcome in order to attach and stick each magnet 
element together to complete the construction indicated through the FEMM models. The 
forces between two magnets (NdFeB-N52), of a 0.5 inch cube were numerically calculated 
for a set of magnetisation orientation configurations by Barnsley [116]. For example, the 
forces were 165 N, 124 N, and 58.5 N for two magnets that had the same magnetisation 
orientation of 90⁰, for a magnet which has a 90⁰ magnetisation angle connected with a 
block with a 30⁰ magnetisation angle and for a magnet which had a 90⁰ orientation 
connected with a magnet with a 180⁰ magnetisation angle, respectively. The magnetisation 
configuration of the two magnets shared either a face or an edge. The maximum calculated 
force was 330 N, which came from two magnets that shared a surface and were connected 
so the positive pole of one magnet attracted the negative pole of the other magnet [116].  
A Halbach magnet array with two layers of a 5 × 5 array of magnets, 50 magnets in 
total, was assembled using an aluminium brace [182]. Removable rods contained the 
arrays to prevent them from movement. The magnet was assembled layer by layer and in 
each layer the assembly was row by row. When the assembly of each layer was completed, 
a sheet of aluminium was used as a sliding lid to cover the layer and then each rod was 
removed column by column from the base of the brace. After which, the base, from the 
bottom, and the lid, from the top, were pushed to align the layers together. The magnetic 
field obtained was around 0.3 T and reached up to 20 mm, and this increased as the layers 
of the magnet were increased to reach 1.3 T at up to 50 mm. The total weight of the 
magnet, including the base and lid, was 1.3 kg. The magnet was intended for use in MDT 
applications, therefore, in vitro experiments were conducted to demonstrate the magnet’s 
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ability to separate and retain microbubbles loaded with MNPs against a constant flow. 
Although the magnetic field strength was considered to be promising for MDT, it would 
not be suitable for brain tumour patents due to its large weight (1.3kg). 
Another technique that has been used to help in constructing Halbach arrays is 
where two 3D plastic printed holders are used to hold five bar magnets of 6.35 mm width, 
6.35 mm height, 50.8 mm length. The magnetisation orientation of these magnets varied 
clockwise by 90o between successive magnets. While the magnets were kept still by the 
holders, a metal plate bonded to the epoxy adhesive was applied from the rear (weaker 
side) of the magnet to secure the magnet [165].   
      Assembling a Halbach magnet array can require specialized equipment to avoid the 
hazard that may occur when using high strength magnets such as N52 grade, due to large 
and sometimes unpredictable forces between the magnets [182]. Tools including a band 
saw; a lathe, a milling machine and simple hand-finishing are sometimes used for high 
performance assembly. Long cylindrical Halbach arrays were constructed by Tayler et al., 
using permanent magnets for NMR applications i.e. pre-polarisation and subsequent 
detection that occur at different locations [182]. In this model a group of magnets with 
different material types were used (i.e. NdFeB- N52 and N48SH) to build a multiple layer 
magnet with a total of 38 magnets. The dimensions of each magnet were 2, 0.5, 0.5 inch3 
and each was magnetized through the side with 0.5 inch thickness. Aluminium casings 
were fabricated to assemble 2, 4, 8 and 24 block magnet arrays. These Halbach magnet 
arrays generated a high magnetic field but were not suitable for our research due to their 
high weight, which was unsuitable for brain tumour patients. The final assembled magnets 
weighed a total of 1.3 kg (8-block) plus 3.0 kg (24-block) and external dimensions were 4 
inch width and depth and 3 inch height. 
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Assembling Halbach arrays using tens or hundreds of small separate magnets offers 
many advantages rather than using a few large magnets. For example, small magnets allow 
different patterns of magnetisation orientations, which can help to strengthen the magnetic 
field on a magnet side. Also it helps to control the overall magnet size to fit for personal 
treatment [183].  
4.2 Aims and Objectives 
Hypothesis 
The FEMM Halbach array magnets modelled in chapter 3 have a strong magnetic 
field gradient that can trap SPIONs within a brain model at depths of around 5 to 10 cm. 
We also hypothesise that large volume Halbach array magnets generate both high 
magnetic field strength and field gradients. 
Aims 
To test this, both Halbach array Model 1 and 2 were assembled and measurements 
were made to validate the FEMM models in terms of maximum magnetic field, field 
gradient and hence magnetic force as well as maximum penetration depth using a 
Gaussmeter (GM 08, HIRST, Magnetic instruments Ltd).  
Specific objectives 
 To assemble both Halbach array magnets based on the FEMM model. 
 To measure the strength of magnetic field, field gradient and magnetic field of each 
layer of each model at different distances. 
 To optimise the Halbach array for the SPION trapping experiment with the 
tumour/head phantom model. 
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 To determine the maximum depth at which the tumour could be located within the 
brain using the 3D head/tumour phantom model.  
4.3 Assembly of Halbach array magnets based on FEMM 
model  
Chapter 3 demonstrated the simulation of two Halbach array models in terms of 
magnetic field strength, field gradient and magnetic force. To validate the FEMM model, 
both Halbach array models were physically assembled. Based on the FEMM models, a 
cubic magnet element of 1 cm3 and Neodymium Iron Boron (NdFeB)-grade N52 were 
chosen for the assembly of the magnets. Both magnets had the same magnetisation 
orientation but with different configurations. The magnetisation orientations of the 
magnets were adjusted based on the FEMM models. In the centre of the magnet array, the 
magnetisation orientation angle was set to be θ = 90° with the positive pole pointing out of 
the paper. For all the other magnets in the array, the magnetisation orientation angles were 
set to be θ = 180°, orthogonally magnetized towards the array centre, as illustrated in 
Figure 4.1. Black circles in the magnet refer to the position where the magnetic field 
strength measurements were taken, perpendicular to the magnet’s surface.   
Each magnet was placed on a ferritic stainless steel sheet with an area of 30 cm2, 
which was used to keep the magnets in place. In addition, a cyanoacrylate adhesive was 
used to stick the magnets together. After gluing two magnets, a block of ferritic stainless 
steel was placed on top of the glued magnet faces to ensure that they remained held 
together for several hours (between 7 and 24 h). After that, the block was removed and the 
next magnet put into place and this process was repeated until the assembly was complete. 
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Model 1 started with five magnets, one in the centre and four surrounding the 
centre, making a cross shape, the polarisation of the central magnet pointed up, forming 
the positive pole, whereas the surrounding magnets pointed towards the centre of the 
magnet. A total of 15 magnets were used to create all three layers. Similarly, for Model 2, 
the same shape and magnetisation orientations were applied, but with four magnets in the 
centre and eight surrounding magnets for the first layer and 24 and 36 magnets for the 
second and third layers, respectively. 
Model 1 Model 2 
Figure 4.1: Constructed Halbach arrays for both models; Model 1 & Model 2. Both models have the 
same magnetisation orientations but different configuration. The single (+) in the magnets refers to the 
magnetization vector set of θ=90◦, which means that the magnetic force points out of the paper. The 
black arrows display the magnetization vector set of θ=180◦ which are orthogonally magnetized to the 
centre. Each magnet element is constrained of the volume of 1 cm3. The first, second and third row of 
the figure shows the first, second and third layer of the magnet respectively. Black circles in the 
magnet refer to the position where the magnetic field strength measurements were taken, 
perpendicular to the magnet’s surface 
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The main challenge faced during the assembly procedure was management of the 
repulsive forces that arise between neighbouring permanent magnet elements. This issue 
was made more difficult with increasing magnet array size. The challenge of attaching the 
additional layers was overcome by segmenting the configuration into smaller groups (two 
magnet elements in each group). Using steel blocks to surround each group of magnets 
while keeping the base of the magnet array attached to the steel sheet, helped to reduce the 
repulsive dipole forces. 
4.4 Measurements of the Halbach arrays  
Based on the FEMM model simulations in chapter 3, Model 2 demonstrated 
superiority over Model 1 in terms of magnetic field strength, field gradient and magnetic 
force. It was also shown that when the volume of the magnet increases, the magnetic field 
strength, and hence both the field gradient and the magnetic force increase. In order to 
validate the simulations, measurements of the magnetic field strength of the assembled 
Halbach arrays were taken for each layer and for both models using a Gaussmeter (GM 08, 
HIRST, Magnetic instruments Ltd). The field strength was measured over a range of 
distances from the magnet surface. The field gradient and magnetic force were then 
calculated based on the magnetic field strength measurements. 
Figure 4.2 (a-f) demonstrates the magnetic field, field gradient and magnetic force 
measurements for each layer and for both magnets.  
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Figure 4.2: Measurement of magnetic field strength and magnetic force for model 1 and 2. (a-f) show the 
measured magnetic field (B), field gradient (G) and magnetic force (F) of each layer for both models, 1 & 2, 
at a range of distances until the magnetic field strength reached zero (integral). 
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As can be observed from Figure 4.2, the maximum magnetic field generated from 
the first layer of Halbach array Model 1 was 0.95 T at the surface of the magnet. This 
value increased with increasing number of layers i.e. 1 T and 1.06 T after adding the 
second and third layers, respectively. The field values dropped off sharply at 0.5 cm away 
from the magnet i.e. 0.3 T, 0.36 T and 0.47 T for the first, second and third layers 
respectively. Beyond this distance, the magnetic field strength decreased more gradually.  
For Halbach array Model 2, (Figure 4.2), it can be observed that the maximum 
magnetic field generated by the first layer was 0.93 T at the surface of the magnet. This 
value increased as the number of layers of magnet increased to 1.06 T and 1.08 T for the 
second and third layers respectively, again dropping off sharply at 0.5 cm away from the 
magnet, i.e. 0.3 T, 0.4 T and 0.5 T for the first, second and third layers, respectively.  
It is worth mentioning that the maximum magnetic depth penetration of Model 1 of 
each layer was 7.5 cm, 9 cm and 9.5 cm for magnets made up of one, two and three layers, 
respectively, where the magnetic field strength at these points for all layers was 0.001 T. 
The maximum field gradient and magnetic force for the first layer of Model 1 were 12.7 
T/m and 12.0 T2/m respectively (up to 7.5 cm). When the second layer was added, the total 
field gradient and magnetic force were 11.1 T/m and 11.1 T2/m respectively (up to 9 cm). 
For the third layer, the total field gradient and magnetic force were 11.1 T/m and 11.81 
T2/m respectively (up to 9.5 cm). The magnetic force values increased as the number of 
layers of the magnet increased, as predicted from the FEMM values.  
Although the magnetic field strength reached up to 13 cm for Model 2, it was so 
weak at that depth that it would be unlikely to be able to trap SPIONs. For example, the 
maximum magnetic depth penetration for Model 2 for each layer, was 10 cm, 12.5 cm and 
13 cm when the magnet contained one, two and three layers, respectively, but the magnetic 
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field strength at these points for all layers was 0.001 T. The maximum field gradients as 
each layer was added were 8.8 T/m, 8.3 T/m and 8.53 T/m, respectively. The magnetic 
force was 8.2 T2/m (up to 10 cm) when there was one layer, 9 T2/m (up to 12.5 cm) when 
there were two layers and 9.3 T2/m (up to 13 cm) when there were three layers. These 
depth points cannot be considered useful for MDT, therefore, due to the weak magnetic 
field strength, field gradient and force values.  
Figure 4.3 shows that Model 2 has a slight increase in terms of magnetic force 
compared to Model 1. 
 
Figure 4.3: Magnetic force of the constructed Halbach array of Model 1 & 2. 
 
As mentioned earlier, these magnets were developed to deliver magnetised drugs to 
brain tumours. The size/volume of the device should therefore be suitable and convenient 
for patients. All the magnets were weighed in the lab using an accurate weighing scale. It 
was found out that the weight of Model 1 with one, two and three layers was 36.6, 55, and 
110 g, respectively. For Model 2 the weight of the first, second and third layers was 88.5, 
177.1, 265.7 g respectively. Adding the third layer generated a strong repulsive force as 
explained previously on page 91, hence, its configuration required use of more adhesive. 
This explains why the volume/weight of the magnet is the largest in the presence of three 
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layers. Overall, it seems that Model 2 with three layers was the heaviest at 265.7 g but this 
can still be considered to be low enough for MDT use. Figure 4.4 below demonstrates the 
differences in weight for each layer and for both magnets.  
 
As alluded to earlier, it was necessary to identify the model that works most effectively in 
terms of directing drugs that are loaded with SPIONs to the desired depth. Model 2 
produced a slightly higher magnetic field strength at the surface of the magnet (0 cm) 
compared to Model 1. As the distance from the magnet increased, for example to 2.5 cm, 
Model 1 produced a slightly higher magnetic field in comparison to Model 2. In terms of 
magnetic force, there is no major difference between the models, Figure 4.3. Overall, it can 
be concluded that Model 1 is better for small, superficial brain tumours because this model 
produced very focused magnetic fields, as can also be seen in the FEMM model in chapter 
3. On the other hand, Model 2 should be better for large, deep brain tumours as it produced 
a larger, more extended magnetic field.  
In terms of comparing between the simulated and constructed Halbach array, 
Figure 4.5 below illustrates the comparison of the main properties between the simulated 
and constructed Halbach array (as a whole) of Model 2. 
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Figure 4.4: The weight of both magnets (a) Model 1 and (b) Model 2. Magnet 2 was 
heaviest but was still considered reasonable for MDT.  
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Figure 4.1: Comparison between the simulated and constructed Halbach array for Model 2. a) The 
magnetic field strength profile, b) Field gradient of 1st 2nd and 3rd layer.  
 
The reason of the differences between both versions of the model was already discussed in 
3.6 (limitation). 
The primary objective of this research project was to build a Halbach array with a 
high magnetic field strength that has the capacity to reach deep within tissue in order to 
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steer the drugs that are loaded with SPIONs to brain tumours. It was concluded that Model 
2 has a more effective configuration to produce extended trapping forces.  
4.5 Optimisation of Model 2 for improved magnetic targeting 
Several strategies to improve Model 2 are now described. The first strategy to optimise 
the magnetic field strength was to ensure that no magnetic field could escape from the 
corners of the model (Figure 4.1). In order to close the gaps (convert the shape from a 
cross to a square) a magnetic element of the same magnet grade-N52, with a magnetisation 
orientation of 45o, was attached in each corner, as illustrated in Figure 4.6 (a). The 
magnetic field strength was measured using the Gaussmeter and the values were plotted in 
Figure 4.6 (b). For the sake of demonstration of the principle this optimisation was applied 
for only one layer. 
The maximum magnetic field for the optimised model was 1.16 T compared with 0.93 
T for the non-optimised Model 2. The maximum penetration depth was improved from 10 
cm to 12.5 cm for the optimised model. At 2.5 cm the magnetic field gradient and 
magnetic force were 44.16 T/m and 51.22 T2/m respectively compared with 36 T/m and 33 
T2/m respectively for the non-optimised model.  
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The second strategy for optimising the magnet involved housing the magnet within 
a stainless steel case as illustrated in Figure 4.7 (a) below. This was applied for the first 
layer only as this provided enough evidence for the subsequent configurations. The 
magnetic field strength was measured and the average magnetic field and force were 
calculated and plotted in Figure 4.7 (b, c, d). The maximum magnetic field for the model 
with a steel case was 1.17 T, compared with 1.16 T for the non-cased model at the surface 
of the magnet. The difference in the magnetic field strength between the models with and 
without the steel case is not noticeable, however, its effect is observed in MDP where 12.5 
cm of the model without steel case compare to 14 cm with steel case. This suggests that 
cover the magnet with steel case can help to improve MDP in MDT. 
 
(a) (b) 
0
0
. 5 1
1
. 5 2
2
. 5 3
3
. 5 4
4
. 5 5
5
. 5 6
6
. 5 7
7
. 5 8
8
. 5 9
9
. 5 1
0
1
0
. 5 1
1
1
1
. 5 1
2
1
2
. 5
0 . 0
0 . 5
1 . 0
1 . 5
M a g n e t i c  F i e l d  ( B )  v s  D i s t a n c e  ( X )
X  ( c m )
B
 
(
T
)
B  ( T )
Figure 4.6: Optimised Halbach array of Model 2: (a) Constructed Model 2 Halbach array with one 
layer after optimisation by closing the corners. The sign (+) on the magnets refers to the 
magnetization orientation sets with θ=90°, which means that the magnetic force points out of the 
paper. The black arrows display the magnetization orientation set with θ=180°, 0°, which are 
orthogonally magnetised towards the centre as well as 45 degrees from the corners. Each magnet 
element had a volume of 1 cm3. (b) Magnetic field strength of the optimised Halbach array versus 
distance. The magnetic field strength and magnetic penetration depth were slightly increased. Black 
circles in the magnet refer to the position where the magnetic field strength measurements were 
taken, perpendicular to the magnet’s surface. 
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After the promising data obtained from the optimization of one layer of the 
Halbach array, it was decided to assembly a three layer optimized Halbach array magnet, 
which thus had 48 magnet elements compared to 36 in the original version. With increased 
magnet numbers, the strength of both the attractive and repulsive magnetic forces were 
increased, which made it very difficult to safely build in the lab. As a result, expert help 
was sought (from the Magnet Expert Company, UK). A confidentiality agreement was 
Figure 4.7: Optimised Halbach array of Model 2: (a) optimized Model 2 Halbach one layer array 
with closed corners and a steel case. (b) Magnetic field strength of the magnet with and without 
the steel case which showed slightly increased magnetic field strength at 0.5 cm and further 
penetration depth with the steel case. (c & d ) show that there was no significant difference in 
magnetic field gradient and magnetic force for Halbach array magnets with/without a steel case. 
Black circles in the magnet refer to the position where the magnetic field strength measurements 
were taken, perpendicular to the magnet’s surface.  
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signed by the company to protect any IP resulting from the magnetic arrays. After this the 
magnet design and requirements were sent to the company. 
   Interesting results were found when the magnetic field strength was measured away 
from the surface of the magnet. It is noteworthy that the magnetic strength at the magnet 
surface varies depending on the orientation of each magnet. Figure 4.6 (a) shows two 
main areas where the magnetic field strength was different; blue areas which involved a 
meeting point with four different magnetisation orientations and yellow areas which also 
involved a meeting point of four magnetisation orientations, but all with the same angle, 
i.e. 90°. The difference in the magnetic field strength at these areas were measured and 
plotted, as illustrated in Figure 4.8 (b). The magnetic strength of the areas indicated with 
blue squares was higher than the magnetic strength of the middle area marked by the 
yellow square. With increasing distance, however, it was found that the magnetic strength 
and penetration depth of the middle area (yellow) were higher than the corners (blue) as 
illustrated in Figure 4.8 (c-d). The average values of the field gradient and magnetic force 
were calculated from both areas and the results plotted in Figure 4.8 (e-f). These finding 
are worth considering when applying MDT for deep brain tumour targeting. It is 
commonly assumed that the area having the highest magnetic field at the magnet surface is 
the best region to be located directly above the tumour. This is true for superficial 
treatment but for deeper treatment, the weaker magnetic field strength region seemed to be 
the best as it had a higher magnetic field gradient at further depth.    
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Figure 4.8: Optimised Halbach array of Model 2: (a) blue (corners) and yellow (middle) (b) Strength 
of magnetic field for both areas. The yellow areas (middle) showed the weakest magnetic field 
strength. (c-d) Magnetic field strength increased at further depth for the yellow areas. (e-f) 
Calculated average values of field gradient and magnetic force for both areas clearly indicate that 
the weakest surface magnetic field strength area (middle) has the highest field strength as well as 
magnetic force at depth. The orange arrow refers to the direction of the magnetic field 
measurement which was parallel to the magnet. Data was analysed using two way ANOVA-PRISM. 
****P<0.0001. 
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4.5.1 Development of a phantom model to assess SPION trapping 
An MRI scan of a brain tumour as well as a head of a patient was taken (provided 
by Professor Martyn Paley). The data was extracted and transferred to 3-D software in 
order to print a 3-D tumour phantom from clear photopolymer resin, using a Formlabs 
Form2 printer. The internal structure of the original prototype was created using a careful 
exploitation of the printing process, where the lattice infill of the printed component 
represented the internal flow structure of the tumour. For the head model, it was first 
attempted to extract surface/dimensional data from MRI data sets.  Although it was 
possible to gather data from these data sets, the quality of the model was severely 
lacking.  A compromised solution was therefore applied, where a downloaded 
photogrammetry head model was transformed to fit the size and shape of the low quality 
MRI extracted model.  This head model was then modified to provide access, a mounting 
point, and a 'skull thickness' was added.  The head model was printed on a 3D Systems 
ProJet 6000SD in clear photopolymer resin.  A base plate with mounting points was 
created from a piece of acrylic on a CNC router.  
All the 3D modelling was done using Blender, a 3D surface modelling software, 
which is excellent at creating organic surfaces and complex models, which would be very 
difficult to achieve using traditional parametric CAD modelling techniques.  The DICOM 
data surface extraction was done using 3D Slicer. This was carried out at the medical 
Advanced Manufacturing Research Centre (mAMRC) by Mr Marcus Crossley.  
Figure 4.9 represents the 3D head model, which geometrically mimicked the 
surface of the head of a patient. An x,y,z Cartesian coordinate framework (3-D) was used, 
where x represented the distance from the top to the bottom of the head, y represented the 
distance from the front of the head (forehead) to the back of the head and z represented the 
distance from the left ear to the right ear.   
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With the magnetic device placed on top of the head, the distance to the tumour was 
7.5 cm. On the other hand, if the magnetic device was placed on the front or back of the 
head, the maximum distance to the tumour was 10 cm. Last but not least, if the magnetic 
device was placed on the left or right side of the head, the maximum distance to the 
tumour would be 8.25 cm. Therefore, the maximum tumour depth would be (X = 8.25cm, 
Y = 10cm, Z = 7.5 cm). 
A simulated brain tumour, approximately 3 cm in diameter, was printed, using a 
synthetic polymer, with a positioning matrix allowing the tumour to be relocated anywhere 
within the printed head (Figure 4.10). The inside of the tumours were designed so that 
they had a complex flow network and had an inlet and outlet for connecting to a flow 
system. 
Figure 4.9: 3-D simulated head phantom with the tumour held on a stand on the 
grid matrix. The tumour was located at the maximum depth within the head for 
measurements; 16.5 cm from side to side, 20 cm from forehead to the back and 15 
cm from top head to down (nose level). The target depth was (8.25, 10, 7.5 cm). 
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4.6 Discussion  
Two Halbach arrays were assembled physically based on the FEMM model design 
configurations in chapter 3. The main challenge in the assembly procedure was to 
overcome the forces generated from using two different magnetisation angles for two 
magnet elements i.e. repulsive forces. NdFeB-N52 magnetic blocks create very strong 
magnetise fields ~1T [183]. It was therefore necessary to restrain the magnet blocks during 
the assembly procedure.      
In general, the data generated from FEMM models were slightly higher than those 
obtained from the assembled Halbach magnets. For example, from the FEMM model, the 
(d) (c) 
(b) (a) 
Figure 4.10: 3D printed tumour: (a & b) show the simulated tumour with a stand on a 
grid matrix. (c & d) show the printed  tumour  where (c) shows the complex flow 
network inside the tumour, (d)  shows the tumour from outside with the inlet and 
outlet connectors.  
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magnetic field strength was 1 T while the magnetic field strength from the physical model 
was 0.93 T. This discrepancy could be a result of technical errors in the way the magnets 
were simulated including the boundary conditions of the model. It is also possible that the 
difference could be due to the way the models were assembled, for example, due to high 
repulsive forces, gaps emerged between magnets with similar positive polarities. Also 
using glue to stick the magnets resulted in slight gaps. This discrepancy between simulated 
and assembled magnets was also noted by Bashyam et al. when a Halbach array magnet 
was designed, modelled and assembled for single-sided magnetic resonance [183]. In their 
study, the magnetic field strength of the assembled magnet was 0.17T while that of the 
simulated magnet was 0.174T. Similarly to our observations they attributed the 
discrepancy to variations between magnets and imperfections (gaps) in magnet assembly. 
In general, gaps between the magnets within the assembly are often inevitable, but using 
an adhesive with iron particles loaded into the glue the magnet may help to overcome this 
issue. Iron-loaded epoxy may also help focus and shape the magnetic field [168]. 
Assembling both models with multiple layers allowed assessment of the effect of 
the magnet volume on magnetic field strength, field gradient and hence magnetic force, as 
well as the penetration depth. Figure 4.1 provided clear information on the impact of 
adding more magnet layers to both models. It was noticed that the magnetic field strength 
for both models with three layers was slightly higher than those with one or two layers. 
There was a significant change in field gradient and magnetic force for both models with a 
third layer, however. It can be confirmed that increasing the volume/size of the magnet 
helps to increase the magnetic field strength, field gradient and force which agrees with 
results found in the literature [183][184][162]. Both models showed a sharp drop off in 
magnetic field strength, field gradient and magnetic force between 0 cm and 0.5 cm but 
after this, the drop off was more gradual.  
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In a comparison between models, it was found that Model 2 produced slightly 
higher magnetic field, field gradient and magnetic force than Model 1 for all numbers of 
layers. In terms of penetration depth, however, Model 2 had a significantly deeper 
penetration depth compared with Model 1. Some studies have reported a maximum 
penetration depth from Halbach arrays of between 5 mm and 50 mm [184] while our 
Halbach model ranged between 50 mm to 100 mm.   
It is worth mentioning that MPD for models 1 and 2 was 7.5cm and 9cm, 9.5 cm 
and 10cm, 12.5 cm and 13 cm for first, second and third layers, respectively. Although the 
field gradient is weak at those distances (~ 8 - 10 T/m), preliminary theoretical studies 
carried out by Voltairas and Ruuge proved that the required field gradients to trap MNPs 
should be 8-100 T/m (Ref), which confirm the ability of Halbach array to trap MNPs at 
those distances [185] [186]. In dynamic conditions, MNP trapping will occur if Fm in Eq 
1.5 of MNPs exceeds FD in Eq 1.6. This will be investigated experimentally in the next 
chapter.      
 
Model 2 was superior to Model 1 in terms of magnetic field strength, field gradient 
and magnetic force. Given that the primary objective of the study was to identify a model 
that produces higher magnetic field strength as well as penetration depth, Model 2 was 
therefore selected as the best Halbach array to use for further investigation. 
According to measurements from the 3D head/tumour phantom, the maximum 
depth of a tumour located within the head would be 10 cm. It was noted from the 
Gaussmeter measurements that the strength of the magnetic field is weak at 10cm. 
Therefore, further efforts were also made in order to further optimise the value of the 
magnetic field strength, field gradient and hence magnetic force of Model 2 at 10 cm. The 
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optimisation strategies that were considered for Model 2 included closing the corners with 
45° magnetisation orientation pointing towards the middle of the magnet array, as well as 
covering the magnet with a steel case to help shield and redirect the magnetic field. 
Interestingly, it was found out that the area that had less magnetic field strength at 
the surface of the magnet demonstrated the highest magnetic field gradient and force as 
well as magnetic penetration depth. In this case, therefore, to get an effective delivery of 
drugs to deep locations will require pointing the centre of the magnet towards the location 
of the brain tumour. The ability of the Model 2 Halbach array to steer SPIONs to the 
desired location of a simulated brain tumour will be discussed in the following chapter 5.  
Limitations 
One of the challenges associated with the assembling of Halbach arrays magnets 
was the magnetic forces that acted between each element, which made it difficult to 
assemble the multiple layers. To overcome this limitation, it was necessary to find an 
expert company to construct multiple layer magnet, but this can be costly and required that 
a confidentiality agreement was put in place.  
The other limitation is that only uniform shape magnets, i.e. square, can be 
assembled but such a shape would create a gap from the magnet edges when placed on a 
patient’s head. A curved shape would overcome this limitation, but a special machine 
would be needed to bend the magnet, this was not available for the current study.     
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Halbach Array trapping of SPIONs 
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5.1 Introduction 
The success of magnetic drug targeting (MDT) depends strongly on the ability of 
the magnet to steer and trap SPIONs that are loaded with drugs to the desired location. 
When the desired location is far from the external magnet, a strong magnetic field gradient 
is required, as it has been proved that magnetic field gradients drop off sharply with 
increasing distance between the magnet and the target [165]. As a result, the higher the 
magnetic field gradient, the higher the chances of trapping the SPIONs [187] [170]. In 
addition, the vascularisation of the target area is a crucial parameter in MDT and steering 
the SPIONs to a target with a complex vasculature is challenging [188] [189].  
Previous studies have been conducted to investigate the movement of SPIONs 
under the effect of magnetic fields in blood vessels in two models, namely in silico and in 
vitro [190] [191] [192]. Together, these studies show that movement of magnetised 
SPIONs under the effect of a magnetic field provokes interactions between the magnetised 
SPIONs leading to the creation of aggregates in the direction of the homogeneous field. 
Furthermore, the magnetic gradients are capable of steering the aggregates, as a whole, to 
the target.  
Kang et al., tested the ability of a Halbach permanent magnet array to separate 
living cells magnetically (Staphylococcus aureus-bacterial cells) over distances of up to 
30 mm. Magnetic micro-particles were bound to the cells and then placed in a 50 ml tube 
before exposing them to the magnet. In this study they used both a Halbach array (0.8 T) 
made with rectangular bar magnets and compared this to a conventional alternating 
magnet. The Halbach array was more effective and removed more than 95% of the 
bacterial cells compared to only 70% when they used the alternating array [165]. This 
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suggests that Halbach arrays could be used in high-throughput magnetic devices for 
separation of cells, molecules and toxins. 
Additional evidence that indicates the ability of the Halbach array to capture 
SPIONs in a desired location was shown in a study by Gitter& Odenbach in which they 
modelled a blood vessel supplying a tumour using a half Y-shaped glass tube and steered 
the SPIONs (7.5 nm) to a specific location [193]. The fluid flow was run for 10 min. The 
tube had a diameter of 1.6 mm and the flow rate was 12.3 mm/s, which was constant for 
the whole experiment. The magnetic field was generated by an axially magnetised 
cylindrical Halbach array with a diameter of 10 mm, a height of 5 mm and a magnetic flux 
density at the centre of the surface of 310 mT. It was claimed that injecting SPIONs 
towards and closer to the target area would result in the trapping of a higher SPIONs 
concentration in that area. In this case, it was observed that the targeting efficiency reached 
up to 97% of the SPIONs in the chosen branch [193]. Although they used an artificial 
system, the aim was to achieve MDT for tumour treatment. 
Magnetic fields can be used effectively to manipulate the movement of MNPs in a 
flow model with varied flow rates. This was confirmed by Munir et al.[194], where a 
microfluidic model containing 75 mm long and 800 µm diameter tangential microfluidic 
channels was used to switch MNPs from lesser to greater flow rates. The channel was set 
up to form an X-shaped where the lower rate flowed with MNPs and the upper flow rate 
flowed with water only. The flow rate was varied from 0.6–11 µl/s and was pumped using 
a peristaltic micro-pump. The MNPs consisted of an inner core made up of magnetite 
(Fe3O4) crystals of about 12 nm diameter, to form an overall size of 200 nm diameter at a 
concentration of 1 mg/ml. A permanent neodymium magnet (N52) was placed at the centre 
of the X-shaped channel. The magnet had dimensions of 1 × 1 inch 3/8-inch thickness with 
a flux density of 14 800 Gauss. It was found that negligible switching of MNPs takes place 
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in the absence of a magnetic field, whereas 90% of switching was observed when the 
magnetic field was employed. 
5.2 Aims and Objectives 
Hypothesis 
We hypothesise that our Halbach array can trap SPIONs in a 3D printed phantom 
(head/tumour) flow model at distances between 0 to 10 cm. 
Aim 
This chapter sought to demonstrate the ability of the Halbach array of Model 2 to 
trap different concentrations of SPIONs (Fe3O4) at different distances.   
The main challenge that has been focused on in this project is estimating the 
distance between a brain tumour (pg7) and the external magnet which allows trapping. For 
this reason, it was decided to use the technique of a 3D printer in order to print a model of 
a head and tumour based on that of a patient. By doing so, it would be possible to change 
and control the tumour location. Therefore, a physical head (not the brain/tumour) was 
modelled in order to place (fix) the magnet on the surface and control the magnet to 
tumour distances. The 3D printed tumours were  not hollow from inside but consisted of  a 
mimicry vessel network, typical of that seen in tumours. For this reason, the printed 
tumour is considered to have a complex vessel network inside. Evaluating HA using an in 
vitro model has an advantage over in vivo models e.g. a mouse model, where the head size 
is not comparable with a human head, and hence, the distance between the tumour and the 
magnet is too small.  
The following objectives were chosen based on the above conditions. 
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Specific objectives 
 To use a 3D printed phantom flow model with plastic and bio-phantom tumours 
to assess the trapping ability of SPIONs at different distances 
 To use a custom-made vasculature model to investigate the amount of time 
required for the SPIONs to be trapped within the vasculature tubing and how 
long the SPIONs remain trapped in the target area after removing the Halbach 
array. 
 To apply different techniques including magnetic resonance image (MRI), 
inductively coupled plasma microscopy (ICP) and nuclear magnetic resonance 
(NMR) to assess iron trapping within the models.  
This project is a preclinical study designed to use a lightweight, inexpensive and 
powerful permanent magnet (HA) for MDT. With the hope of eventually using this for 
clinical studies (see pg7). Therefore, in this preclinical study, three main objectives were 
defined;  
1. Use of in silico methods to design the required HA.  
2. Evaluation of the constructed HA in the lab using an in vitro method. This was to 
evaluate the trapping ability of HA for SPIONs.  
3. Evaluate the constructed HA using an in vivo model. This work was done in 
collaboration with a postdoctoral researcher (Dr Priya Patel) in mice. The results of 
these experiments were highly promising, see pg164.  
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5.3 Halbach array based on Model 2 traps SPIONs in a 
phantom flow model 
In this experiment, a head and tumour phantom model were used to evaluate the 
ability of Halbach array to trap SPIONs (Figure 5.1). From optical and MR scan data, a 
3D head model was printed which geometrically mimics the surface of the head of a 
patient as described in Chapter 4 Figure 5.1 a. Also, a brain tumour was printed using 
transparent material (synthetic polymer), with a positioning matrix allowing the tumour to 
be relocated anywhere within the printed head (Figure 5.1 b). The inside of the tumours 
were designed so that when printed they had a complex network and had an inlet and 
outlet for connecting to a flow system (Figure 5.1 c). The structure of the tumour model 
has been explained in more detail in section 2.2.3.2. A Halbach array magnet was placed 
on top of the head in order to trap SPIONs in the tumour whilst under flow conditions. The 
surface of the head was 0.8 cm in thickness, and the magnet was in direct contact with this. 
Ferrofluids with a range of SPION concentrations, i.e. from 1 mg/ml to 10 mg/ml were 
placed in 50 ml tubes and the fluid was run in an open loop through a fluid flow system 
using a syringe pump at a flow rate of 10 ml/min.  
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In these experiments, the tumour was placed directly below the head (from inside).  
SPIONs flowed at 10 ml/min were instantly held within the tumour and could be seen by 
eye. Figure 5.2a shows very little trapping of SPIONs in the control experiment in which 
no magnet was in place. On the other hand, the iron was instantly trapped after placing the 
magnet above the head Figure 5.2b. Once the iron was trapped there was a change in the 
colour of the collected fluid (Dark brown - SPIONs are concentrated) and after trapping of 
SPIONs (light brown - fewer SPIONs present) (Figure 5.2c).   
(b) 
 
Figure 5.1: A 3D printed phantom model to assess SPION trapping. (a) 3D printed adult 
head based on a patient MRI scan. (b) A transparent 3D printed tumour. (c) Interior 
structure of the tumour. SPIONs are pumped in an open loop through a flow system 
using a syringe pump at a rate of 10 ml/min. The magnet was placed in the centre of the 
head, in contact with the head (0 cm) and 8 mm way from the tumour (skull thickness). 
The flow was run until the fluid in the tube of 50 ml finished, for about 5 min. 
(a) 
(C) 
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Once the trapping of iron was complete, both the inlet and outlet of the 3D tumour 
phantom models were sealed with a silicone sealant to prevent the particles from leaking 
out and keep them inside the tumour. The tumours were then scanned via MRI in order to 
confirm SPION trapping. 
Figure 5.3 confirms the trapping of iron inside the tumour in the presence of the 
Halbach array. For the MRI scans, tumours were imaged following trapping of SPIONs at 
different concentrations of ferrofluid. MRI scans showed that the number of SPIONs 
trapped in the tumours increased with increasing concentration of the particles. This can be 
seen by the differences in the intensity of the colour in the samples where the control (with 
 (a)                                ( b)                             ( c) 
Figure 5.2: Halbach array traps SPIONs undergoing flow. SPIONs at 5 mg/ml in a 3D tumour 
phantom in an open loop through a flow system using a syringe pump at a rate of 10 
ml/min. The magnet was placed in the centre of the head, in contact with the head (0 cm) 
and 8 mm way from the tumour (skull thickness). The flow was run until the fluid in the tube 
of 50 ml was finished, for about 5 min. 
a. Shows the control tumour where the magnet was not applied where all SPIONs are 
the bottom of the tumour. 
b. Shows the tumour where most of SPIONs were trapped because the Halbach array 
magnet was placed on top of the head while the tumour was contained within the 
head. 
c. Shows collected SPIONs in the control tumour, before placing the magnet (dark 
brown) as all SPIONs came through the tumour, the collected SPIONs in the light 
brown tube shows that SPIONs were released from the fluid due to the presence of 
the magnet. 
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no magnet and trapped SPIONs) was the clearest. The more concentrated the SPIONs the 
more iron was present within the tumour.     
 
In addition, pixel values were extracted from the same region of interest from each 
tumour for scans with two different echo times i.e. TE 4.60s and TE 20s. The natural 
logarithm of the signal, Ln (signal) was calculated and plotted against time (Figure 5.4). 
The slope of the graph provides a measure of the T2* relaxation time. 
SPIONs in the tumour scan can be quantified by measuring the ratio of the signal 
intensity (SI) where pixel values were extracted from the same region of interest from each 
tumour with two different echo times, i.e. TE 4.60s and TE 20s, then signal intensity ratios 
(SIRs) in both TE was measured. The equation that was used to calculate T2* was 
described in chapter 2. Figure 5.4 below illustrates the values of T2* for each SPION 
concentration which show that the higher the level of iron concentration, the less the T2* 
value, as expected. These experimental results confirmed that iron particles with different 
Figure 5.3: T2* weighted MR images of four tumour models with different SPION 
concentrations. The MRI scan shows the SPIONs trapped within the tumours in the presence 
of the magnet. The darker the colour, the more SPIONs were trapped. In the control sample 
no magnet was present. The tumours were placed underneath the head (0.8 cm away from 
the magnet). The scans were obtained using a 3T neonatal MRI system with a dual gradient 
echo sequence, TE=4.60ms and 20ms. 
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concentrations were trapped adequately using the Halbach array magnet for the flow rate 
used.  
 
 
 
5.3.1 Ability of the Halbach magnet array to trap SPIONs at a 
range of distances  
Here, the iron trapping experiment was conducted in two parts. The first part involved 
trapping the iron alone, while the second part entailed trapping white blood cells (WBCs) 
loaded with iron. All the WBCs were incubated with SPIONs at a different range of 
concentrations for 24 hours. WBCs were seeded at 300,000 and incubated with 0.1, 1, 5, 
10 and 20 mg/ml. WBCs were harvested from healthy blood donors (n = 3). All the 
Figure 5.4: T2* decreases with increasing SPION concentrations. T2* values were 
calculated after SIRs were measured from 3T MRI scans at two different TE values; 4.60s 
and TE 20s.  
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procedures were explained in 2.2.12. Then the fluid was flowed using the same model as 
above. 
Both parts aimed to trap the iron at different distances, such as at 0.8 cm and 5 cm 
away from the magnet. The previous procedure was applied, to explore the effectiveness of 
the technique at different tumour depths within the head. When the fluid flow was run until 
the experiment was completed, the fluid iron inside the tumour was flushed out into a 
small tube in order to be prepared for ICP. This was another technique that was used to 
confirm the ability of the Halbach array to trap the iron particles with different 
concentrations at different distances. Interestingly, the trapping ability can be confirmed 
via the naked eye, as can be seen in Figure 5.5 below, where the attracted SPIONs 
decreased with increasing distance from the magnet. 
 
After the flow process was completed, the fluid in the tumour containing iron was 
flushed out into a small tube in preparation for ICP. The results obtained are shown in 
Figures 5.6 and 5.7 below. The results demonstrate the trapping ability of the Halbach 
array magnet at 0 cm (plus 0.8 cm which is the skull thickness) and 5 cm (plus 0.8 cm) 
Figure 5.5: the SPIONs at an initial concentration of 5 mg/ml flushed from the tumour after 
trapping at different distances. 
From right to left, control, at the internal head surface (0.8 cm away from the magnet), at 5 
cm and 10 cm away from the magnet. Halbach array magnet was used to trap SPIONs at a 
concentration of 5 mg/ml in a 3D tumour phantom in an open loop through a flow system 
using a syringe pump at a rate of 10 ml/min. When the trapping procedure was completed, 
the SPIONs trapped within the tumour were flushed out into a 15ml falcon tube to visualize 
the trapped SPIONs at different distances.   
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away from the magnet without WBCs as well as with WBCs. The results showed that the 
Halbach array trapped SPIONs at both distances but that the trapping efficacy decreased as 
the distance increased, i.e. 5 cm. 
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Figure 5.6: ICP data demonstrate the trapped SPIONs that were flushed out from the tumour phantom 
after applying a Halbach array magnet with one layer. The tumours were located at two different 
distances; (a) 0 cm away from the magnet and (b) 5 cm away from the magnet. When the trapping 
procedure was completed, the trapped SPIONs of different concentration, i.e. 1, 10, 15 mg/ml within the 
tumour were flushed out into a 15 ml falcon tube to be ready to detect SPIONs using ICP. Data are the 
mean and SD of N=3 experiments. All data was analysed using one way anova-prism.*p <0.01, **p 
=0.001 and ***p <0.001.  
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Figure 5.7: ICP data demonstrate the trapped SPIONs-WBCs that were flushed out from the tumour 
phantom after applying Halbach array magnet of one layer. The tumours were located at two different 
distances; (a) 0 cm away from the magnet and (b) 5 cm away from the magnet. When the trapping 
procedure was completed, the trapped SPIONs of different concentrations, i.e. 1, 10, 15 mg/ml within the 
tumour were flushed out into a 15 ml falcon tube to be ready to detect SPIONs using ICP. Data are the 
mean and SD of N=3 experiments. All data was analysed using one way anova-prism.*p <0.01, **p =0.001 
and ***p <0.001.  
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The previous data were sufficiently encouraging to consider trapping SPIONs at a 
greater distance, therefore, it was attempted to trap SPIONs at 10 cm. For simplicity, only 
one SPION concentration, i.e. 5 mg/ml, was used in the flow model with the Halbach array 
of three layers. 
Interestingly, although the magnetic field strength which was obtained both 
theoretically from the simulated FEMM and measured from the assembled Halbach 
models was very weak, i.e. 0.001 T at 10 cm, nonetheless SPIONs were still trapped at 
such a distance. ICP data in Figure 5.8 below showed a slight difference between the 
control and trapped sample but a significant difference between both samples where 
WBCs were loaded with SPIONs. 
This can confirm that our Halbach array was able to trap the iron at this depth (10 
cm) even with a weak magnetic field. 
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In general, the concentration of trapped SPIONs in the phantom flow model was 
different depending on the initial concentration of SPIONs and the location of the tumours 
within the head phantom. As expected, the further away the tumour was from the magnet, 
the fewer SPIONs were trapped. For example, at 5 cm depth, the concentration of SPIONs 
was 241 mg/l whereas at 10 cm, the concentration of SPIONs was 183 mg/l.   
Figure 5.8: ICP data demonstrates the trapped (a) SPIONs and (b) WBCs loaded with SPIONs of 5 ml/mg 
at 10 cm away from the Halbach array magnet of three layers. The control demonstrated the SPION 
concentration when no magnet was applied, while SPIONs+Mag demonstrates the trapped SPIONs where 
the magnet was applied.  When the trapping procedure was completed, the fluid that was inside the 
tumour was flushed out and transferred into a 15 ml falcon tube to be ready for detecting SPIONs using 
ICP. All data was analysed using t-test-PRISM.**p =0.702 and ***p =0.0824. 
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It was proved from the FEMM model that the Halbach magnet array is able to 
reach a depth of 10 cm with B = 0.001 T. Although the magnetic intensity is weak, it was 
interesting to confirm the trapping ability around that distance.  
In summary, it can be confirmed that our Halbach array magnet was able to trap iron 
particles with and without WBCs with different iron concentrations at different distances 
in a tumour model with a simple vasculature, i.e. a 3D printed tumour model with flow in a 
simple supply tube simulating a vessel.  
5.3.2 WBCs ability to take up SPIONS with minimal cell toxicity  
Next, the uptake of SPIONs by WBC and cell viability was confirmed. When SPIONs of 
different concentrations were incubated with WBCs for 24 hours, Prussian blue staining 
was used to confirm the distribution of SPIONs within the WBCs (Figure 5.9). 
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Flow cytometry was used to assess the cell viability. In flow cytometry, cells can 
be morphologically described by two main axes; forward scatter (FSC) and side scatter 
(SSC). The forward scatter represents the cell size and the side scatter represents the 
quality and condition of the cells. 2 μl of a 50 mg/ml stock of the viability dye propidium 
iodide (PI) was added to each sample immediately before analysing on a BD FACS 
(a) (b) 
(c) (d) 
Figure 5:9: Prussian blue staining showed SPION distribution within WBCs. (a) Control 
WBCs (pink). (b-d) SPIONs of 0.1, 1 and 10 mg/ml (dark) were distributed within WBCs. 
SPIONs of different concentrations were incubated with WBCs for 24 hours, then 
500,000 cells of 1 ml were centrifuged using the Cytospin technique. After applying 
Prussian blue staining, the slides were ready for analysis using light microscopy, Leica 
DM1000. 
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Calibur. PI is a membrane impermeant dye that is generally excluded from viable cells. It 
binds to double stranded DNA by intercalating between base pairs of dead cells [160].   
The viability of WBCs with and without SPIONs is illustrated in Figure 5.10 (a) 
below. The gated area (R1) presents the population of live cells and highlights that the 
different WBC populations can be distinguished based on the scatter profile i.e. 
lymphocytes, monocytes and granulocytes. All debris was removed by applying a gating 
strategy so that the analysis was only performed on cells. On the right is the gated area 
(R2), which represents the dead cells that have been stained with PI. The uptake of 
SPIONs at different concentrations was evaluated by flow cytometry. Figure 5.10 b shows 
representative fluorescent dot plots of the control cells- where no SPIONs were present, 
and the lowest and highest SPIONs at 0.1 mg/ml and 1 mg/ml respectively. What is 
interesting is that the WBCs increase in size in the presence of the SPIONs compared to 
the untreated cells. This is shown in the change in the side scatter profile of the cells (y-
axis). This suggests that cells have taken up the iron. Figure 5.10 (c) shows there was no 
significant effect on WBC viability in response to SPIONs, even at high concentrations i.e. 
20 mg/ml.  
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Figure 5.10: WBC take up SPIONs and do not undergo cell death. (a) Representative 
Flow cytometry dot plot of WBCs in SSC-FSC analysis (R1) which shows all types of WBCs 
including granulocyte, monocyte and lymphocytes based on their scatter profile. All the 
cell debris was gated out and a further gate applied to the cells (R2) to detect the dead 
cells with PI staining in the FL3-H channel. (b) Control sample, cells with 1 mg/ml SPION. 
(c) WBCs death percentage, where the cells were exposed to different SPIONs 
concentrations and incubated for 24 h. No toxicity effects were found. 
(a) (b) 
Chapter Five 
- 132 - 
 
It is also worth investigating the ability of the Halbach magnet array to trap iron in 
a more complex vasculature model. This will be demonstrated in the section below. 
5.4 Halbach array based on Model 2 traps SPIONs in Bio-
phantom flow model 
In this experiment, a more complex tumour vessel model was developed. A solid 
homogeneous piece of material with MRI properties close to the average properties of 
human brain tissue was designed. This is referred to as the bio-phantom tumour. The 
material has realistic MRI and mechanical properties and is suitable for MR imaging. The 
tumour used had a complex internal network and had two inlets to be connected to the 
flow tubes. Figure 5.11 below. 
 
In order to assess the trapping ability of the Halbach array magnet with a more 
complex tumour model, the bio-phantom brain tumour model was initially attached to a 
simple vasculature supply. This was located 5 cm away from the magnet, as illustrated in  
Figure 5.12. An iron concentration of 5 mg/ml was used with a flow rate of 150 
ml/min. The same trapping procedure as discussed for the previous model was applied in 
Figure 5.11: the internal design of bio-tumour where shows the complex 
network of the 3D tumour. 
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this experiment. It can be seen that iron particles were mostly trapped in the area close to 
the magnet (yellow circle). Although the tumour was 5 cm away from the magnet, trapped 
iron can be seen by naked eye (dark spots in the red circle). 
 
MR images of 9.4 T were also acquired to confirm the trapping (Figure 5.13). This 
showed that SPIONs were trapped at 5 cm distance (dark area). The dark area in the MR 
images demonstrates the iron particles passing through the tumour. When the magnet was 
in place, however the iron particles were trapped more effectively and created a dark area, 
as shown on the RHS. This confirmed the ability of the magnet array to trap iron particles 
in a complex model at a distance as high as 5 cm. 
 
 
 
 
Figure 5.12: A three layer Halbach array magnet was used to trap SPIONs applied at a 
concentration of 5mg/ml in a bio-phantom tumour model that was attached to a complex 
vasculature model where the tumour was located 5 cm away from the magnet. The fluid flow 
was run in a closed loop through a flow system using a peristaltic pump at a rate of 150 
ml/min. The magnet was placed in the centre of the main tube parallel to the tumour. The fluid 
was flowed until most of the SPIONs were trapped and the fluid was clear.  
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For further investigation, a more complex model was designed to assess the 
trapping ability of the array magnet and this is discussed in the section below.  
5.5 Halbach array based on Model 2 traps SPIONs in a 
complex vasculature flow model 
In this experiment, a complex vasculature model was developed in attempt to come 
closely mimic real human blood vessels. This model had multiple channels with four 
branches, each with an internal diameter of 2 mm, branched from a main supply vessel 
(tube) with a 3 mm internal diameter at different distances i.e. 3 cm, 5 cm, 8 cm and 10 
cm, as shown in Figure 5.14. The main tube had an open inlet and outlet, which were 
connected to the 50 ml tube, allowing the flow of the iron fluid in a closed loop. This was 
to assess the magnet’s trapping ability in a more complex model. The Halbach array was 
placed on top of the model until all the SPIONs were trapped and this helped to investigate 
how long the magnet should be kept in place before removing it.   
Figure 5.13: 9T MRI scans show the trapped SPIONs in the bio-phantom tumour model. (a) SPIONs 
where no magnet was applied, (b) SPIONs with applied magnet. A three-layer Halbach array. SPIONs 
were used at a concentration of 5mg/ml in a bio-phantom tumour model that was attached to a 
complex vasculature model where the tumour was located 5 cm away from the magnet. When the 
trapping procedure was completed, the tumour was removed from the vasculature model and the 
edges were sealed ready for MRI.  
(b) (a) 
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The second objective of this experiment was to investigate the time that was 
required to trap all the iron particles in the initial 5 mg/ml solution in a 50 ml tube, as well 
as the length of time that the iron particles would remain in place after removing the 
magnet. This experiment was conducted at two different flow speeds; 150 ml/min and 300 
ml/min. The results are discussed below. 
The trapped iron particles were observed in the main vessels as well as in the first 
main branched tube- 3 cm away (Figure 5.15). At distances from 5 cm and upwards, 
however, it was hard to visualise the trapping of the iron particles.  
MNP trapping over time can be seen in Figure 5.15, where MNPs accumulated 
over time. It is evident that MNPs were trapped more effectively in the tube close to the 
magnet than in the tube that was 3 cm away from the magnet. 
3 cm 
10 cm 
8 cm 
5 cm 
Figure 5.14: A three-layer Halbach array was used to trap SPIONs at a concentration of 5 mg/ml in a 
complex vasculature model. This consisted of four channels attached to the main vessel supply at 
different distances i.e. 3, 5, 8, 10 cm away from the magnet. The fluid flow was run in a closed loop 
through a flow system using a peristaltic pump at a rate of 150 ml/min. The magnet was placed in the 
centre of the main tube. The fluid was flowed until most of the SPIONs were trapped and the fluid was 
clear. 
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Figure 5.15: Trapped SPIONs in the complex vasculature model at two different distances with different 
flow rates. Photographs showing 0 cm and 3 cm away from the magnet - black and red circles respectively, 
at two different flow speeds; (a) 300 ml/min and (b) 150 ml/min. A three-layer Halbach array magnet was 
used to trap SPIONs applied at a concentration of 5 mg/ml in a complex vasculature model. The fluid flow 
was run in a closed loop through a flow system using a peristaltic pump at the two flow rates above. The 
magnet was placed in the centre of the main tube. The fluid was flown until most of the SPIONs were 
trapped and the fluid was clear. The results showed that the lower the flow rate the more effective the 
trapping of the SPIONs. 
 
10 sec 
sec 
40 sec 180 sec  80 sec  
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It can be seen from the above Figure that the volume of MNPs was increased over 
time. It was difficult to quantify the volume of trapped MNPs inside the tube, however, the 
pixel signal of MNPs (intensity) was considered. To do this, a video of the trapping 
experiment was taken with clips captured at different times. Each clip was then imported 
to ImageJ software for iron particle analysis (see Appendix IX). The mean intensity of the 
iron particles was calculated at different times for each tube as illustrated in Figure 5.16 
below.  
 
 
Figure 5.16: Intensity of trapped SPIONs of 150ml/min flow rate at different time interval for (a) the tube 
close to the magnet (0 cm), (b) 3 cm way from the magnet   
    
Since the flow rate in human capillaries is very high, it would be interesting to see 
whether or not the magnet was able to trap the iron at higher flow rates. The maximum 
flow rate that our vasculature model could tolerate was 300 ml/min, anything more than 
this resulted in the branch tubes being damaged. The experiment was therefore run again at 
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300 ml/min and the magnet placed on top of the tube model until all the magnetic particles 
were fully trapped. The mean of intensity signals (volume) of the iron particles was 
calculated at different times for each tube as illustrated in Figure 5.17. 
 
 Figure 5.17: Intensity (volume) of trapped SPIONs at 300ml/min flow rate at different time interval for 
(a) the tube close to the magnet (0 cm), (b) 3 cm way from the magnet.  
5.6 Discussion & Conclusion  
This chapter has focused on assessing the ability of the Halbach array to trap iron 
particles in two different phantom models as well as two different vasculature models. 
It was mentioned earlier that a strong magnetic field strength plays a major role in 
effective MDT. Besides that, both the hydrodynamic and physiological parameters play a 
major role in determining the success of MDT when SPIONs (ferrofluids) are administered 
intravenously or intra-arterially. Hydrodynamic parameters include blood flow rate, 
viscosity of the fluid, ferrofluid concentration, infusion route and circulation time. 
Physiological parameters include tissue depth to the target site (i.e. distance from the 
magnetic field source), reversibility and strength of the drug/carrier binding, and tumour 
volume [195]. 
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The hydrodynamics of drug targeting in MDT has been studied and preliminary 
investigations have suggested that for most magnetite-based carriers, including SPIONs, 
flux densities at the target site must be of the order of 0.2 T with field gradients of 
approximately 8 Tm-1 for femoral arteries and greater than 100 Tm-1 for carotid arteries 
[185]. This suggests that targeting is likely to be most effective in regions of slower blood 
flow, particularly if the target site is closer to the magnet source. 
To understand the trapping procedure, forces that are applied on SPIONs in order to trap 
them in a fluid flow model are as follows (Figure 5.18):  
  
Several forces need to be considered in MDT, i.e. magnetic force, fluid (drag) force 
as well as gravity force. Once the SPIONs reach the magnetic field area, they start to 
accumulate and form an aggregate. In this case, the magnetic forces that affect the SPIONs 
are stronger than the force of the flow, and therefore the SPIONs stop moving and stick to 
the side near the magnet until the size of the aggregate increases so that the flow force 
again exceeds the magnetic force and they are released. Hence, to achieve a successful 
magnetic trap in a flow model the magnetic force must exceed all the other forces.  
Magnet 
Iron Particles 
Fluid flow force 
Magnetic force 
Figure 5.18: A hypothetical magnetic drug delivery system in a simple fluid flow model. 
The Halbach array is placed outside the tube so that its magnetic field gradient might 
capture SPIONs flowing in the circulatory system. 
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In this project, MRI scans confirmed the ability of a specially designed Halbach 
array to trap iron particles at different concentrations i.e. 1 mg/ml, 5 mg/ml and 10 mg/ml. 
It was observed that the main challenge with the 3D printed tumour model was that the 
plastic material itself had short lived signals (T2) [196] which led to the creation of dark 
areas in the control tumour even where no iron was present (Figure 5.3). Calculation of 
T2* showed that the tumours that had more iron particles in them, had shorter T2* (Figure 
5.4) as expected. 
ICP data showed that the trapping of iron particles in the presence of the Halbach 
array increased as the initial concentration of particles was increased. This phenomenon 
was observed at different distances; that is, the trapping of particles increased with 
increasing concentration at 0, 5 and 10 cm away from the magnet. The quantity of trapped 
particles decreased with increasing distance from the magnet, as shown in. The same result 
was observed when the iron particles were incubated with WBCs. When a cell is loaded 
with MNPs and an aggregation of magnetic particles forms, the particles will typically act 
as a single magnetic particle which led them to be trapped under the effect of the magnetic 
field [197]. Overall, these results suggest that MDT is a promising technique for brain 
tumour therapy.  
In order to improve the visualisation of iron particles, an alternative to the 3D 
printed tumour model was developed. This was named the bio-tumour phantom and was 
fabricated to mimic the T2* of brain tissue and hence obtain clearer MRI images. Another 
more complex model, the vasculature model was also developed. All these were developed 
in search of a model that would mimic brain tumours in vitro. 
Both models were developed to illustrate how the flow is divided into multiple 
paths instead of a simple tube with one path. The MR images showed the ability of the 
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Halbach array magnet to trap iron particles at a depth of 5 cm. Here, it was observed that a 
small aggregation was formed in the more distant tube, i.e. 3 cm compared with the tube 
closer to the magnet at 0 cm. The drag force in the far tube was stronger than the magnetic 
force due to the increased distance, meaning a weaker trapping force. Since the flow force 
is proportional to the total volume of particles (aggregation), smaller aggregated particles 
will experience greater drag due to flow than larger particles [197] . The following 
simplified diagram in Figure 5.19 shows how the trapping procedure was performed in the 
more complex vasculature model. 
  
The flow rates that were used in the models included 10, 150 and 300 ml/min, and 
this is lower than the average human brain flow rate of about 800 ml/min [198]. It was 
difficult to use flow rates above 300ml/min because this resulted in the bursting of the 
tumour and vasculature models.  
Trapping iron particles at further depth, i.e. 10 cm, was also investigated. It was not 
possible to confirm the data via MRI because the vasculature model was too large to fit in 
the available scanners. 
Magnet 
Iron Particles 
Flow direction 
Figure 5.19: The trapping of SPIONs in the complex vasculature model. Fluid with SPIONs divided 
into two ways crossing the Y channel. More SPIONs were trapped in the tube that was closer to the 
magnet 
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The experimental results indicate that flow rate influenced the trapping of the iron 
particles. For instance, the higher the flow rate, the less the amount of iron particles 
trapped in the tubes and this agrees with results from other studies. For instance, in a 
dynamic flow experiment, Riegler et al. constructed an in vitro model to assess the 
feasibility of magnetic cell targeting approaches using SPIONs that travelled in a vascular 
bifurcation (a small artery flow, Y-shaped) phantom at different flow rates; 1, 2, 4 and 6 
cm/s [199]. The diameter of the bifurcation tube was 0.8 mm, with a bifurcation angle of 
30°.  In their study they used MRI with a field gradient of 0.5 T/m to guide the 
magnetically labelled-cells to the desired location. The phantom was connected to an 
infusion pump and placed into the centre of the MRI system. They showed that at all the 
different flow rates, 75% of all magnetised cells were directed to the target but that the rate 
of trapping decreased as flow rates increased: 49%, 31%, 13%, 0.5% for 1, 2, 4 and 6 cm/s 
respectively. 
It was interesting to see that MNPs accumulated over time when the magnet was 
applied. It was clear that the volume of accumulated trapped MNPs increased over time. 
Also, it was shown that the closer MNPs were to the magnet, the more trapping occurred, 
as expected. The volume of trapped MNPs depends on the exposure time to the magnet. It 
was observed from the video clips that the time that was needed for MNPs to be trapped 
completely was about 3 min and 4 min for the tubes that were 0 cm and 3 cm away from 
the magnet, respectively. 
In MDT, it would be interesting to know for how long MNPs and hence the drug 
would remain in place when the magnet was removed. In this project, it was noticed that 
when the magnet was removed (after completing the experiment of Figure 5.14), the 
volume of accumulated trapped MNPs initially flushed away quickly.  MNPs in the tube 
that were 3 cm away from the magnet were released in less than 1 min. while it took 
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around 10 min for the MNPs close to the magnet (0 cm) to be released. The SPIONs lasted 
longer in the tube that was closer to the magnet because of the large size of aggregated 
SPIONs which created stronger magnetised force between the particles capable of resisting 
the fluid flow force [194]. 
In general, in order to apply the Halbach array magnet for MDT for brain tumours, 
several issues should be considered and this include, amongst others, the depth of the 
tumour, the vasculature network as well as the blood component, i.e. the white blood cells 
(WBCs) that will carry the SPIONs to the brain. A consideration of the aforementioned 
issues in this project was essential in order to get a realistic model that closely mimics 
brain tumour conditions found in humans. 
Flow cytometry analysis in this study showed that although a range of SPION 
concentrations were taken up in WBCs, up to 20 mg/ml, the SPIONs’ toxicity was low. In 
a separate study, it has also been proved that SPION MNPs at concentrations of ≤100 μg/ 
mL are non-toxic to cultures of murine macrophage cells (J774) [200]. Although higher 
concentrations were being used in this study, SPIONs did not exhibit any toxic effect on 
WBCs [201] [202]. 
Overall, the in vitro experiments showed that Halbach arrays could trap SPIONs 
with/without WBCs inside the tumour at distances up to 10 cm. This suggests that the 
Halbach arrays have the potential to trap therapeutic drugs labelled with iron particles at 
distances up to 10 cm and we believe this would be useful for targeting of anti-cancer 
therapies to brain tumours.  
Given that the iron particles will be applied inside the patient’s body, testing the 
iron toxicity to human cells is clearly imperative. The testing of iron toxicity in human 
brain cells constitutes the main focus of the next chapter. 
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Limitations; 
This study was carried out with an in vitro 3D flow phantom model, which does 
not have the complex vasculature and BBB found in humans. This model therefore needs 
to be replaced with an animal model, such as pig, in order to mimic the brain vasculature 
networks, the brain flow rate, and the distance between the target site (brain tumour) and 
the magnet.  
In addition, the aggregation caused by accumulating SPIONs, due to the attraction force in 
the tube was not investigated in this study. This may lead to embolization of the blood 
vessels in the target area [195]. Further investigations are required to overcome this issue 
and this could include the coating of SPIONs with appropriate materials to prevent 
aggregation.  
Uncoated SPIONs were used in this study, however, despite being non-toxic at 
high concentrations if these SPIONs are to be used in biomedical therapy suitable coating 
materials should be considered. Coating helps to reduce toxicity and the half-life of the 
particles in circulation and also plays an important role in the conjugation of the SPIONs 
with therapeutic drugs [116].  
The other limitation of this study is that no anticancer drugs were used since the 
model that was used is just a 3D printed flow phantom. This will need to be the focus of 
further studies in an animal model.  
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6.1 Introduction 
In MDT to brain tumours, SPIONs are loaded with anticancer drugs and are 
injected intravenously into the body. An external Halbach array is placed on the patient’s 
head in order to steer and trap all the magnetised drugs to the brain tumour. Injecting 
SPIONs into a biological system results in their interaction with cellular structures, for 
instance, cells within the blood stream, endothelial cells lining the blood vessels, and/or 
epithelial cells in underlying tissues [203]. In chapter 5, it was found that at even high 
concentrations of SPION, human WBCs were not susceptible to cell death following 
incubation with high concentrations of SPIONs.  It is, therefore, significantly important to 
investigate the level of toxicity on the cellular structures in biological systems.  
Although SPIONs have been used for several biomedical applications, including as 
a contrast agent for MRI, and are generally considered to be safe, it is also acknowledged 
that SPIONs can be harmful to cells and tissues in some circumstances [204]. The toxic 
effect on cells as a result of contact with SPIONs depends on several parameters such as 
the type of cell and their sensitivity to the iron, the size of the SPIONs, their concentration 
and incubation time. In addition, other factors such as the type of coating, the nature of the 
cell-medium (its chemical composition), the charge of the iron (oxidation state) and the 
way in which the SPION interacts with protein all contribute to SPION toxicity in cells 
[205]–[207] [208]–[210]. Singh et al., have reported that exposure to SPIONs for a period 
of time is linked to substantial harmful effects such as inflamed neural cells; mitochondrial 
dysfunction, the development of apoptotic bodies and a noticeable increase in 
chromosomal damage, such as the leakage of lactate dehydrogenase through the cell 
membrane, the condensation of chromosomes and an increase in the number of 
micronuclei as well as the condensation of chromosomes [211]. 
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A number of studies have been conducted to investigate the toxicity of different 
types of SPIONs with different coating materials, with the results showing that, in general, 
the toxicity level is either low or negligible, that is, no toxicity at all in the cells with low 
SPIONs concentration (<100 µg/ml). The cells investigated include fibroblasts in vitro 
[206], human dermal fibroblasts in culture [207] and mouse fibroblast cells [208]. It was 
observed, however, that the level of toxicity increased as the concentration of SPIONs 
increased (>100 µg/ml) [211].  
Conjugating cells with SPIONs make the cells sensitive to an external magnetic 
field. In an in vitro study conducted by Sruthi et al. it was found that more than 85% of 
magnetised oligodendricyte cell line 158N (with PEG coated SPIONs) were retained when 
an external magnet was applied and this was verified using Prussian blue staining. The 
incubation time in their study was 24h at a concentration of 50 μg/ml [203].  
Matuszak et al. investigated the toxicity of SPIONs at concentrations between 0 
and 60 mg/mL in human umbilical vein endothelial cells (HUVECs), so as to evaluate the 
effect of SPIONs on the vasculature. Flow cytometry data confirmed that the proportion of 
necrotic cells was not significantly different between untreated control and SPION-treated 
samples. In addition, the effect of SPIONs on endothelial growth in a fluid flow model was 
evaluated using an arterial bifurcation in vitro model-Y shaped micro slide. SPIONs were 
circulated in the model, where 7 x 105 endothelial cells were seeded on to the microslides, 
at a 9.6 mL/min flow rate for 18 hours. An external 37 mT magnet was placed on the outer 
wall of the model. The uptake of SPIONs and their effect on endothelial cells were 
assessed using two methods: real-time cell analysis and live-cell microscopy. The cell 
index measurement showed that there were no significant differences between the control 
and SPION treated sample. The live-cell microscopy data indicated that there was also no 
significant effect on cell morphology in treated cells compared with untreated cells. It was 
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concluded that SPIONs are safe technique to be used as a drug carrier i.e. for 
chemotherapy for MDT.   
In another study, an in vitro BBB Model in Transwell Membrane Plates was used 
to investigate the ability of fluorescence starch-coated iron oxide nanoparticles (IONPs), 
with an average diameter of 117.4 nm and with a range of concentrations (35, 70, and 140 
μg/ mL) to cross the model and enter into a monolayer of cultured brain capillary 
endothelial cells (BCECs). An external magnet was applied to investigate the ability of the 
magnetic force to trap IONPs to the bottom of the plate where the astrocyte cells were 
located. The IONPs were incubated with BCECs for 24 hours with no magnet present, and 
for 5 hours with the magnet present. Cell viability was evaluated using a live−dead 
viability assay, which showed that there were no signs of reduced cell viability either with 
or without the magnet. In addition, fluorescence microscopy showed that the SPIONs were 
distributed within the cell boundaries of the BCEC monolayer as well as trapped in 
astrocytes as a consequence of the magnetic force [212]. 
Coccini et al., meanwhile, assessed the toxic effect of uncoated-IONP-Fe2O4 in 
cerebral cell lines, including neurovascular cells of the brain, namely astrocytes (D384) 
and neuronal (SH-SY5Y) cells [213]. The IONPs were ~20 nm diameter and various 
concentrations, between 1–100 μg/ml, were added to the cells. The incubation time was 
two days and the toxicity was evaluated by MTT assay. It was found that in the first 4 
hours, starting from a concentration of 25 μg/ml, cell viability decreased by between 25 
and 30%. It was also observed that cytotoxicity increased significantly with increasing 
incubation time. The following results were observed: 
 After 24 h, the rate of cell death was between 35–55% and the effect was 
noticed at concentrations of 10 μg/ml.  
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 After 48 h, 25–75% of significant cell death had taken place and this was 
evident from concentrations as low as 1 μg/ml.  
The results indicated that SH-SY5Y cells were less prone to Fe3O4 toxicity than 
D384 cells. It was noticed that the function of the mitochondrial cells was affected after 
only 48 h and there was significant death of the cells of between 35–45%, starting from 10 
to 100 μg/ml [213]. In conclusion, IONPs had a more harmful effect in D384 than in SH-
SY5Y [213]. This was important since the authors wanted to investigate the relationship 
between accumulated IONPs in central nervous system (CNS) cells that may lead to 
neurodegenerative disorders.  
A recent study was conducted to assess that the biocompatibility of BSA‐coated 
SPIONs with a range of hydrodynamic diameter sizes, including 85 ± 10 nm (BSA‐IONP‐
80), 36 ± 6 nm (BSA‐IONP‐40) and 38 ± 6 nm (BSA‐IONP‐PEG) on brain tumour (U251) 
glioblastoma cells [214]. Of all the different materials, it was found that MNPs coated with 
albumin gave the desirable results, that is, a stable and biocompatible shell that prevents 
cytotoxicity caused by the magnetite core. It was also observed that after a long exposure 
time (48h), due to free radical production, the iron oxide nanoparticles become more 
cytotoxic, although this was considered to be at a low level. 
For magnetic drug targeting to the brain, the accumulation of SPIONs in and 
around the BBB may result in toxicity. This needs to be considered since changes in brain 
iron concentrations are strongly correlated with human neurodegenerative diseases [212]. 
Given that SPIONs are able to enter the brain cells, potential negative effects arising from 
the exposure of brain cells to SPIONs have to be taken into consideration [215]. In this 
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chapter we have used compared concentrations of SPIONs at 0.1 mg/ml and 1 mg/ml on 
cell toxicity. The cells investigated were originated from the brain. 
6.2 Aims and objectives 
Hypothesis 
Guiding magnetised drugs to brain tumours with the help of an external magnetic 
field requires the use of MNPs. The size, coating and concentration of these iron particles 
needs to be taken into consideration in a therapeutic setting. We hypothesise that our 
SPIONs of <50 nm in diameter are taken up by cells of the brain and result in minimal cell 
toxicity.   
Aims 
The aim was to evaluate the uptake of SPIONs and the viability of brain cells and 
brain tumour cells. The permeability of the BBB is controlled by brain microvasculature 
endothelial cells (BMVEC) which are supported by the neurovascular unit (NVU), i.e. the 
microglia, astrocytes, pericytes and neurons that together form the so-called 
neurodegenerative unit [216]. Therefore, human brain endothelial cells (hBMEC-D3), as 
well as one of the NVU, i.e. human astrocyte cells (HA), were chosen in order to assess 
their uptake and viability as they are the main components of the BBB. In addition, a 
human glioblastoma cell line (U138) was investigated given that glioblastoma is the most 
common brain tumour in adults [217].  
Specific objectives 
1. To use transmission electron microscopy (TEM) to assess the SPION size and 
evaluate the intracellular uptake of SPIONs in the cells.  
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2. To assess cell viability following incubation of the different cell types with 
SPIONs for 24h. Flow cytometry was used to measure cell death using Propidium 
iodide (PI). 
6.3 Uncoated SPIONs are not uniform in size or shape 
The SPIONs used in this study were prepared for imaging with TEM as described 
in chapter 2 section 5.1.2. A concentration of 0.1 mg/ml was diluted in PBS and a final 
volume of 300 μL was prepared for TEM imaging. 
As shown in Figure 6.1a the SPIONs were surprisingly very different in both size 
and shape (octagonal and heptagonal) these appeared to aggregate in large clumps, which 
is typical due to the attraction forces between SPIONs. The average diameter of the 
SPIONs was measured using ImageJ software from the TEM images. Although the 
commercial SPIONs were labelled as having a specific diameter of less than 50 nm, our 
measurement showed that a 60 nm particle was identified (Figure 6.1 b) The average size 
of 23 particles was calculated to be 30 nm, however. This could have significant impact on 
drug delivery and access to the BBB.  
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6.4 Cell uptake and viability following incubation with 
SPIONs 
All the cells were incubated with SPIONs at a different range of concentrations for 
24 hours. Endothelial cells, astrocyte cells and brain tumour cells were seeded at a density 
of 300,000 cells/well in 2 ml of medium, and 24 h later incubated with 0.1 and 1 mg/ml of 
iron.  
Flow cytometry was used to assess cell viability. In flow cytometry, cells can be 
morphologically described by two main axis; forward scatter (FSC) and side scatter (SSC). 
The forward scatter represents the cell size and the side scatter represents the quality and 
condition of the cells. A 2 μl of a 50 mg/ml stock of the viability dye propidium iodide (PI) 
was added to each sample immediately before analysing on a flow cytometer (BD FACS 
Figure 6.1: SPION identified using TEM are not uniform in size or shape. (a) TEM images of 
SPIONs at a concentration of 0.1 mg/ml.  The size and shape of the particles varied. Images 
were taken with FEI Tecnai Biotwin operated at 120kV with an Orius 1000 camera using 100-
200nm magnification scales. (b) Calculated average SPION size was measured using ImageJ 
software. The sizes were measured from TEM images, different sizes were found, up to 60 
nm in diameter.  
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Calibur). PI is a membrane impermeant dye that is generally excluded from viable cells. It 
binds to double stranded DNA by intercalating between base pairs of dead cells [160]. 
Transmission electron microscopy (TEM) was used to investigate the intracellular 
localization of SPIONs in the cells. 
The viability of endothelial, astrocytes and glioblastoma cells with and without 
SPIONs is illustrated in Figure 6.2, 6.3 and 6.4 respectively. In each case, the gated area- 
black dots in (R1) in part (a) of each figure presents the population of live cells while the 
gated area- red dots (R2) in part (b) represents the dead cells of control (no SPIONs), cells 
with 0.1mg/ml and 1mg/ml of SPIONs respectively. 
The cell viability was visualised by calculating the percentage of live cells that 
remained after exposing SPIONs to the cells. The reason for calculating the live cells 
instead of dead cells is that there were many dead cells that were not PI positive (most 
likely typical cellular debris), as a result, plotting the percentage of live cells was 
considered more accurate than plotting the percentage of dead cells. 
In endothelial cells, it was found out that these concentrations had a significant 
effect, although still very low, but that it increased with increasing SPION toxicity, Figure 
6.2(c).  
In astrocytes, cell viability results were significant, in that it was found that 
SPIONs at a concentration of 0.1 mg/ml had a small toxicity effect, while a 1 mg/ml 
concentration had a high toxicity effect, Figure 6.3 (c). This means that astrocyte cells are 
sensitive to SPIONs. 
In glioblastoma cells, it was found that the toxicity of the 0.1 mg/ml was slightly 
significant but the effect increased with increasing concentration, i.e. 1 mg/ml, Figure 6.4 
(c). 
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In order to visualise the SPIONs within the cells, TEM images were taken, as 
illustrated in Figure 6.2 (d), 6.3 (d) and 6.4 (d). On the left hand side are the control cells, 
in which no SPIONs were present, whereas SPIONs are clearly visualised accumulated in 
the cytoplasm area on the right hand side image (see blue arrows).   
 
 
 
 
 
 
Chapter six 
- 155 - 
 
  
Figure 6.2: Endothelial cells take up SPIONs and undergo cell death: (a) Representative flow 
cytometry dot plot of endothelial cells in SSC-FSC analysis (R1), based on their scatter profile. (b) All 
the cell debris was gated out and a further gate applied to the cells (R2) to detect the dead cells with 
PI staining in the FL3. (c) The percentage of live cells presented and a multiple comparisons test was 
performed and slight toxicity effects were found with the 0.1 mg group compared with the control, 
while a more significant effect was found with the 1 mg group compared with control. Data are the 
mean and SD of N=3 experiments. All data was analysed using one- way ANOVA-PRISM.*p <0.01,**p 
=0.001 and ***p <0.001. (d) TEM images of endothelial cells; control-LHS and 0.1 mg/l SPIONs within 
the cells-RHS (blue arrows). 
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Figure 6.3: Astrocyte cells take up SPIONs and seems to be sensitive to SPIONs: (a) 
Representative Flow cytometry dot plot of WBCs in SSC-FSC analysis (R1) which shows all types 
of WBCs, including granulocytes, monocytes and lymphocytes based on their scatter profile. (b) 
All the cell debris was gated out and a further gate applied to the cells (R2) to detect the dead 
cells with PI staining in the FL3-H channel. Top- control sample, middle- cells with 0.1 mg/ml 
SPIONs and bottom- cells with 1 mg/ml SPIONs. (c) WBCs death percentage, where the cells 
were exposed to different SPION concentrations and incubated for 24h. A multiple comparisons 
test was performed and significant toxicity effects were found. Data are the mean and SD of N=3 
experiments. All data was analysed using one way ANOVA-PRISM.****p <0.0001. (d) TEM 
images of endothelial cells; control-LHS and 0.1 mg/l SPIONs within the cells-RHS (blue arrows). 
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Figure 6.4: Glioblastoma cells take up SPIONs and do undergo cell death at high SPIONs 
concentrations  
(a) FACs- flow cytometry of brain tumour cells in SSC-FSC analysis (R1) -control- shows both live 
and dead cells. SSC-FL3 (R2) plot shows the dead cells with PI staining. (b) cells with 0.1 mg/ml, 
1 mg/ml SPION, respectivly. (c) Cell viability when exposed to different SPIONs concentrations 
and incubated for 24h. A multiple comparisons test was performed and no toxicity effects were 
found. Data are the mean and SD of N=3 experiments. All data was analysed using one way 
ANOVA-PRISM.***p =0.0007,  ****p <0.0001. No toxicity effects were found with 0.1 mg/ml, 
however, low toxicity were found with 1 mg/ml SPIONs for 24h. (d) TEM images of brain 
tumour cells; control-LHS and 0.1 mg/ml SPIONs within the cells-RHS (blue arrows). 
(a)                                     ( b)           Control      0.1 mg/ml                 1 mg/ml       
    
(d)                             Control                    SPIONs    
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6.5 Discussion & Conclusion 
In this experiment, SPION uptake and cell toxicity were investigated using some 
BBB cells including endothelial cells (hBMEC-D3) and astrocyte cells. Brain tumour, i.e. 
human glioblastoma cells (U138) were also used.  
Shape and size are crucial parameters of SPIONs that should be considered for 
MDT. An ultra-small SPION i.e. < 9 nm diameter is rapidly cleared from the circulation 
[218]. It also would be difficult for them to be trapped by external magnetic field due to 
the large flow force, which would exceed the magnetic force.  Larger SPIONs of 50 – 100 
nm diameter have been found to be better than ultra-small SPIONs but they carry the risk 
of thrombosis due to their attachment to the blood vascular system. Although the ultra-
small SPION are difficult to trap due to their small size, it has been suggested that they are 
ideal for use in MDT as they help to prevent the formation of large aggregates. In addition, 
particles whose surfaces are mainly hydrophobic are coated with plasma components and, 
therefore, can be removed rapidly from the circulation. In contrast, particles whose 
surfaces are mainly hydrophilic are resistant to this coating process, hence they can be 
cleared from the circulation more slowly [218]. 
In this chapter, it has been shown that 0.1 mg/ml of SPIONs has less effect on cell 
toxicity on endothelial and glioblastoma cells, however, the results showed that astrocyte 
cells were more sensitive to SPIONs even at their low concentration of iron. These results 
are consistent with observations made in previous studies. For instance, it has been shown 
that SPION concentrations which are used as MRI contrast agent applications have no 
toxic effect on endothelial cells in vitro and in vivo [219] [220]. Here, it was also 
demonstrated that at 1 mg/ml there is toxicity in all the cell lines investigated but this was 
more pronounced in astrocytes, where hardly any cells survived. As a result, it was 
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concluded that astrocyte cells are more sensitive to SPIONs than endothelial cells. 
Glioblastoma cells seemed to be more resistant to SPIONs and this might be explained by 
the overexpression of antioxidant enzymes, for example, superoxide dismutase, catalase, 
glutathione peroxidase, and glutathione reductase. These enzymes help to decrease toxicity 
on cell growth by participating in ROS neutralisation [214]. It was not possible to measure 
these enzymes in this study due to time constraints but this is something that could be 
considered in future work. Also, a study into the mechanisms of cell death is warranted. 
Markers for apoptosis, autophagy and ferroptosis should also be investigated. The latter is 
a form of non-apoptotic programmed cell death characterised by iron dependent build-up 
of lipid hydroperoxides. An increased number of studies have linked ferroptosis and 
nanomedicine as reviewed in [221].   
Previous research has shown that SPIONs do not cause cytotoxicity in nerve cells 
up to a concentration of 100 μgFe/ml. This concentration range is considered as safe with 
regard to cell viability [200]. Naqvi et al.  cultured murine macrophages with SPIONs of 
mean diameter 30 nm which were coated with Tween 80. They then used the H₂DCFDDA 
assay to quantify the generation of intracellular reactive oxygen species (ROS), finding 
that at concentrations higher than 100 μg/mL, SPIONs result in oxidative stress in murine 
macrophage (J774) cells [200]. It was concluded that exposure of cells to a higher 
concentration of nanoparticles resulted in enhanced ROS which causes cellular damage. 
The same study also investigated cell viability using the MTT assay, reporting >95% 
viability with lower SPION concentrations (25-200 μg/mL) and up to three hours of 
exposure, whereas at higher concentrations (300-500 μg/mL) and prolonged (six hours) 
exposure viability was reduced to 55%-65%.  The cytotoxicity could depend on the type of 
brain cells, however: indeed, no relevant toxicity was obtained for neurons and astrocytes 
[222], whereas a toxic effect was observed for microglial cells [223]. 
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Since SPIONs would be used for MDT for brain tumours, it is worth investigating 
the interaction of SPIONs with different brain cells [203]. In an in vitro study, the 
interaction of SPIONs (8.9 nm) with murine oligodendrocytes 158N was investigated. The 
SPIONs of 1, 5, 10, 50 and 100 μg/mL were functionalized using the polymer, 
PolyEthylene Glycol (PEG) and a fluorophore (Rhodamine). After 6 hours of incubating 
time it was found that SPIONs were taken up by the cells via endocytosis, which was 
verified using flow cytometry, transmission electron microscopy and confocal microscopy. 
It was found that SPIONs had no toxicological responses, including morphological 
changes, loss of viability, oxidative stress or inflammatory response, which means that 
SPIONs have good biocompatibility. It was concluded that SPIONs have no side effects on 
158N cells, and constitute interesting tools for biomedical applications across the brain, 
including cellular imaging and targeting. Our study demonstrated similar results, however, 
the SPIONs were uncoated and the incubation time was 24 hours. In this case, uptake of 
SPIONs in brain cells takes place whether the SPIONs are coated or uncoated. 
In this chapter, TEM images helped to show the distribution of SPIONs in each of 
the cells under investigation. SPION uptake depends on the properties and function of the 
cells. For example, it seems that the SPIONs were taken up by cytoplasm, i.e. by the 
lysosome of the cells, this is consistent with previous studies that demonstrated the uptake 
and metabolism of iron oxides nanoparticles in brain cells [217].  
A 24 h time point was used in this study; it would be interesting to carry out further 
investigations to see whether SPIONs would be transported to other parts of the cells over 
a longer incubation time, i.e. 48 h and more. Co-localisation of the SPIONs with other 
markers of the cell using fluorescent microscopy would also be interesting. Using markers 
for endosomes or lysosomes in combination with fluorescent labelled iron particles would 
provide information on the position of the SPIONs in the cells over time.   
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In general, SPIONs at the specific concentrations that were investigated in this 
study were toxic to the cell but at the low concentration this was minimal. Future studies 
could also include much lower concentrations of SPIONs. These findings indicate that 
using SPIONs for magnetic targeting applications could be a promising and safe technique 
for the delivery of drugs to brain tumours.   
It is worth noting that certain concentrations have to be used to ensure the safe 
delivery of drugs. For instance, 1mg/mL of SPIONs is considered safe for the in vitro 
experiment in this PhD research project. However, more in vivo research needs to be 
conducted to confirm the safe dose for human beings. From clinical research, Lubbe [95] 
suggested that for MDT, SPIONs in fluid should be no more than 0.5% of the estimated 
blood volume whereas the drugs such as epirubicin should be 1mg/mL of the body weight. 
 
Limitations; 
There were some limitations in this study due to the timeframe of this project. 
Quantification of SPIONs in brain cells was not conducted. The quantification of SPIONs 
could have been assessed using either ICP (as in the previous chapter), Prussian blue 
staining or SQUID [203].  Fluorescence can also be used to label the SPIONs for 
quantification purposes. Many different types of fluorescent labels are available and have 
been used in the past including green fluorescent protein that was used to label SPIONs 
[92].  
Naked SPIONs are cleared rapidly from circulation, therefore, it would not be 
appropriate to use them for MDT, hence, it would be interesting to consider SPIONs 
coated with different materials. The toxicity assessments here were conducted on cultured 
cells and it would be worthwhile to investigate toxicity in an in vivo model of brain cancer. 
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Also, the toxicity of SPIONs in this experiment was conducted without using an external 
Halbach array magnet. It would be interesting to investigate in future studies how the 
SPIONs affect cell viability in the presence of an external magnetic field. Does this 
increase the accumulation of the iron in the cells? Could this lead to an increase in the 
temperature of the cells, its metabolic properties  etc., this is worth investigating in the 
future.  It would also be interesting if oxidative stress could be measured; this can be 
evaluated by measuring the intracellular ROS production by H2DCF-DA assay [203]. 
Inflammatory response measurement would also be worth investigating, and inflammatory 
cytokine secretion under treatment with SPIONs, which can be carried out using an ELISA 
assay. Importantly, conjugating of the SPIONs with an appropriate drug to target brain 
tumour in vivo and is currently being investigated by a post-doctoral researcher in our 
research group. Drugs including Temozolomide and Lomoustine are currently being 
investigated and have been conjugated to SPIONs like those used in this study. Both these 
drugs are administered to patients with brain tumours.  
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7.1 Summary and outlook 
7.1.1   Summary of major findings 
This study helped to demonstrate that it is possible to use FEMM software to design 
and model different Halbach arrays and to identify the most effective model for use in MDT 
of brain tumours. In chapter 3, the study findings revealed that in order to use the Halbach 
array for brain tumour treatment, a number of factors should be considered including the size 
of the magnet, the orientation of magnetisation of each magnet element and the choice of 
SPION for MDT. For the latter, Lua scripting modelling of different sizes of SPIONs showed 
that smaller sizes of SPIONs require less magnetic force to move them towards the target site. 
As discussed in chapter 3.6, this result resonates with observations made by others [168] 
where it was shown that the amount of magnetic force required to move SPIONs to the target 
site is directly proportional to the volume of the SPIONs. It is therefore an advantage to use 
small size SPIONs (nano) as they require less magnetic force to be moved to the target area. 
In addition, the use of small sized MNPs has the advantage of preventing aggregation and 
subsequent clotting inside the blood vessels [116].   
The size of the magnet device and the orientation of magnetisation also play an 
important role in generating strong magnetic field strength. It was established that increasing 
the layers of magnets (size of the magnet device) resulted in increased magnetic field/gradient 
and magnetic force. This echoes findings from previous study, for instance, a study by Sarwar 
et al. revealed that the more layers of magnet resulted in a stronger magnetic field strength 
[61]. In general, by increasing the number of layers of the magnets, the volume of the device 
is increased and can be inconvenient for use with brain tumour patients, however, our model 
consists of small magnetic elements (1cm ×1cm × 1 cm) which make it possible to increase 
the number of layers without increasing the volume of the magnet device massively (4000g of 
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3 × 3 × 3cm). The other benefit of using small size magnetic elements was that it was easy to 
change the orientation of magnetisation when creating the model to facilitate the generation of 
stronger magnetic field. 
Several simulation studies of Halbach array models have been conducted to reach 
higher depth, for example, 30mm [165], 50mm [116] with magnetic field strength of 1.5T and 
0.8T, respectively. These models cannot be adapted for application in the treatment of brain 
tumours for various reasons including their weak magnetic field strength, short penetration 
distance and the overall volume of the magnet devices. Our Halbach array magnet of model 2 
successfully achieved the highest magnetic field strength of 1.2T with a smaller overall size 
(6cm3) and greater penetration depth of 6cm. Due to the boundary of the model, we were 
unable to measure penetration depth at more than 6cm, however, this was achieved in vitro as 
will be discussed in the subsequent paragraphs. 
In order to focus the magnetic field strength and to enhance the guidance of the MNPs 
to the target site, iron-loaded epoxy resin was modelled to fill the gaps between the head 
surface and the magnet. This was confirmed to be effective in our FEEM Model (Figure 
3.10). Use of iron-loaded epoxy resin enables the magnetic field strength to penetrate greater 
depth. This interesting result needs to be pursued in further studies in this area and should be 
considered when designing a helmet to host the magnetic device.  
There were slight differences observed between the FEMM model and the assembled 
Halbach array magnets in terms of the magnetic field strength, field gradient and magnetic 
force and this confirmed observation made previously [183]. Bashyam et al., showed minor 
difference between the magnetic strength of the assembled and simulated magnet and this is 
due to assembling imperfections, for example, use of adhesive glue to stick the magnet 
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elements together created slight gaps that might have contributed to the reduction of the 
magnetic field strength. 
When assembling the Halbach array magnets the major challenge was to overcome the 
repulsive forces caused by the magnetisation orientation of each magnet element. This was 
achieved by using small magnet elements of 1cm3 attached to each other using adhesive glue 
and supported by the ferritic stainless steel sheets and blocks. However, when the Halbach 
array magnet was optimised to have a square shape it was difficult to attach a second layer 
due to the strength of the repulsive forces between the magnets, hence, expert help was sought 
from the Magnet Expert Company, UK. In future, it is important to consider having such 
manufacturing abilities in house or in collaboration with industrial partners when developing 
our complex Halbach arrays. 
As observed in the in silico model, an increase in the size of the magnet leads to 
increased strength of the magnetic field and this was also confirmed when the magnetic field 
strength was measured using the Gaussmeter. Although an increase in the size of the magnet 
can be viewed positively given that it produces stronger magnetic field that can reach further 
depth in the body, the downside is that the large volume of Halbach array. The device then 
becomes heavy and uncomfortable for use with brain tumour patients. In this case, use of a 
bigger magnet would require consideration regarding how to hold the magnet on top of the 
patient’s head without discomfort. The unique feature of our Halbach array (Model 2) is the 
configuration of magnetisation orientation which helped to generate a strong magnetic field 
capable of reaching further depth (6cm3) and weighing 400g. The optimised Halbach array 
magnet of model 2 would be beneficial in MDT in patients with deep brain tumours while 
Halbach array model 1 would be more appropriate for use in the treatment of superficial brain 
tumours due to its focused magnetic field strength at the surface of the magnet.  
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In vitro experimental data demonstrated the ability of the Halbach array to trap 
SPIONs at different distances in a 3D flow phantom model. It emerged from the experiments 
that there are some key factors that should be considered for the effective targeting. For 
example, the magnetic field strength should be strong enough to overcome the hydrodynamic 
parameters which include the blood flow rate, viscosity of the fluid and ferrofluid 
concentration. In addition, the magnetic field strength should also overcome physiological 
parameters such as the tissue depth to the target site and for brain tumour the resistance of the 
BBB. Riegler et al., showed that the flow rate plays a pivotal role in the trapping of SPIONs, 
and increasing the flow rate leads to a decrease in the trapping of the SPIONs [224]. In 
addition, the study indicated that increasing the distance between the target and the magnet 
results in a decrease in the trapping of the SPIONs. As a result, the aggregated SPIONs at a 
further distance are cleared away quickly when the external magnet is removed. The 
observations made by Riegler et al. were confirmed in our study where it was found that 
increasing the flow rate and the distance between the magnet and the target leads to a decrease 
in the trapping of the SPIONs. Given the findings by Riegler et al., future studies should 
compare different flow rates and using reagents of different viscosity, for example, use of 
blood instead of water in the pump. 
This study showed that SPIONs of average size of 30 nm in diameter are taken up by 
WBC with no significant toxic effect. The study also revealed that WBCs are able to take up 
SPIONs of different concentrations up to 20mg/ml with little toxicity. Within that range of 
SPION concentration, 0.1mg/ml and 1.0mg/ml were selected to assess the toxicity and uptake 
on brain cells as well as brain tumour cells as any concentration higher than this would be 
harmful to the brain cells [211], [213]. It was concluded that the SPIONs have concentration-
dependent toxicity on brain cells, i.e. an increase in concentration results in an increase in 
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toxicity. Our results resonate with findings from other studies, for example, [219], [220]. On 
the other hand, the results indicated that glioblastomas are less susceptible to SPION toxicity.  
As discussed above, the findings from this study help to confirm the overall 
hypothesis that it is possible to model, design and build an inexpensive, portable and powerful 
Halbach array that could be used for MDT in brain tumour treatment. 
7.1.2  Limitations of the study and future work 
The modelling in this study made use of FEMM software because it was freely 
accessible, however, this software only allowed us to design 2D models. 2D models were 
limited given that they could not give us a full picture of the actual device in 3D. As a result, 
it was difficult to achieve precise measurements of the magnetic field strength of the actual 
magnet. Other software is available commercially such as  COMSOL [181], however, this 
was expensive and required specific training that was not available locally. This is something 
that has been discussed with colleagues and will be considered in the future.  
The modelling procedures conducted in this study were in magnetostatic state and 
future studies could explore similar modelling procedures but in a dynamic state to include all 
the aspects of MDT in brain tumour treatment. For instance, modelling the magnet with iron-
loaded epoxy resin and everything fixed to the holder (helmet) attached to the head containing 
the brain tumour and the BBB, to mimic the real situation of the treatment of the brain 
tumour; that is, from the time of the introduction of the magnetised therapeutic agent 
intravenously to the trapping of the MNPs at the desired site. It is anticipated that this would 
provide a clear and comprehensive in silico model which would facilitate the observation of 
the behaviour of MNPs under the effect of our Halbach array in a flow model. 
The assembling of the Halbach array could benefit from an exploration of new 
techniques to assemble the device. This is necessary in order to overcome the existing 
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challenges of assembling the device including how to overcome the repulsive forces and the 
use of adhesive glue. It is important to find an effective way to design a Halbach array model 
for personalised treatment for brain tumour patients. Using a 3D printer to print the complete 
model of Halbach array for individual patient needs based on MRI scan data. Alternatively, 
the 3D printer can be used to print out the design or holder where different magnet elements 
of multiple layers can be placed in the right positions based on the in silico model. Another 
less costly technique involves the use of iron-loaded epoxy resin instead of adhesive glue. 
This helps to overcome the downside of adhesive glue which creates slight gaps between the 
magnets in the device. 
This study made use of the 3D flow phantom model which is not ideal for mimicking 
the human brain, i.e. the actual brain vasculature, the brain blood flow rate and the BBB. In 
addition, the use of an external magnetic field resulted in the aggregation of SPIONs which 
may result in the creation of aggregate whilst in circulation [98]. This aspect has not been 
investigated in the current study, hence, there is potential for further studies to explore ways 
of preventing aggregation of SPIONs in the blood vessels. One consideration is coating the 
SPIONs to weaken the aggregates.  
In the experimental work aimed at assessing the uptake of SPIONs and viability of 
cells, the experiment was not conducted in a flow model with exposure to the magnetic field. 
As a result, future studies should be conducted using a sophisticated flow model and should 
also include the use of Halbach array magnet. Furthermore, in order to mimic the real brain 
blood flow rate which is approximately 800ml/min, future studies should consider the use of 
high quality material of the 3D flow phantom model capable of with standing such high blood 
flow rates such as SynBBB 3D Blood Brain Barrier model [225]. The materials used in this 
study could only withstand up to 300ml/min.  
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On the other hand, further studies should explore the application of this magnet, in 
particular, its effectiveness in in vivo models such as rodents and pigs. This could be done 
with existing brain cancer drugs like Temozolomide or with drugs that are not as effective at 
crossing the BBB. MDT opens up the possibility of using drugs that would be deemed 
unsuitable for brain tumours and therefore has the potential to improve patient outcome for a 
disease that is incurable and has such poor prognosis. In the same vein, future studies can 
investigate the effectiveness of using a range of anticancer drugs conjugated with a range of 
SPIONs coated with different materials to help identify the best combination to target the 
brain tumours.  Furthermore, it will be interesting if future studies can also focus on the 
investigation of the transportation of SPIONs within the cells for periods of more than 24 
hours. This study indicated that the SPIONs are distributed in the lysosomes after 24 hours of 
incubation time. In the same vein, further studies can also explore the quantification of 
SPIONs in the brain tumour cells as well as in other healthy cells, something that has not been 
explored in this study. 
Indeed, a preliminary study carried out by Dr Priya Patel in our research group carried 
out an in vivo study using a miniaturised magnetic device. The device was designed and 
modelled in FEMM and built using small magnets of 3mm. The magnetic strength of the 
device was 0.7 T and this was able to trap iron in a phantom flow model at distances up to 1.8 
cm.  For the in vivo study, Priya implanted luciferase labelled CT2A murine glioblastoma 
cells intracranially into male C57BL/6 mice. Once tumours were visible by bioluminescence 
imaging, 5 mg/kg of SPIONs was administered intravenously into tumour bearing mice in the 
presence of the Halbach array that was secured to the head of the mouse for 30 min. From 
these unpublished observations it was clear by both MRI and histology that the presence of 
the Halbach array resulted in successful transfer of the SPIONs across the BBB into the 
tumour without any harm to the animal (Figure 7.1).  These results are very encouraging and 
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further studies are now investigating drug delivery into the tumour using this approach to 
determine anti-tumour responses. 
 
 
Figure 7.1: MDT of SPIONs in mice. (A) Left: In vitro Magnetic SPIONs trapping in presence of 0.7T 
magnetic device. SPIONs were added to water (1mg/15ml) and pumped around clear plastic tubing 
using a peristaltic pump. The magnetic device was placed underneath the plastic tubing at different 
distances and trapping was achieved up to a maximum distance of 1.8 cm. Middle: A custom-made 
helmet made from 3D printed material designed to fit securely on a mouse head. The magnetic array 
fit into the helmet to create a magnetic helmet and was positioned on top of the head. Right: 
Representative image from IVIS-bioluminescence imaging system showing a brain tumour in a mouse. 
CT2A luciferase labelled glioma cells were implanted via the intracranial route into C57Bl/6 mice. 
Bioluminescence imaging was used to monitor tumour growth over time. (B) SPIONs infiltrate brain 
tumours in the presence of the magnetic helmet. Once tumours were visible via IVIS mice to be 
imaged received an intravenous injection of (5mg/kg) SPIONs in water (100ul) in the 
presence/absence of the magnetic helmet. MRI scans were taken on a 7 Tesla MR imaging system. All 
mice underwent a pre-scan before the SPIONs were injected to determine the tumour location (T). 
The post-scan was taken 30 min after i.v. injection of SPIONs in both the no helmet and magnetic 
helmet group. 
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Finally, in order to develop this magnetic device for patient use it is important to 
consider how it would be fitted to a patient’s head. This work is ongoing in our laboratory and 
discussions around the type of housing and material required to develop this have been 
initiated. So far, a helmet that allows the device to be positioned in multiple locations 
depending on where the tumour is located and that is made of comfortable materials has been 
suggested. These discussions have evolved as a result of this PhD study and have involved 
patient and public involvement groups, neuro-oncologists, physicists and material engineers.  
The next steps are to design and engineer the helmet with comfort for patients in mind. 
Furthermore, studies using larger animals are warranted. Pigs have similar brain physiology to 
humans and it is necessary to see how MDT affects the brain physiology prior to clinical 
studies in human.  
It is worth mentioning that Halbach arrays of Model 2 was filed on 22nd October 2018 
in order to obtain a patent for the device to be used for delivering anticancer drugs for 
targeting brain tumours (Appendices X).   
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Appendices 
Appendix I. Developing Halbach array-Model 3   
Model 3 consists of a hundred of cube shaped magnets with a volume of 1 cm3 each. The 
model contains of ten layers and each layer has a set of magnets in different magnetisation.  
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Appendix II. The strength and the shape of magnetic field of Model 3 at 
different distances (FEMM) 
 
Distance (cm) Magnetic field (T) Graph/peak shape 
0.5 0.65 
 
1.5 0.44  
2 0.34  
2.5 0.28  
3.5 0.24  
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4  0.2 
 
5 0.17  
6 0.15  
7 0.13  
20 0.02  
25 0.016  
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Appendix III. Developing Halbach array-Model 4 
Model 4 consists of a 12 of cube shaped magnets of 2 sets of orthogonal and horizontal 
sets (connected from the corner) with a volume of 1 cm3 each. The model contains of 2 
layers and each layer has a set of magnets in different magnetisation.  
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Appendix IV. The strength and the shape of magnetic field of Model 4 at 
different distances (FEMM)  
Distance (cm ) Magnetic field (T) Graph/peak shape 
0.5 1.3  
1.5 1.2 
 
2 0.2  
2.5 0.1  
3  0.055  
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Appendix V. Developing Halbach array-Model 5  
Model 5 consists of a 12 of cube shaped magnets of 2 sets of orthogonal and horizontal 
sets (connected from the corner) with a volume of 1 cm3 each. The model contains of 2 
layers and each layer has a set of magnets in different magnetisation. 
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Appendix VI. The strength and the shape of magnetic field of Model 5 at 
different distances (FEMM)  
Magnetic field strength at 0 cm 
 
 
Distance (cm) Magnetic field (T) Graph/peak shape 
0.5 1.4  
1 1.3  
1.5 1.1  
2 0.25  
2.5 0.15  
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3  0.09  
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Appendix VII. Developing Halbach array-Model 6  
Model 6 was modeled to be a rectangular shape, which consists of two main blocks with 
different magnetisation orientation. The top block has five layers and each layer has eight 
magnets giving fourteen magnets in total.  
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Appendix VIII. The strength and the shape of magnetic field of Model 6 at 
different distances (FEMM)  
 
Distance (cm) Magnetic field (T) Graph/peak shape 
0.5 1  
1 0.7  
1.5 0.6 
 
2 0.5 
 
2.5 0.42 
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3  0.37 
 
3.5 0.34 
 
4 0.3 
 
4.5 0.23 
 
6 0.22 
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Appendix IX. An intensity histogram of detected SPIONs at different distance 
and time intervals in the vessels 
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An intensity histogram of detected SPIONs at different time intervals in the vessels that were 3cm to 
the magnet with a 150 ml/min flow rate. Video was taken for the trapping experiment where the 
three-layer Halbach array was applied to trap SPIONs in the complex vasculature model. Several video 
clips were taken at different time intervals, and then imported to ImageJ software to generate the 
intensity histogram. 
 An intensity histogram of detected SPIONs at different time intervals in the vessels that were closest 
to the magnet with a 150 ml/min flow rate. Video was taken for the trapping experiment where the 
three-layer Halbach array was applied to trap SPIONs in the complex vasculature model. Several video 
clips were taken at different time intervals, and then imported to ImageJ software to generate the 
intensity histogram. 
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 Time required for SPIONs to be trapped using a Halbach array magnet in the complex 
vasculature model at two different distances. (a) 0 cm and (b) 3 cm away from the magnet, at a 
flow rate of 150 ml/min. 
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An intensity histogram of detected SPIONs at different time intervals in the vessels that were 3cm to the 
magnet with a 300 ml/min flow rate. Video was taken for the trapping experiment where the three-layer 
Halbach array was applied to trap SPIONs in the complex vasculature model. Several video clips were 
taken at different time intervals, and then imported to ImageJ software to generate the intensity 
histogram. 
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An intensity histogram of SPIONs detected at different time intervals in the vessels that were 
closest to the magnet with a 300 ml/min flow rate. Video was taken for the trapping 
experiment where the three-layer Halbach array magnet was applied to trap SPIONs in the 
complex vasculature model. Several video clips were taken at different time intervals and then 
imported into ImageJ software to generate the intensity histogram. 
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Time required for the SPIONs to be released completely from the complex vasculature model after being 
trapped using a Halbach array magnet. The SPIONs was trapped at two different distances- (a) 0 cm and 
(b) 3 cm away from the magnet, at a flow rate 150 ml/min.  
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Appendices X. Filing receipt of Halbach array of model 2 
The patent application of Halbach array (Mosel 2) was filed on the 22nd October 2018. The 
number of the application is GB1817176.9 
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Appendix XI. Description of Halbach array of Model 2  
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Appendix XII. Suggested helmet for Halbach array of Model 2  
 
 
 
 
 
 
 
 
 
